[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1075
1. Prade-Houdellier N, Frébet E, Demur C, Gautier EF, Delhommeau F, Bennaceur-Griscelli AL, Gaudin C, Martinel V, Laurent G, Mansat-De Mas V, Beyne-Rauzy O: Human telomerase is regulated by erythropoietin and transforming growth factor-beta in human erythroid progenitor cells. Leukemia; 2007 Nov;21(11):2304-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human telomerase is regulated by erythropoietin and transforming growth factor-beta in human erythroid progenitor cells.
  • Thus, whereas it has been described that hTERT gene is regulated along the differentiation of primitive myeloid progenitors, the effect of specific cytokines on telomerase expression in each myeloid lineage is currently unknown.
  • Based on these considerations, we have investigated hTERT expression in erythroid cells treated with erythropoietin (EPO) and transforming growth factor beta (TGFbeta), as putative positive and negative regulators, respectively.
  • We describe here that EPO activates hTERT gene transcription in in vitro-expanded primary erythroid precursors as well as in UT7 erythroleukemia cells.
  • [MeSH-major] Erythroid Precursor Cells / metabolism. Erythropoietin / metabolism. Gene Expression Regulation, Leukemic. Telomerase / biosynthesis. Transforming Growth Factor beta / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17713555.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Proto-Oncogene Proteins c-myc; 0 / Transforming Growth Factor beta; 11096-26-7 / Erythropoietin; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


2. Olave IA, Doneanu C, Fang X, Stamatoyannopoulos G, Li Q: Purification and identification of proteins that bind to the hereditary persistence of fetal hemoglobin -198 mutation in the gamma-globin gene promoter. J Biol Chem; 2007 Jan 12;282(2):853-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Purification and identification of proteins that bind to the hereditary persistence of fetal hemoglobin -198 mutation in the gamma-globin gene promoter.
  • Expression of the gamma-globin gene is silenced in adult humans.
  • However, certain point mutations in the gamma-globin gene promoter are capable of maintaining expression of this gene during adult erythropoiesis, a condition called non-deletion hereditary persistence of fetal hemoglobin (HPFH).
  • Among these, the British form of HPFH carrying a T-->C point mutation at position -198 of the Agamma-globin gene promoter results in 4-10% fetal hemoglobin in heterozygotes.
  • In this study, we used nuclear extracts from murine erythroleukemia cells to purify a protein complex that binds the HPFH -198 gamma-globin gene promoter.
  • Sp1, which was previously considered responsible for HPFH -198 gamma-globin gene activation, was not identified.
  • The potential role of these proteins in the reactivation and/or maintenance of gamma-globin gene expression in the adult transcriptional environment is discussed.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1993 Sep 25;268(27):20482-9 [8376403.001]
  • [Cites] Nucleic Acids Res. 1989 Dec 25;17(24):10231-41 [2481268.001]
  • [Cites] Mol Cell Biol. 1994 Apr;14(4):2593-603 [8139561.001]
  • [Cites] J Biol Chem. 1994 Aug 12;269(32):20682-90 [8051169.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5655-9 [7539923.001]
  • [Cites] Nature. 1996 Feb 1;379(6564):466-9 [8559255.001]
  • [Cites] Anal Chem. 1996 Mar 1;68(5):850-8 [8779443.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Nov 12;93(23):13371-6 [8917598.001]
  • [Cites] J Biol Chem. 1997 Feb 28;272(9):5833-7 [9038199.001]
  • [Cites] Mol Cell Biol. 1998 Apr;18(4):2130-42 [9528785.001]
  • [Cites] EMBO J. 1998 Nov 16;17(22):6723-9 [9822615.001]
  • [Cites] Mol Cell Biol. 1998 Sep;18(9):5492-9 [9710633.001]
  • [Cites] Ann N Y Acad Sci. 1998 Jun 30;850:38-44 [9668525.001]
  • [Cites] Mol Cell. 1998 Dec;2(6):751-9 [9885563.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 1998;63:83-103 [10384273.001]
  • [Cites] Cancer. 1999 Aug 15;86(4):689-96 [10440698.001]
  • [Cites] J Biol Chem. 1999 Aug 20;274(34):24250-6 [10446200.001]
  • [Cites] J Biol Chem. 2005 Mar 4;280(9):7452-9 [15613485.001]
  • [Cites] Nat Genet. 2000 Jan;24(1):88-91 [10615135.001]
  • [Cites] Gene. 2000 Jan 25;242(1-2):265-73 [10721720.001]
  • [Cites] Nat Genet. 2000 Jul;25(3):269-77 [10888872.001]
  • [Cites] Nat Genet. 2000 Jul;25(3):338-42 [10888886.001]
  • [Cites] Genes Cells. 2000 Aug;5(8):677-88 [10947852.001]
  • [Cites] Nucleic Acids Res. 1990 Oct 11;18(19):5685-93 [1699206.001]
  • [Cites] Blood. 1991 Oct 1;78(7):1853-63 [1912570.001]
  • [Cites] Nature. 1992 Aug 6;358(6386):499-502 [1379347.001]
  • [Cites] Exp Cell Res. 2000 Nov 25;261(1):166-79 [11082287.001]
  • [Cites] EMBO J. 2000 Dec 1;19(23):6569-81 [11101529.001]
  • [Cites] Anal Biochem. 2001 Mar15;290(2):147-78 [11237318.001]
  • [Cites] EMBO J. 2001 Jan 15;20(1-2):157-64 [11226166.001]
  • [Cites] Mol Cell Biol. 2001 May;21(9):3083-95 [11287613.001]
  • [Cites] EMBO J. 2001 Aug 15;20(16):4337-40 [11500360.001]
  • [Cites] Genes Dev. 2002 Jan 1;16(1):6-21 [11782440.001]
  • [Cites] EMBO J. 2002 Feb 15;21(4):779-88 [11847125.001]
  • [Cites] Oncogene. 2002 Aug 12;21(35):5361-79 [12154399.001]
  • [Cites] Nat Genet. 2003 Jan;33(1):61-5 [12496760.001]
  • [Cites] Genome Biol. 2003;4(2):206 [12620113.001]
  • [Cites] Mol Cell Biol. 2003 Apr;23(8):2834-43 [12665582.001]
  • [Cites] Nucleic Acids Res. 2003 May 1;31(9):2305-12 [12711675.001]
  • [Cites] Mol Cell Biol. 2003 Jun;23(12):4056-65 [12773551.001]
  • [Cites] Oncogene. 2003 Jun 5;22(23):3511-7 [12789259.001]
  • [Cites] Nat Struct Mol Biol. 2004 Jan;11(1):73-80 [14718926.001]
  • [Cites] J Biol Chem. 2004 Jul 2;279(27):27915-27 [15087453.001]
  • [Cites] J Biol Chem. 1989 May 25;264(15):8913-21 [2566609.001]
  • [Cites] Nature. 1989 Jun 8;339(6224):446-51 [2725678.001]
  • [Cites] EMBO J. 1994 Jan 15;13(2):471-83 [8313892.001]
  • (PMID = 17114178.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R56 DK045365; United States / NIDDK NIH HHS / DK / R37 DK045365-07S1; United States / NIDDK NIH HHS / DK / DK61805; United States / NIDDK NIH HHS / DK / DK045365-07S1; United States / NIDDK NIH HHS / DK / R37 DK045365; United States / NIDDK NIH HHS / DK / R01 DK061805; United States / NIDDK NIH HHS / DK / DK045365-06S1; United States / NHLBI NIH HHS / HL / HL73439; United States / NIDDK NIH HHS / DK / R01 DK045365-06S1; United States / NHLBI NIH HHS / HL / R01 HL073439; United States / NIDDK NIH HHS / DK / R01 DK045365; United States / NIDDK NIH HHS / DK / DK45365
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nuclear Matrix-Associated Proteins; 0 / Sp1 Transcription Factor; 0 / Transcription Factors; 0 / Transcription Factors, TFII; 9004-22-2 / Globins; 9034-63-3 / Fetal Hemoglobin; EC 2.1.1.37 / DNA (Cytosine-5-)-Methyltransferase; EC 2.1.1.37 / DNA (cytosine-5-)-methyltransferase 1; EC 3.6.4.12 / transcription factor TFIIF
  • [Other-IDs] NLM/ NIHMS172023; NLM/ PMC2819221
  •  go-up   go-down


3. Ni R, Mulligan AM, Have C, O'Malley FP: PGDS, a novel technique combining chromogenic in situ hybridization and immunohistochemistry for the assessment of ErbB2 (HER2/neu) status in breast cancer. Appl Immunohistochem Mol Morphol; 2007 Sep;15(3):316-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Given the important prognostic and predictive utility of v-erb-b2 erythroblastic leukemia viral oncogene homolog 2 (ErbB2) [human epidermal growth factor receptor-2 (HER2/neu)] in breast cancer, it is recommended that ErbB2 testing be performed on all invasive breast cancers at the time of diagnosis.
  • Immunohistochemistry to detect protein overexpression and fluorescence in situ hybridization (FISH) to detect ErbB2 gene amplification are the most frequently used methods.
  • As no one detection method fulfills all necessary requirements of reliability, reproducibility, and ease of use, we developed a novel approach in the form of a simple assay we refer to as protein and gene double staining (PGDS) which simultaneously evaluates protein overexpression and gene amplification by combining immunohistochemistry with chromogenic in situ hybridization (CISH).
  • A total of 134 invasive breast carcinomas, including 81 cases with a full-face section and 53 cases included in a tissue microarray (TMA), were assessed by PGDS, and the results were correlated with ErbB2 gene amplification status as determined by FISH.
  • ErbB2 gene copy number determined by CISH analysis in the PGDS assay showed excellent concordance with that of FISH (correlation coefficient 0.82; P<0.001 with full-face section cases, and 0.98; P<0.001 with cases in a TMA).
  • The overall concordance rate for gene amplification status between PGDS and FISH was 90.12% in cases with a full-face section and 92.45% with TMA cases.
  • This newly developed PGDS method represents a novel approach to ErbB2 status determination that combines the assessment of both protein overexpression and gene amplification in one simple assay.


Advertisement
4. Sun CF, Chen DP, Tseng CP, Wang WT, Liu JP: Identification of a novel A1v-O1v hybrid allele with G829A mutation in a chimeric individual of AelBel phenotype. Transfusion; 2006 May;46(5):780-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of a novel A1v-O1v hybrid allele with G829A mutation in a chimeric individual of AelBel phenotype.
  • Some of these minor alleles have mutations in the ABO gene coding sequence.
  • The following was performed for the samples from the AelBel proposita: cloning and sequencing of the genomic DNA of the ABO gene, reverse transcription-polymerase chain reaction (PCR) analysis of cDNA transcript of the ABO gene, sequence-specific priming (SSP)-PCR analysis and direct sequencing of the ABO gene, SSP-PCR DNA typing of generic HLA-ABC and HLA-DRB, and short-tandem repeat (STR)-PCR typing on 15 autosomal, 2 X-chromosomal, and 6 Y-chromosomal loci.
  • The A1v-O1v hybrid gene contains two missense mutations: C467T and G829A, resulting in Pro156Leu and Val277Met substitution.
  • CONCLUSION: Formation of the A1v-O1v hybrid allele appears to result from de novo recombination in the germ line of the mother during meiosis.
  • G829A with Val277Met appears to be responsible for the decrease in A-transferase activity and Ael phenotypic expression in the proposita.
  • [MeSH-minor] Adult. Amino Acid Substitution. Base Sequence. Chromosomes, Human, X / genetics. Chromosomes, Human, Y / genetics. DNA Mutational Analysis. Exons. Female. Gene Expression. Humans. Male. Molecular Sequence Data. Phenotype

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16686846.001).
  • [ISSN] 0041-1132
  • [Journal-full-title] Transfusion
  • [ISO-abbreviation] Transfusion
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ AY727862
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABO Blood-Group System
  •  go-up   go-down


5. Achutan C, Tubbs RL: A task-based assessment of noise levels at a swine confinement. J Agromedicine; 2007;12(2):55-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A task-based assessment of noise levels at a swine confinement.
  • The time weighted average noise levels were all well below the Occupational Safety and Health Administration's (OSHA) Permissible Exposure Limit, but exceeded the National Institute for Occupational Safety and Health's Recommended Exposure Limit on three of seven occasions.
  • When the data were extrapolated to depict exposures where specific tasks were carried out over a full shift, tasks such as power washing and snout snaring would exceed the OSHA Action Level (AL).
  • [MeSH-minor] Animal Husbandry. Animals. Iowa. Occupational Exposure / prevention & control. Swine

  • MedlinePlus Health Information. consumer health - Farm Health and Safety.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18086655.001).
  • [ISSN] 1059-924X
  • [Journal-full-title] Journal of agromedicine
  • [ISO-abbreviation] J Agromedicine
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Liagre B, Bertrand J, Leger DY, Beneytout JL: Diosgenin, a plant steroid, induces apoptosis in COX-2 deficient K562 cells with activation of the p38 MAP kinase signalling and inhibition of NF-kappaB binding. Int J Mol Med; 2005 Dec;16(6):1095-101
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We previously showed that diosgenin induced apoptosis in human erythroleukemia (HEL) cells.
  • In order to elucidate the mechanism of its apoptotic activity, we investigated the effect of diosgenin on nuclear factor-kappaB (NF-kappaB) binding and on three groups of human mitogen-activated protein kinases (MAPKs) in relation to diosgenin-induced apoptosis in different erythroleukemia cell lines (K562 and HEL).
  • This inhibition of NF-kappaB binding was correlated with strong apoptosis in both erythroleukemia cell lines.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16273292.001).
  • [ISSN] 1107-3756
  • [Journal-full-title] International journal of molecular medicine
  • [ISO-abbreviation] Int. J. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Imidazoles; 0 / NF-kappa B; 0 / Phytosterols; 0 / Pyridines; 0 / SB 203580; EC 1.14.99.1 / Cyclooxygenase 2; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases; K49P2K8WLX / Diosgenin
  •  go-up   go-down


7. Zenke-Kawasaki Y, Dohi Y, Katoh Y, Ikura T, Ikura M, Asahara T, Tokunaga F, Iwai K, Igarashi K: Heme induces ubiquitination and degradation of the transcription factor Bach1. Mol Cell Biol; 2007 Oct;27(19):6962-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The transcription repressor Bach1 is a sensor and effector of heme that regulates the expression of heme oxygenase 1 and globin genes.
  • We found that hemin further induced the degradation of endogenous Bach1 in NIH 3T3 cells, murine embryonic fibroblasts, and murine erythroleukemia cells.
  • In contrast, succinylacetone, an inhibitor of heme synthesis, caused accumulation of Bach1 in murine embryonic fibroblasts, indicating that physiological levels of heme regulated the Bach1 turnover.
  • Expression of dominant-negative HOIL-1 in murine erythroleukemia cells resulted in higher stability of endogenous Bach1, raising the possibility that the heme-regulated degradation involved HOIL-1 in murine erythroleukemia cells.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1991 Sep 1;88(17):7729-33 [1679235.001]
  • [Cites] J Biol Chem. 2004 Feb 13;279(7):5480-7 [14660636.001]
  • [Cites] Cell. 1994 Sep 9;78(5):787-98 [8087846.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Feb 10;101(6):1461-6 [14747657.001]
  • [Cites] EMBO J. 2004 Jul 7;23(13):2544-53 [15175654.001]
  • [Cites] Mol Cell Biol. 2004 Aug;24(16):7130-9 [15282312.001]
  • [Cites] Antioxid Redox Signal. 2004 Oct;6(5):819-24 [15345141.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Nov 5;324(1):77-85 [15464985.001]
  • [Cites] J Biol Chem. 1977 Apr 10;252(7):2428-36 [321458.001]
  • [Cites] EMBO J. 1995 Jan 16;14(2):313-20 [7835342.001]
  • [Cites] Mol Cell Biol. 1996 Nov;16(11):6083-95 [8887638.001]
  • [Cites] J Biol Chem. 1998 Feb 27;273(9):5358-65 [9478996.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):4924-8 [9560204.001]
  • [Cites] J Biol Chem. 1998 May 8;273(19):11783-90 [9565602.001]
  • [Cites] Mol Cell Biol. 2004 Dec;24(24):10941-53 [15572695.001]
  • [Cites] Mol Cell Biol. 2005 Jan;25(1):162-71 [15601839.001]
  • [Cites] J Biol Chem. 2005 Mar 4;280(9):7671-6 [15613477.001]
  • [Cites] Genes Cells. 2005 Mar;10(3):277-85 [15743416.001]
  • [Cites] Tohoku J Exp Med. 2005 Apr;205(4):297-318 [15750326.001]
  • [Cites] J Biochem. 2005 Mar;137(3):287-96 [15809329.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9559-64 [15972813.001]
  • [Cites] Mol Cell. 2005 Jul 22;19(2):171-81 [16039587.001]
  • [Cites] Mol Cell Biol. 2005 Sep;25(18):8044-51 [16135796.001]
  • [Cites] Mol Cell Biol. 2006 Jan;26(1):221-9 [16354693.001]
  • [Cites] Antioxid Redox Signal. 2006 Jan-Feb;8(1-2):107-18 [16487043.001]
  • [Cites] Genes Cells. 2006 Jul;11(7):791-803 [16824198.001]
  • [Cites] FEBS J. 2006 Jul;273(14):3136-47 [16787441.001]
  • [Cites] J Biol Chem. 2007 Apr 6;282(14):10480-6 [17242398.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Nov 9;96(23):13056-61 [10557272.001]
  • [Cites] J Biol Chem. 2000 Feb 18;275(7):5171-8 [10671563.001]
  • [Cites] Blood. 2000 Nov 1;96(9):3241-8 [11050009.001]
  • [Cites] Mol Cell Biol. 2001 Feb;21(3):691-702 [11154257.001]
  • [Cites] EMBO J. 2001 Jun 1;20(11):2835-43 [11387216.001]
  • [Cites] Mol Cell. 2002 Jan;9(1):155-62 [11804594.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Jan;3(1):11-20 [11823794.001]
  • [Cites] Nat Cell Biol. 2002 May;4(5):E131-6 [11988758.001]
  • [Cites] J Biol Chem. 2002 Jun 7;277(23):20724-33 [11923289.001]
  • [Cites] EMBO J. 2002 Oct 1;21(19):5216-24 [12356737.001]
  • [Cites] Science. 2002 Dec 20;298(5602):2385-7 [12446832.001]
  • [Cites] Nat Cell Biol. 2003 Apr;5(4):336-40 [12629548.001]
  • [Cites] J Biol Chem. 2003 Jun 13;278(24):21592-600 [12682069.001]
  • [Cites] Nature. 2003 Oct 2;425(6957):531-5 [14523450.001]
  • [Cites] Tohoku J Exp Med. 2003 Aug;200(4):167-86 [14580148.001]
  • [Cites] Mol Cell Biol. 2003 Nov;23(22):8137-51 [14585973.001]
  • [Cites] J Biol Chem. 2003 Dec 5;278(49):49246-53 [14504288.001]
  • [Cites] Methods Enzymol. 2003;370:430-44 [14712665.001]
  • [Cites] Nat Struct Mol Biol. 2004 Jan;11(1):73-80 [14718926.001]
  • [Cites] Science. 1993 Jan 22;259(5094):522-5 [8424176.001]
  • (PMID = 17682061.001).
  • [ISSN] 0270-7306
  • [Journal-full-title] Molecular and cellular biology
  • [ISO-abbreviation] Mol. Cell. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bach1 protein, mouse; 0 / Basic-Leucine Zipper Transcription Factors; 120904-94-1 / Polyubiquitin; 42VZT0U6YR / Heme; 743LRP9S7N / Hemin; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  • [Other-IDs] NLM/ PMC2099246
  •  go-up   go-down


8. Yassin A, Yebesi F, Tingle R: Occupational exposure to crystalline silica dust in the United States, 1988-2003. Environ Health Perspect; 2005 Mar;113(3):255-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occupational exposure to crystalline silica dust in the United States, 1988-2003.
  • The purposes of this study were a) to summarize measurements of airborne (respirable) crystalline silica dust exposure levels among U.S. workers, b) to provide an update of the 1990 Stewart and Rice report on airborne silica exposure levels in high-risk industries and occupations with data for the time period 1988-2003, c) to estimate the number of workers potentially exposed to silica in industries that the Occupational Safety and Health Administration (OSHA) inspected for high exposure levels, and d) to conduct time trend analyses on airborne silica dust exposure levels for time-weighted average (TWA) measurements.
  • Compliance inspection data that were taken from the OSHA Integrated Management Information System (IMIS) for 1988-2003 (n = 7,209) were used to measure the airborne crystalline silica dust exposure levels among U.S. workers.
  • A second-order autoregressive model was applied to assess the change in the mean silica exposure measurements over time.
  • The overall geometric mean of silica exposure levels for 8-hr personal TWA samples collected during programmed inspections was 0.077 mg/m3, well above the applicable American Conference of Governmental Industrial Hygienists threshold limit value of 0.05 mg/m3.
  • Surgical appliances supplies industry [Standard Industrial Classification (SIC) 3842] had the lowest geometric mean silica exposure level of 0.017 mg/m3, compared with the highest level, 0.166 mg/m3, for the metal valves and pipe fitting industry (SIC 3494), for an 8-hr TWA measurement.
  • Although a downward trend in the airborne silica exposure levels was observed during 1988-2003, the results showed that 3.6% of the sampled workers were exposed above the OSHA-calculated permissible exposure limit.
  • [MeSH-major] Air Pollutants, Occupational / adverse effects. Air Pollutants, Occupational / analysis. Occupational Exposure. Occupations. Silicon Dioxide / adverse effects. Silicon Dioxide / analysis

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Occup Hyg. 2003 Mar;47(2):111-22 [12581996.001]
  • [Cites] Am J Ind Med. 1995 Jul;28(1):49-70 [7573075.001]
  • [Cites] Appl Occup Environ Hyg. 2003 Jan;18(1):18-21 [12650545.001]
  • [Cites] Occup Environ Med. 2003 Apr;60(4):237-43 [12660371.001]
  • [Cites] Am J Respir Crit Care Med. 1997 Feb;155(2):761-8 [9032226.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 1997;68:1-475 [9303953.001]
  • [Cites] Am J Ind Med. 1998 Dec;34(6):547-58 [9816412.001]
  • [Cites] Ann Occup Hyg. 2002 Apr;46(3):341-6 [12176721.001]
  • [Cites] Occup Environ Med. 2000 Apr;57(4):264-7 [10810113.001]
  • [Cites] Ann Occup Hyg. 2001 Apr;45(3):201-7 [11295143.001]
  • [Cites] Arthritis Rheum. 2002 Jul;46(7):1840-50 [12124868.001]
  • [Cites] Int Arch Occup Environ Health. 2003 May;76(4):318-22 [12768284.001]
  • [Cites] AIHA J (Fairfax, Va). 2003 May-Jun;64(3):319-28 [12809537.001]
  • [Cites] Am J Ind Med. 2003 Aug;44(2):141-7 [12874846.001]
  • [Cites] J Natl Cancer Inst. 1986 Oct;77(4):883-9 [3020298.001]
  • [Cites] Am J Ind Med. 1995 Apr;27(4):485-509 [7793421.001]
  • [Cites] Occup Med. 1995 Apr-Jun;10(2):453-81 [7667753.001]
  • [Cites] Appl Occup Environ Hyg. 2003 Apr;18(4):268-77 [12637237.001]
  • (PMID = 15743711.001).
  • [ISSN] 0091-6765
  • [Journal-full-title] Environmental health perspectives
  • [ISO-abbreviation] Environ. Health Perspect.
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Air Pollutants, Occupational; 0 / Dust; 7631-86-9 / Silicon Dioxide
  • [Other-IDs] NLM/ PMC1253748
  •  go-up   go-down


9. Madl AK, Donovan EP, Gaffney SH, McKinley MA, Moody EC, Henshaw JL, Paustenbach DJ: State-of-the-science review of the occupational health hazards of crystalline silica in abrasive blasting operations and related requirements for respiratory protection. J Toxicol Environ Health B Crit Rev; 2008 Aug;11(7):548-608
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This article presents a comprehensive historical examination of the literature on exposure, health effects, and personal protective equipment related to silica and abrasive blasting operations over the last century.
  • In the early 1900s, increased death rates and prevalence of pulmonary disease were observed in industries that involved dusty operations.
  • Studies of these occupational cohorts served as the basis for the first occupational exposure limits in the 1930s.
  • Early exposure studies in foundries revealed that abrasive blasting operations were particularly hazardous and provided the basis for many of the engineering control and respiratory protection requirements that are still in place today.
  • Studies involving abrasive blasters over the years revealed that engineering controls were often not completely effective at reducing airborne silica concentrations to a safe level; consequently, respiratory protection has always been an important component of protecting workers.
  • During the last 15-20 yr, quantitative exposure-response modeling, experimental animal studies, and in vitro methods were used to better understand the relationship between exposure to silica and disease in the workplace.
  • In light of Occupational Safety and Health Administration efforts to reexamine the protectiveness of the current permissible exposure limit (PEL) for crystalline silica and its focus on protecting workers who are known to still be exposed to silica in the workplace (including abrasive blasters), this state-of-the-science review of one of the most hazardous operations involving crystalline silica should provide useful background to employers, researchers, and regulators interested in the historical evolution of the recognized occupational health hazards of crystalline silica and abrasive blasting operations and the related requirements for respiratory protection.
  • [MeSH-major] Air Pollutants / toxicity. Occupational Exposure / prevention & control. Silicon Dioxide / toxicity. Silicosis / prevention & control
  • [MeSH-minor] Animals. Crystallization. History, 20th Century. History, 21st Century. Humans. Inhalation Exposure / history. Inhalation Exposure / prevention & control. Maximum Allowable Concentration. Protective Clothing. Respiratory Protective Devices

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18584454.001).
  • [ISSN] 1521-6950
  • [Journal-full-title] Journal of toxicology and environmental health. Part B, Critical reviews
  • [ISO-abbreviation] J Toxicol Environ Health B Crit Rev
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Air Pollutants; 7631-86-9 / Silicon Dioxide
  • [Number-of-references] 367
  •  go-up   go-down


10. Hickman JW, Harwood CS: Identification of FleQ from Pseudomonas aeruginosa as a c-di-GMP-responsive transcription factor. Mol Microbiol; 2008 Jul;69(2):376-89
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of FleQ from Pseudomonas aeruginosa as a c-di-GMP-responsive transcription factor.
  • High levels of the intracellular signalling molecule cyclic diguanylate (c-di-GMP) supress motility and activate exopolysaccharide (EPS) production in a variety of bacterial species.
  • In many bacteria part of the effect of c-di-GMP is on gene expression, but the mechanism involved is not known for any species.
  • We have identified the protein FleQ as a c-di-GMP-responsive transcriptional regulator in Pseudomonas aeruginosa.
  • FleQ is known to activate expression of flagella biosynthesis genes.
  • Here we show that it also represses transcription of genes including the pel operon involved in EPS biosynthesis, and that this repression is relieved by c-di-GMP.
  • Our in vivo data indicate that FleQ represses pel transcription and that pel transcription is not repressed when intracellular c-di-GMP levels are high.
  • FleN, a known antiactivator of FleQ also participates in control of pel expression.
  • In in vitro experiments we found that FleQ binds to pel promoter DNA and that this binding is inhibited by c-di-GMP.
  • FleQ binds radiolabelled c-di-GMP in vitro.
  • FleQ does not have amino acid motifs that resemble previously defined c-di-GMP binding domains.
  • Our results show that FleQ is a new type of c-di-GMP binding protein that controls the transcriptional regulation of EPS biosynthesis genes in P. aeruginosa.

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Bacteriol. 2007 Jul;189(14):5383-6 [17496081.001]
  • [Cites] Res Microbiol. 2007 Jul-Aug;158(6):521-8 [17572072.001]
  • [Cites] J Bacteriol. 2000 Jan;182(2):357-64 [10629180.001]
  • [Cites] Nature. 2000 Oct 12;407(6805):762-4 [11048725.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2752-7 [11226312.001]
  • [Cites] Lancet. 2001 Jul 14;358(9276):135-8 [11463434.001]
  • [Cites] J Bacteriol. 2001 Nov;183(22):6636-44 [11673434.001]
  • [Cites] J Bacteriol. 2002 Oct;184(19):5251-60 [12218010.001]
  • [Cites] J Bacteriol. 2002 Nov;184(21):5946-54 [12374828.001]
  • [Cites] Mol Microbiol. 2003 Mar;47(6):1695-708 [12622822.001]
  • [Cites] J Bacteriol. 2003 Apr;185(7):2066-79 [12644476.001]
  • [Cites] Mol Microbiol. 2003 Apr;48(1):199-210 [12657055.001]
  • [Cites] J Biol Chem. 2003 Aug 1;278(31):28711-8 [12759352.001]
  • [Cites] J Clin Invest. 2003 Nov;112(10):1466-77 [14617746.001]
  • [Cites] Mol Microbiol. 2003 Nov;50(3):809-24 [14617143.001]
  • [Cites] Mol Microbiol. 2007 Aug;65(4):876-95 [17645452.001]
  • [Cites] Structure. 2007 Aug;15(8):915-27 [17697997.001]
  • [Cites] Mol Microbiol. 2007 Sep;65(6):1474-84 [17824927.001]
  • [Cites] Annu Rev Microbiol. 2007;61:131-48 [17480182.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Nov 13;104(46):18247-52 [17989226.001]
  • [Cites] J Bacteriol. 2008 Jan;190(2):463-75 [17993515.001]
  • [Cites] J Bacteriol. 2008 Feb;190(3):851-60 [17993539.001]
  • [Cites] PLoS Biol. 2008 Mar 25;6(3):e67 [18366254.001]
  • [Cites] Nature. 1987 Jan 15-21;325(6101):279-81 [18990795.001]
  • [Cites] Curr Opin Microbiol. 2006 Apr;9(2):180-6 [16487743.001]
  • [Cites] Curr Opin Microbiol. 2006 Apr;9(2):218-28 [16530465.001]
  • [Cites] J Bacteriol. 2006 May;188(9):3365-70 [16621831.001]
  • [Cites] Mol Microbiol. 2006 May;60(3):602-16 [16629664.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14339-44 [14617778.001]
  • [Cites] Mol Microbiol. 2004 Feb;51(3):675-90 [14731271.001]
  • [Cites] J Bacteriol. 2004 Jul;186(14):4457-65 [15231777.001]
  • [Cites] Mol Microbiol. 2004 Aug;53(3):857-69 [15255898.001]
  • [Cites] Mol Microbiol. 2004 Aug;53(4):1123-34 [15306016.001]
  • [Cites] Mol Microbiol. 2004 Oct;54(1):264-77 [15458421.001]
  • [Cites] J Cyst Fibros. 2002 Dec;1(4):249-54 [15463822.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Jul;85(14):4976-80 [2839825.001]
  • [Cites] Microbiol Rev. 1991 Mar;55(1):35-58 [2030672.001]
  • [Cites] Cell. 1991 Oct 4;67(1):155-67 [1833069.001]
  • [Cites] J Mol Biol. 1996 Jul 19;260(3):317-31 [8757796.001]
  • [Cites] Nature. 1997 May 22;387(6631):370-6 [9163420.001]
  • [Cites] J Bacteriol. 1997 Sep;179(17):5574-81 [9287015.001]
  • [Cites] Gene. 1999 Feb 18;227(2):197-203 [10023058.001]
  • [Cites] Science. 1999 May 21;284(5418):1318-22 [10334980.001]
  • [Cites] Int J Antimicrob Agents. 1999 May;11(3-4):217-21; discussion 237-9 [10394973.001]
  • [Cites] Mol Cell. 2004 Nov 19;16(4):497-8 [15546607.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Nov 16;101(46):16316-21 [15534211.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Dec 7;101(49):17084-9 [15569936.001]
  • [Cites] Mol Genet Genomics. 2005 Jun;273(5):415-22 [15887032.001]
  • [Cites] Mol Microbiol. 2005 Aug;57(3):629-39 [16045609.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 4;102(40):14422-7 [16186483.001]
  • [Cites] J Bacteriol. 2005 Dec;187(23):7955-62 [16291668.001]
  • [Cites] Bioinformatics. 2006 Jan 1;22(1):3-6 [16249258.001]
  • [Cites] Mol Microbiol. 2006 Jan;59(2):602-9 [16390453.001]
  • [Cites] J Microbiol Methods. 2006 Mar;64(3):391-7 [15987659.001]
  • [Cites] J Bacteriol. 2006 Apr;188(7):2681-91 [16547056.001]
  • [Cites] J Biol Chem. 2006 Mar 24;281(12):8090-9 [16418169.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2839-44 [16477007.001]
  • [Cites] J Bacteriol. 2006 May;188(10):3600-13 [16672614.001]
  • [Cites] Nature. 2006 May 18;441(7091):300-2 [16710410.001]
  • [Cites] Genetics. 2006 Jun;173(2):515-26 [16624907.001]
  • [Cites] J Biol Chem. 2006 Oct 13;281(41):30310-4 [16920715.001]
  • [Cites] J Bacteriol. 2007 Feb;189(3):717-29 [17122338.001]
  • [Cites] Curr Opin Microbiol. 2007 Feb;10(1):17-23 [17208514.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4112-7 [17360486.001]
  • [Cites] J Biol Chem. 2007 Apr 27;282(17):12860-70 [17307739.001]
  • [Cites] Annu Rev Biochem. 2007;76:539-62 [17328675.001]
  • (PMID = 18485075.001).
  • [ISSN] 1365-2958
  • [Journal-full-title] Molecular microbiology
  • [ISO-abbreviation] Mol. Microbiol.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / GM056665-09; United States / NIGMS NIH HHS / GM / R01 GM056665; United States / NIGMS NIH HHS / GM / GM56665; United States / NIGMS NIH HHS / GM / R01 GM056665-09
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / DNA Transposable Elements; 0 / DNA, Bacterial; 0 / FleQ protein, Pseudomonas aeruginosa; 0 / Trans-Activators; 0 / Transcription Factors; 0 / fleN protein, Pseudomonas aeruginosa; 61093-23-0 / bis(3',5')-cyclic diguanylic acid; H2D2X058MU / Cyclic GMP
  • [Other-IDs] NLM/ NIHMS56223; NLM/ PMC2612001
  •  go-up   go-down


11. Harikumar KB, Kuttan G, Kuttan R: Inhibition of viral carcinogenesis by Phyllanthus amarus. Integr Cancer Ther; 2009 Sep;8(3):254-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Friend murine leukemia virus (FMuLv) is an acutely oncogenic retrovirus, and its infection leads to erythroblastosis and leukemia in mice.
  • In the present study, the authors have evaluated the potential of an extract of Phyllanthus amarus against FMuLv-induced erythroleukemia in BALB/c mice.
  • Injection of newborn mice with FMuLv resulted in leukemia and animals died due to splenomegaly.
  • Oral administration of P.amarus was found to enhance the life span of leukemia-harboring animals and decrease the incidence of anemia.
  • The authors also performed a series of hematological, biochemical, histopathological, and gene expression analyses to evaluate the effect of P.amarus administration on erythroleukemia initiation and progression.
  • The data obtained indicate that P.amarus administration could significantly decrease the progression of erythroleukemia.
  • [MeSH-major] Friend murine leukemia virus. Leukemia, Erythroblastic, Acute / drug therapy. Leukemia, Experimental / drug therapy. Phyllanthus / chemistry. Plant Extracts / therapeutic use. Retroviridae Infections / drug therapy. Tumor Virus Infections / drug therapy
  • [MeSH-minor] Anemia / blood. Anemia / drug therapy. Animals. Blood Cell Count. Body Weight / drug effects. Cell Transformation, Viral / drug effects. Disease Progression. Gene Expression / genetics. Hemoglobins / analysis. Hemoglobins / metabolism. Liver / drug effects. Liver / pathology. Mice. Mice, Inbred BALB C. NF-E2 Transcription Factor, p45 Subunit / genetics. Organ Size / drug effects. Proto-Oncogene Proteins c-bcl-2 / genetics. Spleen / drug effects. Spleen / metabolism. Spleen / pathology. Survival Analysis. Tumor Suppressor Protein p53 / genetics. Uric Acid / blood

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Integr Cancer Ther. 2010 Mar;9(1):122
  • (PMID = 19815595.001).
  • [ISSN] 1552-695X
  • [Journal-full-title] Integrative cancer therapies
  • [ISO-abbreviation] Integr Cancer Ther
  • [Language] eng
  • [Grant] United States / NCCIH NIH HHS / AT / 1K01AT004415-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hemoglobins; 0 / NF-E2 Transcription Factor, p45 Subunit; 0 / Nfe2 protein, mouse; 0 / Plant Extracts; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53; 268B43MJ25 / Uric Acid
  •  go-up   go-down


12. Pappas IS, Lambris JD, Vizirianakis IS, Winters MS, Tsiftsoglou AS: Mechanisms of action of differentiation inducers: detection of inducer binding protein(s) in murine erythroleukemia cells. Oncol Res; 2005;15(1):21-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mechanisms of action of differentiation inducers: detection of inducer binding protein(s) in murine erythroleukemia cells.
  • We have shown previously that murine erythroleukemia (MEL) and human neuroectodermal RD/TE-671 cells are induced to differentiate by ureido derivatives of pyridine (UDPs) and may contain inducer binding protein(s).
  • Microsequencing and sequence alignment search revealed that the p38 protein(s) contains at least two homologous domains, one being part of ABC-type transporters and another found in the Wingless-type (Wnt) proteins.
  • This complex, however, decays later on after commitment to erythroid maturation has been initiated.
  • De novo protein and mRNA synthesis is needed for the UDP-p38 complex to form, as shown by the use of metabolic inhibitors.
  • Purified p38 was used to develop an anti-p38 polyclonal serum, and Western blot analysis revealed that the level of p38 was quite similar in both UDP-inducible and -resistant MEL subclones that we developed.
  • [MeSH-major] Aminopyridines / metabolism. Cell Differentiation. Leukemia, Erythroblastic, Acute / pathology. Neuroectodermal Tumors / pathology
  • [MeSH-minor] Animals. Binding Sites. Cytosol. Disease Models, Animal. Electrophoresis, Polyacrylamide Gel. Kinetics. Ligands. Mice. Multiprotein Complexes. p38 Mitogen-Activated Protein Kinases / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15839303.001).
  • [ISSN] 0965-0407
  • [Journal-full-title] Oncology research
  • [ISO-abbreviation] Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminopyridines; 0 / Ligands; 0 / Multiprotein Complexes; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases
  •  go-up   go-down


13. Lan K, Murakami M, Bajaj B, Kaul R, He Z, Gan R, Feldman M, Robertson ES: Inhibition of KSHV-infected primary effusion lymphomas in NOD/SCID mice by gamma-secretase inhibitor. Cancer Biol Ther; 2009 Nov;8(22):2136-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary effusion lymphoma (PEL) is a common cancer in AIDS patients closely associated with Kaposi's sarcoma-associated herpesvirus (KSHV).
  • Previously, we showed that KSHV latency associated nuclear antigen (LANA) stabilizes intracellular activated Notch1 (ICN) involved in maintenance of the malignant phenotype of KSHV infected PEL cells in vitro.
  • The gamma-secretase inhibitor (GSI) which specifically blocks the production of ICN slows down the proliferation of the KSHV infected PEL cell lines BCBL1, BC3 as well as JSC1 in vitro.
  • In this study, we extended these studies to explore the possibility that manipulation of the Notch signaling by GSI would prevent the growth of the PEL tumors in vivo.
  • We observed that the onset of tumorigenesis of KSHV infected PELs was significantly delayed in GSI treated SCID mice harboring the PEL cell lines.
  • We also found that GSI treatment resulted in necrosis as well as apoptosis in tumors generated by the xenotransplanted KSHV positive PEL cell lines.
  • In contrast, GSI had no effect on mice harboring BJAB cells, a KSHV negative Burkitt's lymphoma cell line where ICN levels were negligible.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer Biol Ther. 2009 Nov;8(22):2144-6 [20068386.001]
  • (PMID = 19783901.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Grant] United States / PHS HHS / / A1067037; United States / NCI NIH HHS / CA / CA091792; United States / NCI NIH HHS / CA / CA108461; United States / NIDCR NIH HHS / DE / DE017338
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Viral; 0 / Dipeptides; 0 / N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester; 0 / Neoplasm Proteins; 0 / Notch1 protein, mouse; 0 / Nuclear Proteins; 0 / Receptor, Notch1; 0 / latency-associated nuclear antigen; EC 3.4.- / Amyloid Precursor Protein Secretases
  •  go-up   go-down


14. Truta-Feles K, Lagadari M, Lehmann K, Berod L, Cubillos S, Piehler S, Herouy Y, Barz D, Kamradt T, Maghazachi A, Norgauer J: Histamine modulates γδ-T lymphocyte migration and cytotoxicity, via Gi and Gs protein-coupled signalling pathways. Br J Pharmacol; 2010 Nov;161(6):1291-300
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histamine modulates γδ-T lymphocyte migration and cytotoxicity, via Gi and Gs protein-coupled signalling pathways.
  • BACKGROUND AND PURPOSE: The biogenic amine, histamine plays a pathophysiological regulatory role in cellular processes of a variety of immune cells.
  • This work analyses the actions of histamine on γδ-T lymphocytes, isolated from human peripheral blood, which are critically involved in immunological surveillance of tumours.
  • EXPERIMENTAL APPROACH: We have analysed effects of histamine on the intracellular calcium, actin reorganization, migratory response and the interaction of human γδ T cells with tumour cells such as the A2058 human melanoma cell line, the human Burkitt's Non-Hodgkin lymphoma cell line Raji, the T-lymphoblastic lymphoma cell line Jurkat and the natural killer cell-sensitive erythroleukaemia cell line, K562.
  • KEY RESULTS: γδ T lymphocytes express mRNA for different histamine receptor subtypes.
  • CONCLUSIONS AND IMPLICATIONS: Histamine activated signalling pathways typical of chemotaxis (G(i) protein-dependent actin reorganization, increase of intracellular calcium) and induced migratory responses in γδ T lymphocytes, via the H(4) receptor, whereas it down-regulated γδ T cell mediated cytotoxicity through H(2) receptors and G(s) protein-coupled signalling.
  • [MeSH-major] Cell Movement / drug effects. GTP-Binding Protein alpha Subunits, Gi-Go / physiology. GTP-Binding Protein alpha Subunits, Gs / physiology. Histamine / physiology. Receptors, Antigen, T-Cell, gamma-delta / metabolism. Signal Transduction / drug effects. T-Lymphocytes / drug effects. T-Lymphocytes / metabolism

  • Hazardous Substances Data Bank. HISTAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. British Journal of Pharmacology © 2010 The British Pharmacological Society.
  • [Cites] J Exp Med. 1990 Dec 1;172(6):1877-80 [2124255.001]
  • [Cites] J Biol Chem. 1989 Nov 5;264(31):18261-4 [2681192.001]
  • [Cites] Annu Rev Immunol. 1993;11:637-85 [8476575.001]
  • [Cites] Int Arch Allergy Immunol. 1993;102(1):1-9 [8400880.001]
  • [Cites] Immunopharmacology. 1993 Sep-Oct;26(2):93-104 [8282542.001]
  • [Cites] Cytometry. 1994 Jan 1;15(1):73-9 [8162827.001]
  • [Cites] J Immunol. 1995 Feb 1;154(3):998-1006 [7529807.001]
  • [Cites] Cell Immunol. 1995 Apr 15;162(1):105-13 [7704898.001]
  • [Cites] Pharmacol Rev. 1997 Sep;49(3):253-78 [9311023.001]
  • [Cites] Eur J Immunol. 1999 Jan;29(1):90-9 [9933090.001]
  • [Cites] Annu Rev Immunol. 1999;17:931-72 [10358778.001]
  • [Cites] Science. 1999 Jul 30;285(5428):727-9 [10426993.001]
  • [Cites] J Physiol. 1952 Aug;117(4):72P-73P [12991263.001]
  • [Cites] Biochem Pharmacol. 2005 Feb 1;69(3):433-49 [15652235.001]
  • [Cites] J Immunol. 2005 May 1;174(9):5224-32 [15843518.001]
  • [Cites] J Invest Dermatol. 2006 Jan;126(1):25-31 [16417214.001]
  • [Cites] Eur J Pharmacol. 2006 Mar 8;533(1-3):69-76 [16448645.001]
  • [Cites] J Immunol. 2006 Jun 1;176(11):7062-70 [16709868.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3538-47 [16849647.001]
  • [Cites] Scand J Immunol. 2007 Aug-Sep;66(2-3):320-8 [17635809.001]
  • [Cites] Nat Rev Immunol. 2007 Sep;7(9):690-702 [17703229.001]
  • [Cites] Inflamm Res. 2007 Apr;56 Suppl 1:S37-8 [17806171.001]
  • [Cites] J Immunol. 2007 Dec 1;179(11):7907-15 [18025238.001]
  • [Cites] Br J Pharmacol. 2008 Mar;153(5):1011-21 [18157166.001]
  • [Cites] Br J Pharmacol. 2008 Mar;153 Suppl 2:S1-209 [18347570.001]
  • [Cites] J Pharmacol Sci. 2008 Mar;106(3):347-53 [18360091.001]
  • [Cites] Physiol Rev. 2008 Jul;88(3):1183-241 [18626069.001]
  • [Cites] World J Gastroenterol. 2008 Nov 7;14(41):6334-8 [19009648.001]
  • [Cites] Br J Pharmacol. 2009 May;157(1):14-23 [19413568.001]
  • [Cites] Br J Pharmacol. 2009 May;157(1):24-33 [19309354.001]
  • [Cites] Int Immunol. 2009 Jun;21(6):667-77 [19461126.001]
  • [Cites] Int Arch Allergy Immunol. 2000 May;122(1):1-7 [10859464.001]
  • [Cites] Semin Cancer Biol. 2000 Feb;10(1):25-8 [10888268.001]
  • [Cites] Mol Pharmacol. 2001 Jan;59(1):1-8 [11125017.001]
  • [Cites] Nature. 2001 May 17;411(6835):380-4 [11357146.001]
  • [Cites] J Immunol. 2001 Jun 1;166(11):6784-94 [11359837.001]
  • [Cites] FASEB J. 2001 Sep;15(11):1963-70 [11532976.001]
  • [Cites] Mol Med. 2001 Oct;7(10):711-22 [11713370.001]
  • [Cites] Int J Biochem Cell Biol. 2002 Jul;34(7):838-54 [11950599.001]
  • [Cites] J Allergy Clin Immunol. 2002 May;109(5):839-46 [11994709.001]
  • [Cites] Mod Pathol. 2003 Jan;16(1):72-8 [12527716.001]
  • [Cites] Sci Prog. 2002;85(Pt 4):347-58 [12661423.001]
  • [Cites] J Invest Dermatol. 2003 May;120(5):829-34 [12713589.001]
  • [Cites] J Pharmacol Exp Ther. 2003 Jun;305(3):1212-21 [12626656.001]
  • [Cites] Inflamm Res. 2004 Mar;53(3):87-92 [15021962.001]
  • [Cites] Nature. 1973 Nov 16;246(5429):156-8 [4357166.001]
  • [Cites] Clin Immunol Rev. 1981;1(1):1-65 [6219848.001]
  • [Cites] Nature. 1983 Apr 28;302(5911):832-7 [6188956.001]
  • [Cites] Nature. 1986 Jul 10-16;322(6075):145-9 [3755221.001]
  • [Cites] J Cell Biol. 1988 Feb;106(2):303-9 [3339093.001]
  • [Cites] Nature. 1989 Sep 21;341(6239):197-205 [2550825.001]
  • [Cites] Nature. 1992 Dec 17;360(6405):684-6 [1465133.001]
  • (PMID = 20977468.001).
  • [ISSN] 1476-5381
  • [Journal-full-title] British journal of pharmacology
  • [ISO-abbreviation] Br. J. Pharmacol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Antigen, T-Cell, gamma-delta; 0 / Receptors, Histamine; 820484N8I3 / Histamine; EC 3.6.5.1 / GTP-Binding Protein alpha Subunits, Gi-Go; EC 3.6.5.1 / GTP-Binding Protein alpha Subunits, Gs
  • [Other-IDs] NLM/ PMC3000654
  •  go-up   go-down


15. Fernandez-Twinn DS, Ekizoglou S, Martin-Gronert MS, Tarry-Adkins J, Wayman AP, Warner MJ, Luan JA, Gusterson BA, Ozanne SE: Poor early growth and excessive adult calorie intake independently and additively affect mitogenic signaling and increase mammary tumor susceptibility. Carcinogenesis; 2010 Oct;31(10):1873-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Rapid post-weaning mammary growth and mammary tissue overexpression of insulin receptor, insulin-like growth factor-1 receptor (IGF-1R), estrogen receptor isoform alpha and v-erb-b2 erythroblastic leukemia viral oncogene homolog 2 (ERBB2), correlated with this risk.
  • Cell cycle control and DNA damage repair gene cyclin-dependent kinase inhibitor 1A (CDKN1A) (p21waf1) was also upregulated (P < 0.05) as was transcription factor nuclear factor of kappa light polypeptide gene enhancer in B-cell (P < 0.05) and adhesion gene CDH1 (P < 0.05).
  • Invasion and metastasis markers matrix metalloproteinase 9 and serpin peptidase inhibitor, clade E, member 1 (SERPIN1) were upregulated (both P < 0.05), whereas metastasis suppressor gene NME1 was downregulated (P < 0.01).
  • PTEN gene expression was reduced both by early protein restriction (P < 0.05) and HPD (P < 0.01), which may induce Akt in cell survival pathways.
  • [MeSH-minor] Animals. Body Weight. Disease Susceptibility. Extracellular Signal-Regulated MAP Kinases / metabolism. Female. Gene Expression Profiling. Mammary Glands, Animal / chemistry. Mammary Glands, Animal / metabolism. Rats. Rats, Wistar. Receptor, ErbB-2 / genetics. Receptor, ErbB-2 / physiology. Receptor, IGF Type 1 / analysis. Receptor, IGF Type 1 / genetics. Sp1 Transcription Factor / analysis. Sp1 Transcription Factor / genetics


16. Xu XS, Hong X, Wang G: Induction of endogenous gamma-globin gene expression with decoy oligonucleotide targeting Oct-1 transcription factor consensus sequence. J Hematol Oncol; 2009 Mar 27;2:15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction of endogenous gamma-globin gene expression with decoy oligonucleotide targeting Oct-1 transcription factor consensus sequence.
  • Human beta-globin disorders are relatively common genetic diseases cause by mutations in the beta-globin gene.
  • Increasing the expression of the gamma-globin gene has great benefits in reducing complications associated with these diseases.
  • The Oct-1 transcription factor is involved in the transcriptional regulation of the gamma-globin gene.
  • The human gamma-globin genes (both Agamma and Ggamma-globin genes) carry three Oct-1 transcription factor consensus sequences within their promoter regions.
  • We have studied the possibility of inducing gamma-globin gene expression using decoy oligonucleotides that target the Oct-1 transcription factor consensus sequence.
  • When K562 human erythroleukemia cells were treated with the Oct-1 decoy oligonucleotide, significant increases in the level of the gamma-globin mRNA were observed.
  • The results of our immunoprecipitation (IP) studies revealed that the treatment of K562 cells with the Oct-1 decoy oligonucleotide significantly reduced the level of the endogenous gamma-globin gene promoter region DNA co-precipitated with the Oct-1 transcription factor.
  • These results suggest that the decoy oligonucleotide designed for the Oct-1 transcription factor consensus sequence could induce expression of the endogenous gamma-globin gene through competitive binding of the Oct-1 transcription factor, resulting in activation of the gamma-globin genes.
  • Therefore, disrupting the bindings of the Oct-1 transcriptional factors with the decoy oligonucleotide provides a novel approach for inducing expression of the gamma-globin genes.
  • It also provides an innovative strategy for the treatment of many disease conditions, including sickle cell anemia and beta-thalassemia.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dev Genet. 1989;10(4):311-7 [2791352.001]
  • [Cites] Mol Cell Biol. 1994 Nov;14(11):7621-32 [7935476.001]
  • [Cites] Blood. 1995 May 15;85(10):2967-74 [7537986.001]
  • [Cites] J Cell Sci. 1995 Aug;108 ( Pt 8):2741-6 [7593315.001]
  • [Cites] Anticancer Res. 1996 Jan-Feb;16(1):61-9 [8615671.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Feb 13;243(2):361-7 [9480814.001]
  • [Cites] Am J Physiol. 1998 Aug;275(2 Pt 2):F278-84 [9691019.001]
  • [Cites] Nucleic Acids Res. 1999 Jul 1;27(13):2806-13 [10373600.001]
  • [Cites] Curr Drug Targets. 2004 Nov;5(8):735-44 [15578953.001]
  • [Cites] Exp Hematol. 2005 Mar;33(3):259-71 [15730849.001]
  • [Cites] Prog Mol Subcell Biol. 2005;38:183-206 [15881896.001]
  • [Cites] Oncol Res. 2005;15(7-8):373-83 [16491955.001]
  • [Cites] J Cell Biochem. 2006 Apr 15;97(6):1161-74 [16408276.001]
  • [Cites] Dev Dyn. 2006 Jul;235(7):1727-37 [16607652.001]
  • [Cites] J Dermatol Sci. 2006 Sep;43(3):207-9 [16790335.001]
  • [Cites] Microbiol Immunol. 2006;50(8):559-63 [16924140.001]
  • [Cites] Br J Haematol. 2007 Feb;136(3):353-65 [17129232.001]
  • [Cites] Clin Exp Nephrol. 2007 Mar;11(1):7-17 [17384993.001]
  • [Cites] Curr Opin Mol Ther. 2007 Apr;9(2):119-25 [17458164.001]
  • [Cites] J Neurosci Res. 2007 May 15;85(7):1420-6 [17348043.001]
  • [Cites] Expert Opin Biol Ther. 2007 Jul;7(7):1021-34 [17665991.001]
  • [Cites] J Gene Med. 2007 Sep;9(9):812-9 [17640082.001]
  • [Cites] J Cell Biochem. 2007 Nov 1;102(4):801-10 [17910027.001]
  • [Cites] Antiviral Res. 2008 Apr;78(1):26-36 [18258313.001]
  • [Cites] Br J Haematol. 2008 May;141(3):335-45 [18410569.001]
  • [Cites] Drug Discov Today. 2008 Jun;13(11-12):513-21 [18549978.001]
  • [Cites] Pharmacol Ther. 2009 Jan;121(1):1-13 [18950657.001]
  • [Cites] Gene. 2000 Jan 25;242(1-2):219-28 [10721715.001]
  • [Cites] Biochemistry. 2000 Apr 25;39(16):4863-8 [10769144.001]
  • [Cites] J Mol Biol. 2000 Oct 6;302(5):1023-39 [11183772.001]
  • [Cites] Methods. 2002 Jan;26(1):37-47 [12054903.001]
  • [Cites] J Cell Physiol. 2002 Dec;193(3):340-8 [12384986.001]
  • [Cites] Pediatr Pathol Mol Med. 2001 Jan-Feb;20(1):87-106 [12673846.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2046-51 [12727818.001]
  • [Cites] Gene Ther. 2003 Nov;10(23):1992-7 [14528323.001]
  • [Cites] J Biol Chem. 2004 Feb 13;279(7):5480-7 [14660636.001]
  • [Cites] Curr Drug Targets. 2004 Jul;5(5):419-30 [15216908.001]
  • [Cites] Int J Mol Med. 2004 Aug;14(2):145-52 [15254756.001]
  • [Cites] Blood. 1988 Mar;71(3):807-10 [2449926.001]
  • [Cites] Blood. 1988 Mar;71(3):815-7 [2449927.001]
  • [Cites] Blood. 1989 Jan;73(1):329-33 [2462941.001]
  • (PMID = 19327156.001).
  • [ISSN] 1756-8722
  • [Journal-full-title] Journal of hematology & oncology
  • [ISO-abbreviation] J Hematol Oncol
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / P30 ES006639; United States / NHLBI NIH HHS / HL / R01 HL062551; United States / NIEHS NIH HHS / ES / P30 ES06639; United States / NHLBI NIH HHS / HL / R01HL62551
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Octamer Transcription Factor-1; 0 / Oligonucleotides; 0 / gamma-Globins
  •  go-up   go-down


17. Makis W, Stern J: Hepatitis C-related primary effusion lymphoma of the pleura and peritoneum, imaged with F-18 FDG PET/CT. Clin Nucl Med; 2010 Oct;35(10):797-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary Effusion Lymphoma (PEL) is a rare form of Non-Hodgkin lymphoma that involves serous body cavities (pleural, pericardial, or peritoneal) with lymphomatous effusions in the absence of lymphadenopathy or organomegaly.
  • PEL is associated with human herpes virus type-8 infection, often presents with rapidly progressive effusions and generally has a poor prognosis.
  • This is a case of a 65-year-old HIV-negative man with Hepatitis C cirrhosis, who presented with abdominal pain.
  • Analysis of the cells in the peritoneal fluid revealed a human herpes virus 8-positive PEL of the peritoneum.
  • As a result the patient was no longer considered a liver transplant candidate and died 2 weeks after the diagnosis.
  • [MeSH-major] Fluorodeoxyglucose F18. Hepatitis C / complications. Lymphoma, Primary Effusion / diagnosis. Peritoneal Neoplasms / diagnosis. Pleural Neoplasms / diagnosis. Positron-Emission Tomography. Tomography, X-Ray Computed


18. McAtee BL, Donovan EP, Gaffney SH, Frede W, Knutsen JS, Paustenbach DJ: Historical analysis of airborne beryllium concentrations at a copper beryllium machining facility (1964-2000). Ann Occup Hyg; 2009 Jun;53(4):373-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Copper beryllium alloys are the most commonly used form of beryllium; however, there have been few studies assessing occupational exposure in facilities that worked exclusively with this alloy versus those where pure metal or beryllium oxide may also have been present.
  • With the exception of a few projects conducted in the 1960s, it is believed that >95% of the operations used copper beryllium alloy exclusively.
  • The average concentration based on area samples (1964-2000) was 0.021 microg m(-3) (SD 0.17 microg m(-3); range 0.00012-2.5 microg m(-3)); 68.8% were below the analytical limit of detection (LOD).
  • Airborne concentrations were consistently below the Occupational Safety and Health Administration permissible exposure limit for beryllium (2 microg m(-3)).
  • Overall, the data indicate that for machining operations involving copper beryllium, the airborne concentrations for >95% of the samples were below the contemporaneous occupational exposure limits or the 1999 Department of Energy action level of 0.2 microg m(-3) and, in most cases, were below the LOD.
  • [MeSH-minor] Copper. Databases, Factual. Environmental Monitoring / methods. Humans. Kaplan-Meier Estimate. Occupational Exposure / analysis. Occupational Health

  • Hazardous Substances Data Bank. BERYLLIUM OXIDE .
  • Hazardous Substances Data Bank. BERYLLIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. COPPER, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19383942.001).
  • [ISSN] 1475-3162
  • [Journal-full-title] The Annals of occupational hygiene
  • [ISO-abbreviation] Ann Occup Hyg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Air Pollutants, Occupational; 0 / Alloys; 2S8NLR37S3 / beryllium oxide; 789U1901C5 / Copper; OW5102UV6N / Beryllium
  •  go-up   go-down


19. Di Bartolo DL, Hyjek E, Keller S, Guasparri I, Deng H, Sun R, Chadburn A, Knowles DM, Cesarman E: Role of defective Oct-2 and OCA-B expression in immunoglobulin production and Kaposi's sarcoma-associated herpesvirus lytic reactivation in primary effusion lymphoma. J Virol; 2009 May;83(9):4308-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary effusion lymphoma (PEL) is a distinct type of B-cell non-Hodgkin lymphoma characterized by the presence of Kaposi's sarcoma-associated herpesvirus (KSHV/human herpesvirus 8).
  • Despite having a genotype and gene expression signature of highly differentiated B cells, PEL does not usually express surface or cytoplasmic immunoglobulin (Ig).
  • Like Ig genes, ORF50, the key regulator of the switch from latency to lytic reactivation, contains an octamer motif within its promoter.

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 1998 Nov;153(5):1609-14 [9811353.001]
  • [Cites] Virology. 1998 Dec 20;252(2):304-12 [9878608.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Jan;24(1):16-23 [9892104.001]
  • [Cites] Leukemia. 1999 Jul;13(7):1093-9 [10400426.001]
  • [Cites] J Virol. 1999 Nov;73(11):9348-61 [10516043.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3326-34 [15284123.001]
  • [Cites] J Virol. 2005 Mar;79(6):3479-87 [15731242.001]
  • [Cites] J Virol. 2006 Oct;80(19):9697-709 [16973574.001]
  • [Cites] Virology. 2007 Mar 1;359(1):19-27 [17055026.001]
  • [Cites] J Immunol. 2003 Dec 15;171(12):6589-98 [14662861.001]
  • [Cites] Am J Surg Pathol. 2004 Nov;28(11):1401-16 [15489644.001]
  • [Cites] Cell. 1981 May;24(2):555-65 [6263501.001]
  • [Cites] J Virol. 2003 Jan;77(1):600-23 [12477864.001]
  • [Cites] Oncogene. 2003 Feb 20;22(7):964-73 [12592383.001]
  • [Cites] Blood. 2003 May 15;101(10):4115-21 [12531789.001]
  • [Cites] J Virol. 2003 Sep;77(17):9590-612 [12915572.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10399-404 [12925741.001]
  • [Cites] Nature. 1984 Jul 5-11;310(5972):71-4 [6330567.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Nov;81(22):7041-5 [6438631.001]
  • [Cites] J Mol Biol. 1984 Nov 25;180(1):1-19 [6096556.001]
  • [Cites] Cell. 1985 Jun;41(2):479-87 [3921262.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Sep;82(17):5870-4 [2994050.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Nov;83(22):8511-5 [3095838.001]
  • [Cites] EMBO J. 1987 May;6(5):1323-30 [3038516.001]
  • [Cites] EMBO J. 1987 Jun;6(6):1685-90 [3111845.001]
  • [Cites] Nature. 1987 Sep 10-16;329(6135):174-8 [3627254.001]
  • [Cites] Cell. 1988 Feb 12;52(3):425-34 [2830986.001]
  • [Cites] Nature. 1988 Dec 8;336(6199):544-51 [2904653.001]
  • [Cites] Nature. 1988 Dec 8;336(6199):551-7 [2904654.001]
  • [Cites] Genes Dev. 1988 Dec;2(12A):1570-81 [3265124.001]
  • [Cites] Genes Dev. 1988 Dec;2(12A):1582-99 [2905684.001]
  • [Cites] Blood. 1989 Feb 15;73(3):792-9 [2537119.001]
  • [Cites] EMBO J. 1988 Dec 20;7(13):4231-8 [2854058.001]
  • [Cites] Cell. 1990 Feb 9;60(3):375-86 [2302733.001]
  • [Cites] Nature. 1990 Mar 8;344(6262):165-8 [2106628.001]
  • [Cites] J Virol. 1983 May;46(2):371-7 [6302308.001]
  • [Cites] Cell. 1983 Jul;33(3):717-28 [6409417.001]
  • [Cites] Cell. 1983 Jul;33(3):729-40 [6409418.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 May;81(9):2650-4 [6425835.001]
  • [Cites] Blood. 2000 Mar 15;95(6):2068-75 [10706876.001]
  • [Cites] J Immunol. 2000 May 15;164(10):5306-12 [10799892.001]
  • [Cites] J Virol. 2000 Jul;74(13):6207-12 [10846108.001]
  • [Cites] Blood. 2000 Oct 1;96(7):2537-42 [11001908.001]
  • [Cites] J Gen Virol. 2000 Dec;81(Pt 12):3043-8 [11086135.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2080-4 [11280769.001]
  • [Cites] Blood. 2001 May 15;97(10):3191-6 [11342448.001]
  • [Cites] J Virol. 2001 Aug;75(15):6894-900 [11435569.001]
  • [Cites] Am J Clin Pathol. 1990 Aug;94(2):170-5 [2371971.001]
  • [Cites] J Clin Pathol. 1990 Nov;43(11):888-90 [2124587.001]
  • [Cites] Nucleic Acids Res. 1991 Feb 25;19(4):933-7 [1901991.001]
  • [Cites] Eur J Immunol. 1991 Jun;21(6):1499-504 [1904361.001]
  • [Cites] Genes Dev. 1991 Jun;5(6):932-43 [1904384.001]
  • [Cites] Neuron. 1991 Sep;7(3):381-90 [1654947.001]
  • [Cites] J Clin Pathol. 1992 Sep;45(9):770-5 [1401205.001]
  • [Cites] Genes Dev. 1993 Jan;7(1):72-83 [8422989.001]
  • [Cites] J Biol Chem. 1993 Feb 5;268(4):2525-34 [8428930.001]
  • [Cites] Mol Cell Biol. 1993 Mar;13(3):1547-53 [8441396.001]
  • [Cites] Genes Dev. 1994 Sep 15;8(18):2212-26 [7958890.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] Nature. 1995 Jan 26;373(6512):360-2 [7779176.001]
  • [Cites] Cell. 1995 Feb 10;80(3):497-506 [7859290.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] Mod Pathol. 1995 Jan;8(1):39-45 [7731940.001]
  • [Cites] Immunol Res. 1994;13(4):280-90 [7616055.001]
  • [Cites] Mol Cell Biol. 1995 Aug;15(8):4115-24 [7623806.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1276-80 [7632932.001]
  • [Cites] Am J Clin Pathol. 1996 Feb;105(2):221-9 [8607449.001]
  • [Cites] Blood. 1996 Jul 15;88(2):645-56 [8695812.001]
  • [Cites] Br J Haematol. 1996 Sep;94(3):533-43 [8790156.001]
  • [Cites] J Virol. 1997 Jan;71(1):314-24 [8985352.001]
  • [Cites] Hum Pathol. 1997 Jul;28(7):801-8 [9224748.001]
  • [Cites] Mol Cell Biol. 1997 Dec;17(12):7295-305 [9372961.001]
  • [Cites] Blood. 1997 Dec 15;90(12):4894-900 [9389706.001]
  • [Cites] Annu Rev Immunol. 1998;16:163-200 [9597128.001]
  • [Cites] Curr Opin Immunol. 1998 Apr;10(2):158-65 [9602304.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10866-71 [9724796.001]
  • (PMID = 19224997.001).
  • [ISSN] 1098-5514
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA068939; United States / NCI NIH HHS / CA / R29 CA068939; United States / NCI NIH HHS / CA / CA68939
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immediate-Early Proteins; 0 / Immunoglobulins; 0 / Octamer Transcription Factor-2; 0 / Rta protein, Human herpesvirus 8; 0 / Trans-Activators
  • [Other-IDs] NLM/ PMC2668464
  •  go-up   go-down


20. Cardellicchio N, Buccolieri A, Giandomenico S, Lopez L, Pizzulli F, Spada L: Organic pollutants (PAHs, PCBs) in sediments from the Mar Piccolo in Taranto (Ionian Sea, Southern Italy). Mar Pollut Bull; 2007;55(10-12):451-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Total PAH concentrations ranged from 380 to 12,750 microg/kg d.w., while total PCB levels ranged from 2 to 1684 microg/kg d.w.
  • PCB and PAH levels in sediments were compared with Sediments Quality Guidelines (ERM-ERL, TEL-PEL indexes) for evaluation probable toxic effects on marine organism.
  • Finally, ERM and PEL quotients were used to evaluate the degree to which chemicals exceed guidelines.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17936311.001).
  • [ISSN] 0025-326X
  • [Journal-full-title] Marine pollution bulletin
  • [ISO-abbreviation] Mar. Pollut. Bull.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Polycyclic Hydrocarbons, Aromatic; 0 / Water Pollutants, Chemical; DFC2HB4I0K / Polychlorinated Biphenyls
  •  go-up   go-down


21. Fiume R, Faenza I, Matteucci A, Astolfi A, Vitale M, Martelli AM, Cocco L: Nuclear phospholipase C beta1 (PLCbeta1) affects CD24 expression in murine erythroleukemia cells. J Biol Chem; 2005 Jun 24;280(25):24221-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nuclear phospholipase C beta1 (PLCbeta1) affects CD24 expression in murine erythroleukemia cells.
  • Inositide-specific phospholipase C (PLC) beta1 is a key enzyme in nuclear lipid signal transduction affecting cell cycle progression and may be directly involved in regulation of gene expression and hematopoiesis.
  • By microarrays, we compared the effect of nuclear PLCbeta1 overexpression with that of PLC M2b cytoplasmatic mutant, which is exclusively located in the cytoplasm, in murine erythroleukemia cells.
  • Out of 9000 genes analyzed, the CD24 gene, coding for an antigen involved in differentiation and hematopoiesis as well, was up-regulated in cells overexpressing nuclear PLCbeta1 as compared with both cells overexpressing the M2b cytoplasmatic mutant and the wild type cells.
  • We also demonstrated that PLCbeta1-dependent up-modulation of CD24 was mediated, at least in part, at the transcriptional level, in that PLCbeta1 affected the CD24 promoter activity.
  • Moreover, the up-regulation of CD24 was higher during erythroid differentiation of murine erythroleukemia cells.
  • Altogether our findings, obtained by combining microarrays, phenotypic analysis, and small interfering RNA technology, identify CD24 as an molecular effector of nuclear PLCbeta1 signaling pathway in murine erythroleukemia cells and strengthen the contention that nuclear PLCbeta1 constitutes a key step in erythroid differentiation in vitro.
  • [MeSH-major] Antigens, CD34 / metabolism. Cell Nucleus / enzymology. Isoenzymes / metabolism. Leukemia, Erythroblastic, Acute / metabolism. Type C Phospholipases / metabolism

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15849202.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / DNA Primers; 0 / Isoenzymes; EC 3.1.4.- / Type C Phospholipases; EC 3.1.4.11 / Phospholipase C beta; EC 3.1.4.11 / Plcb1 protein, mouse
  •  go-up   go-down


22. Fernández-Nestosa MJ, Hernández P, Schvartzman JB, Krimer DB: PU.1 is dispensable to block erythroid differentiation in Friend erythroleukemia cells. Leuk Res; 2008 Jan;32(1):121-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PU.1 is dispensable to block erythroid differentiation in Friend erythroleukemia cells.
  • Friend murine erythroleukemia cell lines derive from erythroblasts transformed with the Friend complex where the spleen-focus forming virus integrated in the vicinity of the Sfpi-1 locus.
  • Erythroleukemia cells do not differentiate and grow indefinitely in the absence of erythropoietin.
  • Activation of the transcription factor PU.1, encoded by the Sfpi-1 gene, is thought to be responsible for the transformed phenotype.
  • Resistant cell lines restart erythroid differentiation, though, if forced to exit the cell cycle or by overexpressing the transcription factor GATA-1.
  • Exposure to 5-Aza-2'-deoxycytidine activates PU.1 expression suggesting that the PU.1 coding gene is highly methylated in the resistant cells.
  • Altogether these results suggest that PU.1 is dispensable to block erythroid differentiation.
  • [MeSH-major] Cell Differentiation. Friend murine leukemia virus. Leukemia, Erythroblastic, Acute / metabolism. Leukemia, Erythroblastic, Acute / pathology. Proto-Oncogene Proteins / metabolism. Trans-Activators / metabolism
  • [MeSH-minor] Acetamides / pharmacology. Animals. Azacitidine / analogs & derivatives. Azacitidine / pharmacology. Drug Resistance. Erythroid Cells / pathology. GATA1 Transcription Factor / metabolism. Genes, myc. Leukemia, Experimental / metabolism. Leukemia, Experimental / pathology. Mice. RNA, Small Interfering / pharmacology. Tumor Cells, Cultured

  • Hazardous Substances Data Bank. AZACITIDINE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17586044.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Acetamides; 0 / GATA1 Transcription Factor; 0 / Gata1 protein, mouse; 0 / Proto-Oncogene Proteins; 0 / RNA, Small Interfering; 0 / Trans-Activators; 0 / proto-oncogene protein Spi-1; 776B62CQ27 / decitabine; LA133J59VU / hexamethylene bisacetamide; M801H13NRU / Azacitidine
  •  go-up   go-down


23. Muraki Y, Hay A: Establishment of mouse erythroleukemia cell lines expressing complete Influenza C virus CM2 protein or chimeric protein consisting of CM2 and Influenza A virus M2. Acta Virol; 2009;53(2):125-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment of mouse erythroleukemia cell lines expressing complete Influenza C virus CM2 protein or chimeric protein consisting of CM2 and Influenza A virus M2.
  • For this purpose, we established a CM2-expressing mouse erythroleukemia (MEL) cell line and determined the biochemical characteristics of the expressed CM2.
  • [MeSH-minor] Animals. Cell Line, Transformed. Cell Line, Tumor. Humans. Influenza A virus / genetics. Influenza A virus / metabolism. Influenzavirus C / genetics. Influenzavirus C / metabolism. Leukemia, Erythroblastic, Acute / virology. Mice. Virology / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19537914.001).
  • [ISSN] 0001-723X
  • [Journal-full-title] Acta virologica
  • [ISO-abbreviation] Acta Virol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U117512708
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / CM2 protein, Influenza C virus; 0 / M2 protein, Influenza A virus; 0 / Recombinant Fusion Proteins; 0 / Viral Matrix Proteins
  •  go-up   go-down


24. Marchisio M, Santavenere E, Paludi M, Gaspari AR, Lanuti P, Bascelli A, Ercolino E, Di Baldassarre A, Miscia S: Erythroid cell differentiation is characterized by nuclear matrix localization and phosphorylation of protein kinases C (PKC) alpha, delta, and zeta. J Cell Physiol; 2005 Oct;205(1):32-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Erythroid cell differentiation is characterized by nuclear matrix localization and phosphorylation of protein kinases C (PKC) alpha, delta, and zeta.
  • Protein kinases C (PKC) zeta expression and phosphorylation at nuclear level during dimethyl sulfoxide (DMSO)-induced differentiation in Friend erythroleukemia cells have been previously reported, suggesting a possible role of this PKC isoform in the DMSO-related signaling.
  • In order to shed more light on this tantalizing topic, we investigated PKC intracellular and sub-cellular localization and activity during DMSO-induced erythroid differentiation.
  • Furthermore, an evident downregulation of the beta-globin gene transcription (differentiation hallmark) was detected upon a progressive inhibition of these PKC isoforms by means of specific inhibitors, indicating, therefore, that PKC alpha, zeta, and delta phosphorylation play a crucial role in the control of erythroid differentiation.
  • [MeSH-major] Cell Differentiation. Erythroid Cells / cytology. Erythroid Cells / metabolism. Nuclear Matrix / metabolism. Protein Kinase C / metabolism

  • Hazardous Substances Data Bank. DIMETHYL SULFOXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15880451.001).
  • [ISSN] 0021-9541
  • [Journal-full-title] Journal of cellular physiology
  • [ISO-abbreviation] J. Cell. Physiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.11.1 / protein kinase C zeta; EC 2.7.11.13 / Protein Kinase C; EC 2.7.11.13 / Protein Kinase C-alpha; EC 2.7.11.13 / Protein Kinase C-delta; YOW8V9698H / Dimethyl Sulfoxide
  •  go-up   go-down


25. Iacomino G, Medici MC, Russo GL: Valproic acid sensitizes K562 erythroleukemia cells to TRAIL/Apo2L-induced apoptosis. Anticancer Res; 2008 Mar-Apr;28(2A):855-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Valproic acid sensitizes K562 erythroleukemia cells to TRAIL/Apo2L-induced apoptosis.
  • In recent years, the clinical application of HDACi has been largely explored for their ability to modulate gene transcription, block cell division cycle, inhibit cell proliferation, induce cellular differentiation and apoptosis.
  • MATERIALS AND METHODS: The ability of valproic acid (VPA), a well-known HDACi, to sensitise the K562 cell line, derived from a human leukemia, to TRAIL/Apo2L-mediated apoptosis was evaluated.
  • CONCLUSION: Our results demonstrated the ability of VPA to sensitize TRAIL/Apo2L-resistant cells to apoptosis, thus providing an attractive approach for the treatment of leukemias and other proliferative malignancies.
  • [MeSH-major] Apoptosis / drug effects. Leukemia, Erythroblastic, Acute / pathology. TNF-Related Apoptosis-Inducing Ligand / pharmacology. Valproic Acid / pharmacology

  • Hazardous Substances Data Bank. VALPROIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18507029.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Receptors, TNF-Related Apoptosis-Inducing Ligand; 0 / TNF-Related Apoptosis-Inducing Ligand; 614OI1Z5WI / Valproic Acid; EC 3.4.22.- / Caspase 3
  •  go-up   go-down


26. Chen CR, Lin CH, Lin JW, Chang CI, Tseng YH, Weng SF: Characterization of a novel T4-type Stenotrophomonas maltophilia virulent phage Smp14. Arch Microbiol; 2007 Aug;188(2):191-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of a novel T4-type Stenotrophomonas maltophilia virulent phage Smp14.
  • Its genome (estimated to be 160 kb by PFGE), containing m4C and two unknown modified bases other than m5C and m6A as identified by HPLC, resisted to digestion with many restriction endonucleases except MseI.
  • Sequencing of a 16 kb region revealed 12 ORFs encoding structural proteins sharing 15-45% identities with the homologues from T4-type phages.
  • Phylogenetic analysis based on gp23 classified Smp14 into a novel single-membered T4-type subgroup.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17440710.001).
  • [ISSN] 0302-8933
  • [Journal-full-title] Archives of microbiology
  • [ISO-abbreviation] Arch. Microbiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Sewage; 0 / Viral Proteins
  •  go-up   go-down


27. Engard DJ, Sandfort DR, Gotshall RW, Brazile WJ: Noise exposure, characterization, and comparison of three football stadiums. J Occup Environ Hyg; 2010 Nov;7(11):616-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Noise exposure, characterization, and comparison of three football stadiums.
  • Personal noise exposure samples were collected from five workers at a large-sized college football stadium and five workers at a medium-sized college football stadium in northern Colorado during three home football games, for a total of 30 personal noise exposures.
  • In addition, personal noise exposure samples were collected from five fans at a National Football League (NFL) stadium, and from two fans at each of the college stadiums during three home football games, for a total of 27 personal noise exposure samples.
  • None of the workers' noise doses were above the Occupational Safety and Health Administration (OSHA) permissible exposure limit of 90 dBA.
  • However, 11 of 28 (39%) workers' noise doses exceeded the OSHA action level of 85 dBA that would require enrollment in a hearing conservation program.
  • Following ACGIH® recommendations for noise exposure limits, 27 of 28 (96%) workers would be considered overexposed.
  • At the 95% confidence level, workers' and fans' noise exposures were not significantly different between the three stadiums.
  • However, there was significant noise level variability between the games in each individual stadium (e.g., 82 dbA vs. 87 dbA mean worker OSHA noise exposure for two games at the large-sized college stadium, p=0.001).
  • Management should include a warning of possible loud-noise exposure during any sporting events held at the stadiums in fan guides, pamphlets, websites, or other appropriate communication tools.
  • This information should include the health effects of loud noise exposure, namely, noise-induced hearing loss, the information should also be specifically targeted to parents of young children, including a strong recommendation that hearing protection be worn by all children during the sporting event.
  • [MeSH-major] Environmental Exposure / analysis. Noise. Occupational Exposure / analysis. Sports

  • MedlinePlus Health Information. consumer health - Noise.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20835945.001).
  • [ISSN] 1545-9632
  • [Journal-full-title] Journal of occupational and environmental hygiene
  • [ISO-abbreviation] J Occup Environ Hyg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


28. Xu X, Martin F, Friedman JS: The familial Parkinson's disease gene DJ-1 (PARK7) is expressed in red cells and plays a role in protection against oxidative damage. Blood Cells Mol Dis; 2010 Oct 15;45(3):227-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The familial Parkinson's disease gene DJ-1 (PARK7) is expressed in red cells and plays a role in protection against oxidative damage.
  • Impaired SOD2 activity in murine hematopoietic cells affects erythroid development, resulting in anemia characterized by intra-mitochondrial iron deposition, reticulocytosis and shortened red cell life span.
  • Gene expression profiling of normal and SOD2 deficient erythroblasts identified the Parkinson's disease locus DJ-1 (Park7) as a differentially expressed transcript.
  • We also investigated DJ-1 protein expression in primary murine erythroid and erythroleukemia cells (MEL).
  • Using MEL cells, we show that DJ-1 is up-regulated at the protein level during erythroid differentiation.
  • These results indicate that DJ-1 plays a physiologic role in protection of erythroid cells from oxidant damage, a function unmasked in the context of oxidative stress.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20800516.001).
  • [ISSN] 1096-0961
  • [Journal-full-title] Blood cells, molecules & diseases
  • [ISO-abbreviation] Blood Cells Mol. Dis.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R21 DK075763; United States / NIDDK NIH HHS / DK / R21DK075763
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oncogene Proteins; 11062-77-4 / Superoxides; EC 1.11.1.15 / DJ-1 protein, mouse; EC 1.11.1.15 / Peroxiredoxins; EC 1.15.1.1 / Superoxide Dismutase; EC 1.15.1.1 / superoxide dismutase 2
  • [Other-IDs] NLM/ NIHMS233074; NLM/ PMC2962440
  •  go-up   go-down


29. Neubauer H, Gall C, Vogel U, Hornung R, Wallwiener D, Solomayer E, Fehm T: Changes in tumour biological markers during primary systemic chemotherapy (PST). Anticancer Res; 2008 May-Jun;28(3B):1797-804
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: Corresponding "baseline" biopsies and post-chemotherapy surgical specimens from 87 patients treated with neoadjuvant anthracycline- or taxane-based chemotherapy were analysed for the expression of the oestrogen receptor (ER), the progesterone receptor (PR), the B-cell lymphoma protein 2 (Bcl-2), the v-erb-b2 erythroblastic leukemia viral oncogene homolog 2 (Her2/neu), the tumour protein p53 and the proliferation-related Ki-67 antigen.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18630463.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


30. Salman H, Bergman M, Djaldetti M, Bessler H: Lycopene affects proliferation and apoptosis of four malignant cell lines. Biomed Pharmacother; 2007 Jul;61(6):366-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lycopene affects proliferation and apoptosis of four malignant cell lines.
  • The aim of the study was to examine its anti-proliferative and apoptotic effect on other malignant cell lines.
  • Cells of the following lines were incubated with 1.0, 2.0, and 4.0microM of lycopene: human colon carcinoma (HuCC), B chronic lymphocytic leukemia (EHEB), human erythroleukemia (K562) and Raji, a prototype of Burkitt lymphoma cell line.
  • The findings point out that the anti-proliferative effect of lycopene on tumor cells and its effect on the apoptotic rate depends on its dosage and on the type of the malignant cells.
  • [MeSH-minor] Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / pathology. Cell Line, Tumor. Colonic Neoplasms / drug therapy. Colonic Neoplasms / pathology. Dose-Response Relationship, Drug. Humans. K562 Cells. Leukemia, B-Cell / drug therapy. Leukemia, B-Cell / pathology. Leukemia, Erythroblastic, Acute / drug therapy. Leukemia, Erythroblastic, Acute / pathology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17448625.001).
  • [ISSN] 0753-3322
  • [Journal-full-title] Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie
  • [ISO-abbreviation] Biomed. Pharmacother.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 36-88-4 / Carotenoids; SB0N2N0WV6 / lycopene
  •  go-up   go-down


31. Ghirlando R, Felsenfeld G: Hydrodynamic studies on defined heterochromatin fragments support a 30-nm fiber having six nucleosomes per turn. J Mol Biol; 2008 Mar 7;376(5):1417-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have compared the physical properties of a 15.51-kb constitutive heterochromatin segment and a 16.17-kb facultative heterochromatin segment that form part of the chicken beta-globin locus.
  • These segments were excised from an avian erythroleukemia cell line by restriction enzyme digestion and released from the nucleus, thus allowing measurement of the sedimentation coefficients by use of calibrated sucrose gradients.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] EMBO J. 1983;2(8):1367-72 [10872332.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Apr 25;103(17):6506-11 [16617109.001]
  • [Cites] Science. 2001 Sep 28;293(5539):2453-5 [11498546.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Oct 9;98(21):11949-54 [11593003.001]
  • [Cites] J Mol Biol. 2004 Feb 20;336(3):597-605 [15095975.001]
  • [Cites] Cell. 2004 Sep 3;118(5):555-66 [15339661.001]
  • [Cites] Proc Natl Acad Sci U S A. 1976 Jun;73(6):1897-901 [1064861.001]
  • [Cites] J Mol Biol. 1977 Nov 5;116(3):593-603 [592392.001]
  • [Cites] Eur J Biochem. 1979 Jul;97(2):593-602 [467433.001]
  • [Cites] J Cell Biol. 1979 Nov;83(2 Pt 1):403-27 [387806.001]
  • [Cites] J Mol Biol. 1980 Jul 15;140(4):505-29 [7431398.001]
  • [Cites] Nature. 1980 Dec 11;288(5791):620-2 [7442809.001]
  • [Cites] J Mol Biol. 1980 Nov 25;144(1):89-93 [7218359.001]
  • [Cites] Eur J Biochem. 1983 Jul 15;134(1):109-15 [6861754.001]
  • [Cites] Nature. 1983 Dec 15-21;306(5944):709-12 [6656872.001]
  • [Cites] J Mol Biol. 1984 Aug 15;177(3):373-98 [6471101.001]
  • [Cites] Cell. 1985 Nov;43(1):207-13 [4075395.001]
  • [Cites] Eur J Biochem. 1986 Jan 15;154(2):343-8 [3943532.001]
  • [Cites] Biochemistry. 1985 Feb 26;24(5):1186-93 [4096899.001]
  • [Cites] Eur Biophys J. 1986;13(3):157-73 [3956445.001]
  • [Cites] Biochemistry. 1986 Dec 2;25(24):8010-6 [3801455.001]
  • [Cites] J Mol Biol. 1987 Jan 5;193(1):57-70 [3586025.001]
  • [Cites] J Mol Biol. 1987 Jan 5;193(1):69-70 [3586026.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Nov;84(22):7802-6 [3479765.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Nov;86(21):8266-70 [2682643.001]
  • [Cites] J Cell Sci Suppl. 1992;16:15-20 [1297648.001]
  • [Cites] Nature. 1994 Mar 24;368(6469):351-4 [8127372.001]
  • [Cites] J Biol Chem. 1994 Dec 23;269(51):32565-71 [7798259.001]
  • [Cites] EMBO J. 1996 May 15;15(10):2496-507 [8665857.001]
  • [Cites] J Mol Biol. 1999 Apr 30;288(2):213-29 [10329138.001]
  • [Cites] EMBO J. 1999 Jul 15;18(14):4035-48 [10406808.001]
  • [Cites] Science. 2004 Nov 26;306(5701):1571-3 [15567867.001]
  • [Cites] J Mol Biol. 2005 Feb 4;345(5):957-68 [15644197.001]
  • [Cites] Nature. 2005 Jul 7;436(7047):138-41 [16001076.001]
  • [Cites] EMBO J. 2001 May 1;20(9):2224-35 [11331588.001]
  • (PMID = 18234217.001).
  • [ISSN] 1089-8638
  • [Journal-full-title] Journal of molecular biology
  • [ISO-abbreviation] J. Mol. Biol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 DK036151-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Heterochromatin; 0 / Nucleosomes; 9004-22-2 / Globins
  • [Other-IDs] NLM/ NIHMS42151; NLM/ PMC2774144
  •  go-up   go-down


32. Krjukova J, Mirtov V, Akerman KE: PC12 and HEL cell communication in a reconstituted synapse analyzed with mathematical modeling. Neurochem Int; 2005 Jan;46(1):83-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A synapse simulating model comprising of the nerve growth factor (NGF)-differentiated PC12 cells releasing neurotransmitter (NT) and sensor 92.1.7.human erythroleukemia (HEL) cells has been used for simulating the connection between neurons and target cells.
  • [MeSH-major] Cell Communication / physiology. Leukemia, Erythroblastic, Acute / pathology. Synapses / physiology

  • Hazardous Substances Data Bank. Norepinephrine .
  • Hazardous Substances Data Bank. NICOTINE .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15567518.001).
  • [ISSN] 0197-0186
  • [Journal-full-title] Neurochemistry international
  • [ISO-abbreviation] Neurochem. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Nicotinic Agonists; 6M3C89ZY6R / Nicotine; 9061-61-4 / Nerve Growth Factor; SY7Q814VUP / Calcium; X4W3ENH1CV / Norepinephrine
  •  go-up   go-down


33. Teruya-Feldstein J: Diffuse large B-cell lymphomas with plasmablastic differentiation. Curr Oncol Rep; 2005 Sep;7(5):357-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Subtypes of DLBCL with plasmablastic features and terminal B-cell differentiation include plasmablastic lymphoma (PBL) of oral mucosa type; PBL with plasmacytic differentiation; primary effusion lymphoma (PEL); KSHV-positive solid lymphoma/extracavitary PEL/HHV-8 associated DLBCL; and DLBCL expressing ALK.
  • In contrast, PBL associated with multicentric Castleman disease, DLBCL with secretory differentiation, pyothorax-associated lymphoma, and atypical Burkitt lymphoma with plasmacytoid differentiation have morphologic appearances of plasma cell differentiation but maintain a mature B-cell (CD20 positive) phenotype.
  • These tumors as well as extramedullary plasmablastic tumors secondary to multiple myeloma or plasmacytomas are included in the differential diagnosis.
  • In this review, we discuss recently described clinicopathologic insights, case observations, and recently reported molecules involved in terminal B-cell or plasma cell differentiation and their possible roles in disease pathogenesis.
  • [MeSH-minor] Adult. Antigens, CD20 / metabolism. B-Lymphocytes / cytology. Cell Differentiation. Cell Proliferation. Empyema, Pleural / metabolism. Giant Lymph Node Hyperplasia / metabolism. Giant Lymph Node Hyperplasia / therapy. Humans. Lymphoma / metabolism. Male. Middle Aged. Mouth Mucosa / pathology. Multiple Myeloma / metabolism. Neoplasms / metabolism. Phenotype. Plasmacytoma / metabolism

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AIDS. 2001 Aug 17;15(12):1483-91 [11504980.001]
  • [Cites] Am J Surg Pathol. 2004 Jun;28(6):736-47 [15166665.001]
  • [Cites] Am J Surg Pathol. 2004 Jan;28(1):41-6 [14707862.001]
  • [Cites] Am J Surg Pathol. 2004 Nov;28(11):1537-8; author reply 1538 [15489660.001]
  • [Cites] Blood. 2000 May 15;95(10):3204-7 [10807789.001]
  • [Cites] Blood. 1997 Feb 15;89(4):1413-20 [9028965.001]
  • [Cites] Blood. 2000 Feb 15;95(4):1406-12 [10666218.001]
  • [Cites] J Clin Pathol. 1996 Mar;49(3):205-7 [8675729.001]
  • [Cites] Blood. 1996 Jul 15;88(2):645-56 [8695812.001]
  • [Cites] Nat Rev Immunol. 2005 Mar;5(3):230-42 [15738953.001]
  • [Cites] Am J Hematol. 2004 Nov;77(3):291-5 [15495247.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2642-4 [12816858.001]
  • [Cites] Histopathology. 1997 Mar;30(3):256-9 [9088955.001]
  • [Cites] Blood. 2005 Feb 15;105(4):1660-8 [15479729.001]
  • [Cites] J Pathol. 2005 Jan;205(1):92-101 [15586381.001]
  • [Cites] J Am Coll Surg. 2004 Oct;199(4):654-5 [15454154.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2568-73 [12763927.001]
  • [Cites] Am J Surg Pathol. 2003 Nov;27(11):1473-6 [14576483.001]
  • [Cites] Am J Clin Pathol. 2004 Feb;121(2):254-63 [14983940.001]
  • [Cites] Hum Pathol. 2004 May;35(5):632-5 [15138941.001]
  • [Cites] J Cutan Pathol. 2005 Jan;32(1):35-9 [15660653.001]
  • [Cites] J Clin Pathol. 1994 May;47(5):418-22 [7517959.001]
  • [Cites] Nat Rev Cancer. 2004 Oct;4(10):757-68 [15510157.001]
  • [Cites] Am J Surg Pathol. 2002 Jun;26(6):724-32 [12023576.001]
  • [Cites] Am J Surg Pathol. 2004 Nov;28(11):1538-40; author reply 1540 [15489661.001]
  • [Cites] Mod Pathol. 1997 Sep;10(9):927-32 [9310957.001]
  • [Cites] Ann Oncol. 2004 Nov;15(11):1673-9 [15520070.001]
  • [Cites] Histopathology. 2005 Mar;46(3):241-55 [15720410.001]
  • [Cites] Pathol Res Pract. 1997;193(9):613-6 [9521019.001]
  • [Cites] Mod Pathol. 2003 Aug;16(8):828-32 [12920229.001]
  • [Cites] Leuk Lymphoma. 2004 Sep;45(9):1881-5 [15223650.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2510-8 [15572586.001]
  • [Cites] Leukemia. 2004 Jan;18(1):146-55 [14603341.001]
  • [Cites] Blood. 1997 Mar 1;89(5):1483-90 [9057627.001]
  • [Cites] Hum Pathol. 2004 Oct;35(10):1285-8 [15492998.001]
  • [Cites] Am J Surg Pathol. 2004 Sep;28(9):1251-2 [15316328.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3415-8 [12384445.001]
  • [Cites] J Virol. 2005 Jan;79(2):1296-307 [15613356.001]
  • [Cites] Blood. 2002 Apr 1;99(7):2331-6 [11895764.001]
  • [Cites] J Clin Pathol. 1997 Jun;50(6):485-9 [9378814.001]
  • [Cites] Histopathology. 2005 Mar;46(3):348-50 [15720425.001]
  • [Cites] Leukemia. 2005 May;19(5):851-5 [15744337.001]
  • [Cites] Br J Haematol. 2001 Mar;112(4):909-15 [11298585.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2638-41 [12750159.001]
  • [Cites] Histopathology. 2005 Jan;46(1):113-5 [15656898.001]
  • [Cites] Am J Surg Pathol. 2004 Nov;28(11):1401-16 [15489644.001]
  • [Cites] Blood. 2001 Apr 1;97(7):2130-6 [11264181.001]
  • [Cites] Blood. 2005 Apr 1;105(7):2812-20 [15576473.001]
  • (PMID = 16091196.001).
  • [ISSN] 1523-3790
  • [Journal-full-title] Current oncology reports
  • [ISO-abbreviation] Curr Oncol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD20
  • [Number-of-references] 50
  •  go-up   go-down


34. Fujiwara T, Ichinohasama R, Miura I, Sugawara T, Harigae H, Yokoyama H, Takahashi S, Tomiya Y, Yamada M, Ishizawa K, Kameoka J, Sasaki T: Primary effusion lymphoma of the pericardial cavity carrying t(1;22)(q21;q11) and t(14;17)(q32;q23). Cancer Genet Cytogenet; 2005 Jan 1;156(1):49-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a case of primary effusion lymphoma (PEL) in a 75-year-old woman without human immunodeficiency virus or hepatitis C virus, which presented as fever, chest pain, and pericardial effusion.
  • We did not detect C-MYC gene rearrangement or BCL-2 expression.
  • The present case demonstrated a rare category of PEL that is not associated with HHV-8 or C-MYC gene rearrangement.
  • [MeSH-major] Lymphoma, B-Cell / genetics. Pleural Effusion, Malignant / genetics. Translocation, Genetic


35. Mackinnon RN, Selan C, Wall M, Baker E, Nandurkar H, Campbell LJ: The paradox of 20q11.21 amplification in a subset of cases of myeloid malignancy with chromosome 20 deletion. Genes Chromosomes Cancer; 2010 Nov;49(11):998-1013
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The paradox of 20q11.21 amplification in a subset of cases of myeloid malignancy with chromosome 20 deletion.
  • Deletion of the long arm of one chromosome 20 (del(20q)) is a well-recognized abnormality in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) and is presumed to cause loss of a tumor suppressor gene at 20q12.
  • In a previously published series of MDS and AML cases, which had lost this region via unbalanced translocation, around 40% of cases were shown to have additional copies of the chromosome 20 abnormalities, with resulting gain or amplification of the retained parts of chromosome 20, most often 20q11.2.
  • The shortest amplified region of 250 kb in a series of five patients with three to ten copies of the 20q11.21 region contained the complete HCK, TM9SF4, PLAGL2, and POFUT1 genes.
  • By RT-PCR we have shown that there is correlation between amplification and increased expression of these four genes in most cases.
  • Localized and high level amplification of the common 250 kb region is evidence for activation of an oncogene in this region in these MDS and AML cases.
  • Cases with 20q11.21 amplification tended to have a high proportion of erythroblasts in the marrow, with two cases diagnosed as erythroleukemia (AML-M6).
  • Chromosome sub-band 20q11.21 amplification may therefore prove to be a marker of a specific subset of AML/MDS with a significant erythroid component.
  • [MeSH-major] Chromosome Deletion. Chromosomes, Human, Pair 20. Myelodysplastic Syndromes / genetics


36. Dăscălescu A, Zlei M, Grigore G, Dănăila C, Jitaru D, Carasevici E: [Prognostic significance of leukemia-associated phenotype in correlation with other biologic markers in acute myeloid leukemia patients]. Rev Med Chir Soc Med Nat Iasi; 2009 Oct-Dec;113(4):1176-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic significance of leukemia-associated phenotype in correlation with other biologic markers in acute myeloid leukemia patients].
  • Leukemic cells have unique aberrant phenotypes, which permit identification of this cells at diagnose and in evolution of the disease.
  • The main aim of the current study is to identify correlation between recognized prognostic factors in acute myeloid leukemia (AML) patients and other phenotypic markers.
  • MATERIAL AND METHOD: Imunophenotypic analysis (BDFACS CantoII, FACSDiva Software) was performed on peripheral blood/bone marrow aspirate samples of 56 patients diagnosed with AML (9 M0, 3 M1, 10 M2, 4 M3, 28 M4/M5, 1 M6, 1 M7) between 2007-2009 in Hematology Department of "Sf.
  • We used an extended panel of monoclonal antibodies and we determined the level of expression of cytokines receptors (IL3Ra, IL7R) and chemokines (CXCR4, CKR5).
  • RESULTS: In our study, IL7R expression on AML blasts was significant correlate with low WBC count at diagnosis (p = 0.04) and with multilinear displasia (p = 0.01), high CXCR4 expression was correlate (p = 0.05) with lack of response at first induction therapy and CD123 (IL3Ra) expression was correlate with M4 FAB phenotype.
  • Survival was negative influenced by presence of IL3R on AML blasts, but flt3 mutations, CXCR4, IL7R expression on leukemic cells, other phenotypic aberrancies did not influenced treatment response and survival in our patients population.
  • CONCLUSION: Complete investigation of leukemic cells phenotype extended with cytokines/chemokines receptors at diagnostic is useful for correct characterization of the disease, for discover new prognostic categories and for better identification of minimal residual disease.
  • [MeSH-major] Biomarkers, Tumor / blood. Leukemia, Myeloid, Acute / immunology. Receptors, Chemokine / blood. Receptors, Cytokine / blood
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Disease Progression. Female. Humans. Male. Middle Aged. Phenotype. Predictive Value of Tests. Prognosis. Receptors, CCR5 / blood. Receptors, CXCR4 / blood. Receptors, Interleukin-3 / blood. Receptors, Interleukin-7 / blood. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20191895.001).
  • [ISSN] 0048-7848
  • [Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
  • [ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, CCR5; 0 / Receptors, CXCR4; 0 / Receptors, Chemokine; 0 / Receptors, Cytokine; 0 / Receptors, Interleukin-3; 0 / Receptors, Interleukin-7
  •  go-up   go-down


37. Gannon AM, Turner EC, Reid HM, Kinsella BT: Regulated expression of the alpha isoform of the human thromboxane A2 receptor during megakaryocyte differentiation: a coordinated role for WT1, Egr1, and Sp1. J Mol Biol; 2009 Nov 20;394(1):29-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Phorbol 12-myristate 13-acetate (PMA) treatment substantially increased TPalpha mRNA and Prm1-directed gene expression in human erythroleukemia and K562 cells.
  • Moreover, PMA increased Egr1, but not WT1 or Sp1, expression while the NGFI-A-binding protein 1 co-repressor impaired PMA induction of Egr1- and Prm1-directed gene expression.
  • Chromatin immunoprecipitations established that WT1 is predominantly bound in vivo to the 5' Prm1 region in non-differentiated human erythroleukemia cells.
  • [MeSH-major] Cell Differentiation. Early Growth Response Protein 1 / metabolism. Gene Expression Regulation. Megakaryocytes / cytology. Receptors, Thromboxane A2, Prostaglandin H2 / genetics. Sp1 Transcription Factor / metabolism. WT1 Proteins / metabolism

  • Hazardous Substances Data Bank. 12-O-TETRADECANOYLPHORBOL-13-ACETATE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19747485.001).
  • [ISSN] 1089-8638
  • [Journal-full-title] Journal of molecular biology
  • [ISO-abbreviation] J. Mol. Biol.
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / EGR1 protein, human; 0 / Early Growth Response Protein 1; 0 / NAB1 protein, human; 0 / PRM1 protein, human; 0 / Protamines; 0 / Protein Isoforms; 0 / RNA, Messenger; 0 / Receptors, Thromboxane A2, Prostaglandin H2; 0 / Repressor Proteins; 0 / Sp1 Transcription Factor; 0 / WT1 Proteins; EC 1.13.12.- / Luciferases; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; NI40JAQ945 / Tetradecanoylphorbol Acetate
  •  go-up   go-down


38. Fasano WJ, Baer KN: The in vitro permeability coefficient and short-term absorption rates for vinyl toluene using human cadaver skin mounted in a static diffusion cell model. Drug Chem Toxicol; 2006 Jan;29(1):39-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of this study was to determine a permeability coefficient (Kp) and short-term absorption rate for vinyl toluene using human cadaver skin mounted in an in vitro static diffusion cell model with an exposure area of 0.64 cm2.
  • These data provide industrial hygienists and safety personnel values to estimate the amount of vinyl toluene that may be absorbed via the dermal exposure route, given a variety of exposure scenarios, and the time it takes (skin absorption time) to reach a body burden equal to the Occupational Safety and Health Administrative permissible exposure level (OSHA PEL) or ACGIH TLV.

  • Hazardous Substances Data Bank. VINYL TOLUENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16455589.001).
  • [ISSN] 0148-0545
  • [Journal-full-title] Drug and chemical toxicology
  • [ISO-abbreviation] Drug Chem Toxicol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Styrenes; 25013-15-4 / vinyltoluene
  •  go-up   go-down


39. Callera F, Mulin CC, Rosa ES, Melo DB, Melo CM: High prevalence of morphological subtype FAB M1 in adults with de novo acute myeloid leukemia in São José dos Campos, São Paulo. Sao Paulo Med J; 2006 Jan 5;124(1):45-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High prevalence of morphological subtype FAB M1 in adults with de novo acute myeloid leukemia in São José dos Campos, São Paulo.
  • CONTEXT AND OBJECTIVE: Geographical variations have been described in acute myelogenous leukemia (AML).
  • The aim of this study was to demonstrate the high prevalence of French-American-British (FAB) M1 subtype in adults with de novo AML in São José dos Campos, State of São Paulo, Brazil.
  • METHODS: Records from 39 consecutive adult patients with de novo AML referred to Hospital Pio XII between January 2002 and September 2004 were reviewed.
  • Peripheral blood and blood marrow smears were reviewed blindly by five hematologists and classified according to FAB criteria.
  • The rates of remission, relapse, mortality according treatment phase, survival and leukemia-free survival were calculated.
  • RESULTS: The prevalence of each category as determined via a consensus among five observers was M0: 0%; M1: 43.6%; M2: 30.7%; M3: 12.8%; M4: 5.1%; M5: 2.6%: M6: 2.6%; and M7: 2.6%.
  • The remission and the relapse rates were 82% and 41% respectively.
  • The mortality rate was 69% (induction of remission: 7/39, 17.9%; post induction: 10/32, 31.2%; and relapse: 10/16, 62.5%).
  • The survival rate was 30% and leukemia-free survival was 33%.
  • CONCLUSIONS: The study demonstrated a high prevalence of FAB M1 subtype in adults with de novo AML in São José dos Campos.
  • Our data suggest the occurrence of different regional prevalences of FAB AML categories in Brazil.
  • [MeSH-major] Leukemia, Myeloid, Acute / pathology

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16612463.001).
  • [ISSN] 1516-3180
  • [Journal-full-title] São Paulo medical journal = Revista paulista de medicina
  • [ISO-abbreviation] Sao Paulo Med J
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  •  go-up   go-down


40. Koca E, Haznedaroglu IC, Acar K, Beyazit Y, Aksu S, Misirlioglu M, Tuncer S, Sayinalp N, Ozcebe OI, Uner A: Renin-angiotensin system expression in the K562 human erythroleukaemic cell line. J Renin Angiotensin Aldosterone Syst; 2007 Sep;8(3):145-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, mRNA expressions of the major RAS components (ACE, renin, and angiotensinogen) in K562 human erythroleukaemia cell line have been searched by Real Time quantitative polymerase chain reaction.
  • K562 blasts are multipotential, haematopoietic malignant cells that spontaneously differentiate into recognisable progenitors of the erythrocyte, granulocyte and monocytic series.
  • Therefore, K562 human erythroleukaemia cell line may serve as an in vitro model to elucidate the role of RAS in leukaemia and to test the effects of RAS-affecting drugs on leukaemic cellular proliferation.
  • [MeSH-major] Angiotensinogen / genetics. Leukemia, Erythroblastic, Acute / metabolism. Peptidyl-Dipeptidase A / genetics. RNA, Messenger / analysis. Renin / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17907103.001).
  • [ISSN] 1470-3203
  • [Journal-full-title] Journal of the renin-angiotensin-aldosterone system : JRAAS
  • [ISO-abbreviation] J Renin Angiotensin Aldosterone Syst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; 11002-13-4 / Angiotensinogen; EC 3.4.15.1 / Peptidyl-Dipeptidase A; EC 3.4.23.15 / Renin
  •  go-up   go-down


41. Carbone A, Gloghini A: HHV-8-associated lymphoma: state-of-the-art review. Acta Haematol; 2007;117(3):129-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • During the first decade after the discovery of primary effusion lymphoma (PEL), sporadic and serial reports suggested that Kaposi-sarcoma-associated-herpesvirus/human-herpesvirus-8 (KSHV/HHV-8)-associated lymphomas in their liquid and solid presentation are clinically distinct, representing part of the spectrum of PEL.
  • In HIV-seropositive patients with serous effusions, these solid lymphomas were reported before the development of an effusion lymphoma and following resolution of PEL.

  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2007 S. Karger AG, Basel
  • (PMID = 17135725.001).
  • [ISSN] 1421-9662
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 27
  •  go-up   go-down


42. Gao N, Zhang Y, Mao JQ, Li GQ, Zhou W, Gao B, Gu J: [Effects of some traditional Chinese drugs on Mdr1 gene and its expression product in K562/A02 cells]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug;16(4):785-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effects of some traditional Chinese drugs on Mdr1 gene and its expression product in K562/A02 cells].
  • This study was purposed to investigate the effects of angelicasinensis (Oliv) Diel compound injection, vauqueline, ephedrine and strychnine on human erythroleukemia multidrug resistance (MDR) K562/A02 cell line Mdr1 gene and p-glycoprotein.
  • The MTT and trypan blue methods were used to analyze the cytotoxic effect of above-mentioned traditional Chinese drug; the expressions of K562/A02 cells Mdr1 gene and p-glycoprotein were detected by semi-quantitative reverse transcription polymerase chain reaction (RT-PCR) and Western blot respectively.
  • The results showed that after K562/A02 cell were treated with angelicasinensis (Oliv) diels compound injection, vauqueline and ephedrine, mRNA transcription of Mdr1 gene was reduced significantly (p < 0.01); the expression of P-gp also decreased (p < 0.01).
  • The expression level P-gp in group treated with vauqueline was the lowest, but the Mdr1 mRNA level and expression of P-gp of K562/A02 cells treated with strychnine did not obviously changed.
  • It is concluded that angelicasinensis (Oliv) diels compound injection, vauqueline, ephedrine can partly reverse the multidrug resistance of K562/A02 cells, the down-regulation of Mdr1 gene causing decrease of p-glycoprotein expression may be one of the MDR reversal mechanisms in K562/A02 cells.

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18718061.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal; 0 / P-Glycoprotein; 0 / RNA, Messenger; 80168379AG / Doxorubicin
  •  go-up   go-down


43. Manwani D, Galdass M, Bieker JJ: Altered regulation of beta-like globin genes by a redesigned erythroid transcription factor. Exp Hematol; 2007 Jan;35(1):39-47
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Altered regulation of beta-like globin genes by a redesigned erythroid transcription factor.
  • OBJECTIVE: Targeted regulation of beta-like globin genes was studied using designer zinc finger transcription factors containing the DNA binding domain of the red cell specific transcription factor erythroid Kruppel-like factor (EKLF) fused to repression domains.
  • METHODS: Globin gene expression was analyzed after introduction of the modified transcription factors into cell lines, embryonic stem cells and transgenic mice.
  • In murine erythroleukemia cells repression of the adult beta-globin gene was accompanied by a reactivation of the endogenous embryonic betaH1-globin gene.
  • Studies in differentiated embryonic stem cells and transgenic mice confirmed the reactivation of embryonic gene expression during development.
  • CONCLUSION: Our studies support a competition model for beta-globin gene expression and underscore the importance of EKLF in the embryonic/fetal-to-adult globin switch.
  • They also demonstrate the feasibility of designer zinc finger transcription factors in the study of transcriptional control mechanisms at the beta-globin locus and as potential gene therapy agents for sickle cell disease and related hemoglobinopathies.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Dev. 2004 Oct 15;18(20):2485-90 [15489291.001]
  • [Cites] Gene Ther. 2003 Mar;10(6):513-22 [12621455.001]
  • [Cites] Blood. 1988 Sep;72(3):1007-14 [2458145.001]
  • [Cites] Cell. 1988 Oct 7;55(1):17-26 [3167976.001]
  • [Cites] Blood. 1989 Feb;73(2):601-5 [2917193.001]
  • [Cites] J Cell Biol. 1989 Aug;109(2):833-41 [2668305.001]
  • [Cites] Nature. 1990 Mar 22;344(6264):309-13 [2314472.001]
  • [Cites] Genes Dev. 1990 Mar;4(3):380-9 [1692558.001]
  • [Cites] Br J Haematol. 1990 May;75(1):132-3 [2375912.001]
  • [Cites] Nature. 1991 Mar 21;350(6315):252-4 [1706482.001]
  • [Cites] Blood. 1991 May 1;77(9):2054-8 [2018842.001]
  • [Cites] EMBO J. 1991 Jun;10(6):1427-33 [1673924.001]
  • [Cites] Genes Dev. 1991 Aug;5(8):1387-94 [1714415.001]
  • [Cites] Mol Cell Biol. 1993 Jan;13(1):473-86 [8417345.001]
  • [Cites] Mol Cell Biol. 1993 May;13(5):2776-86 [7682653.001]
  • [Cites] EMBO J. 1993 Jul;12(7):2723-33 [8334991.001]
  • [Cites] Mol Cell Biol. 1993 Aug;13(8):4836-43 [8336720.001]
  • [Cites] J Biol Chem. 1994 Jan 14;269(2):1493-500 [8288615.001]
  • [Cites] Am J Hematol. 1994 Mar;45(3):265-7 [7507641.001]
  • [Cites] Genes Dev. 1994 May 15;8(10):1184-97 [7926723.001]
  • [Cites] Mol Cell Biol. 1995 Feb;15(2):852-60 [7823951.001]
  • [Cites] J Biol Chem. 1995 Jan 27;270(4):1955-9 [7829533.001]
  • [Cites] Nature. 1995 May 25;375(6529):316-8 [7753194.001]
  • [Cites] Nature. 1995 May 25;375(6529):318-22 [7753195.001]
  • [Cites] Dev Dyn. 1996 Jul;206(3):248-59 [8896981.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 29;93(22):12267-71 [8901569.001]
  • [Cites] Genes Dev. 1996 Nov 15;10(22):2894-902 [8918890.001]
  • [Cites] Cell. 1997 May 2;89(3):349-56 [9150134.001]
  • [Cites] Blood. 1997 Aug 1;90(3):1291-9 [9242564.001]
  • [Cites] Blood. 1998 Apr 1;91(7):2259-63 [9516123.001]
  • [Cites] Mol Cell Biol. 1998 Sep;18(9):5121-7 [9710596.001]
  • [Cites] Genes Dev. 1999 Jan 1;13(1):112-24 [9887104.001]
  • [Cites] Mol Pharmacol. 2004 Dec;66(6):1361-71 [15340042.001]
  • [Cites] J Biol Chem. 2005 Feb 4;280(5):3707-14 [15537646.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):11997-2002 [14514889.001]
  • [Cites] Stem Cells. 2003;21(6):632-7 [14595122.001]
  • [Cites] Methods Enzymol. 2003;365:39-59 [14696336.001]
  • [Cites] Blood. 2004 Jun 1;103(11):4078-83 [14764531.001]
  • [Cites] Genes Dev. 2004 Jun 15;18(12):1495-509 [15198986.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 22;102(47):17065-70 [16286657.001]
  • [Cites] Acc Chem Res. 2006 Jan;39(1):45-52 [16411739.001]
  • [Cites] Gene. 2006 Jan 17;366(1):27-38 [16298089.001]
  • [Cites] Blood Cells Mol Dis. 1999 Oct-Dec;25(5-6):299-304 [10744425.001]
  • [Cites] J Biol Chem. 2000 Sep 15;275(37):28549-54 [10878017.001]
  • [Cites] Cell. 1987 Dec 24;51(6):975-85 [3690667.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 21;97(24):13294-9 [11069298.001]
  • [Cites] J Biol Chem. 2001 Apr 6;276(14):11323-34 [11145970.001]
  • [Cites] Cell. 2002 Apr 5;109(1):29-37 [11955444.001]
  • [Cites] EMBO Rep. 2002 Jul;3(7):610-5 [12101091.001]
  • [Cites] Biochem Pharmacol. 2002 Sep;64(5-6):919-23 [12213587.001]
  • [Cites] Nat Genet. 2002 Dec;32(4):623-6 [12426570.001]
  • [Cites] Nat Med. 2002 Dec;8(12):1427-32 [12415262.001]
  • [Cites] Mol Cell. 2002 Dec;10(6):1453-65 [12504019.001]
  • [Cites] Nat Genet. 2003 Oct;35(2):190-4 [14517543.001]
  • (PMID = 17198872.001).
  • [ISSN] 0301-472X
  • [Journal-full-title] Experimental hematology
  • [ISO-abbreviation] Exp. Hematol.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / P60 HL28381; United States / NCI NIH HHS / CA / R24 CA088302; United States / NIDDK NIH HHS / DK / K08 DK002871; United States / NCI NIH HHS / CA / R24 CA88302; United States / NHLBI NIH HHS / HL / P60 HL028381
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Kruppel-Like Transcription Factors; 0 / Recombinant Fusion Proteins; 0 / Repressor Proteins; 9004-22-2 / Globins
  • [Other-IDs] NLM/ NIHMS16214; NLM/ PMC1892846
  •  go-up   go-down


44. Koumbi D, Clement JC, Sideratou Z, Yaouanc JJ, Loukopoulos D, Kollia P: Factors mediating lipofection potency of a series of cationic phosphonolipids in human cell lines. Biochim Biophys Acta; 2006 Aug;1760(8):1151-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors mediating lipofection potency of a series of cationic phosphonolipids in human cell lines.
  • A series of cationic liposomes known as cationic phosphonolipids (CPs) were evaluated as vehicles for in vitro gene transfer in K562 erythroleukemia cells and 5637 epithelial carcinoma cells.
  • For each CP and target cell type examined, detailed analyses were performed to determine optimal transfection conditions (lipid/ DNA (+/-) charge ratio, amount of complexed episomal DNA, liposomal and lipoplex size, complexation medium and duration of complex-cell exposure time).
  • Lipofection conditions were determined to be both cell- and lipid-type specific.
  • The lipid chemical composition had a strong impact upon lipofection efficiency; DOPE inclusion in the liposome formulations was found to affect the levels of transgene expression in a cell-dependent way.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16730412.001).
  • [ISSN] 0006-3002
  • [Journal-full-title] Biochimica et biophysica acta
  • [ISO-abbreviation] Biochim. Biophys. Acta
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cations; 0 / Phospholipids; 0 / phosphonolipids
  •  go-up   go-down


45. Coulon S, Vandekerckhove J, Dussiot M, Callens C, Suarez F, Kersual J, Asnafi V, Belaid Z, Courtois G, Giraudier S, Dubreuil P, Lepelletier Y, Moura IC, Hermine O: Human erythroleukemia: is the two-hit model of mouse leukemogenesis valid in human disease? Leukemia; 2007 Oct;21(10):2212-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human erythroleukemia: is the two-hit model of mouse leukemogenesis valid in human disease?
  • [MeSH-major] Leukemia / etiology. Leukemia / genetics. Leukemia / therapy. Leukemia, Erythroblastic, Acute / etiology
  • [MeSH-minor] Animals. Apoptosis. Cell Lineage. Cell Proliferation. Cell Transformation, Neoplastic. Chromosome Aberrations. Disease Models, Animal. Humans. Immunophenotyping. Karyotyping. Mice. Mice, Transgenic

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17541393.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


51. Shim HW, Lee JH, Hwang TS, Rhee YW, Bae YM, Choi JS, Han J, Lee CS: Patterning of proteins and cells on functionalized surfaces prepared by polyelectrolyte multilayers and micromolding in capillaries. Biosens Bioelectron; 2007 Jun 15;22(12):3188-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The second region was the polyelectrolyte (PEL) coated surface that promoted protein and cell immobilization.
  • The difference in surface functionality between the PEL region and background PEG microstructures resulted in simple patterning of biomolecules.
  • Fluorescein isothiocyanate-tagged bovine serum albumin, E. coli expressing green fluorescence protein (GFP), and fibroblast cells were successfully bound to the exposed PEL surfaces at micron scale.
  • Compared with the simple adsorption of protein, fluorescence intensity was dramatically improved (by about six-fold) on the PEL-modified surfaces.
  • Although animal cell patterning is prerequisite for adhesive protein layer to survive on desired area, the PEL surface without adhesive proteins provides affordable microenvironment for cells.

  • Hazardous Substances Data Bank. POLYDIMETHYLSILOXANES .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17400439.001).
  • [ISSN] 0956-5663
  • [Journal-full-title] Biosensors & bioelectronics
  • [ISO-abbreviation] Biosens Bioelectron
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Dimethylpolysiloxanes; 0 / Electrolytes; 0 / Proteins; 0 / Silicones; 30IQX730WE / Polyethylene Glycols; 63148-62-9 / baysilon
  •  go-up   go-down


52. Salter WB, Kinney K, Wallace WH, Lumley AE, Heimbuch BK, Wander JD: Analysis of residual chemicals on filtering facepiece respirators after decontamination. J Occup Environ Hyg; 2010 Aug;7(8):437-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Measured amounts of decontaminants retained by the FFRs treated with chemical disinfectants were small enough that exposure to wearers will be below the permissible exposure limit (PEL).

  • Hazardous Substances Data Bank. SODIUM HYPOCHLORITE .
  • Hazardous Substances Data Bank. HYDROGEN PEROXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20526947.001).
  • [ISSN] 1545-9632
  • [Journal-full-title] Journal of occupational and environmental hygiene
  • [ISO-abbreviation] J Occup Environ Hyg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Epoxy Compounds; 0 / Oxidants; 74087-85-7 / dimethyldioxirane; BBX060AN9V / Hydrogen Peroxide; DY38VHM5OD / Sodium Hypochlorite
  •  go-up   go-down


53. Alarcon F, Bonaïti-Pellié C, Harari-Kermadec H: A nonparametric method for penetrance function estimation. Genet Epidemiol; 2009 Jan;33(1):38-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In diseases caused by a deleterious gene mutation, knowledge of age-specific cumulative risks is necessary for medical management of mutation carriers.
  • When pedigrees are ascertained through at least one affected individual, ascertainment bias can be corrected by using a parametric method such as the Proband's phenotype Exclusion Likelihood, or PEL, that uses a survival analysis approach based on the Weibull model.
  • IDEAL is compared with PEL, using family samples simulated from a Weibull distribution and under alternative models.
  • We show that, under Weibull assumption and asymptotic conditions, IDEAL and PEL both provide unbiased risk estimates.
  • However, when the true risk function deviates from a Weibull distribution, we show that the PEL might provide biased estimates while IDEAL remains unbiased.

  • HAL archives ouvertes. Full text from .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18618769.001).
  • [ISSN] 0741-0395
  • [Journal-full-title] Genetic epidemiology
  • [ISO-abbreviation] Genet. Epidemiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Lee VT, Matewish JM, Kessler JL, Hyodo M, Hayakawa Y, Lory S: A cyclic-di-GMP receptor required for bacterial exopolysaccharide production. Mol Microbiol; 2007 Sep;65(6):1474-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A cyclic-di-GMP receptor required for bacterial exopolysaccharide production.
  • Bis-(3',5')-cyclic-dimeric-guanosine monophosphate (c-di-GMP) has been shown to be a global regulatory molecule that modulates the reciprocal responses of bacteria to activate either virulence pathways or biofilm formation.
  • The mechanism of c-di-GMP signal transduction, including recognition of c-di-GMP and subsequent phenotypic regulation, remain largely uncharacterized.
  • The key components of these regulatory pathways are the various adaptor proteins (c-di-GMP receptors).
  • There is compelling evidence suggesting that, in addition to PilZ domains, there are other unidentified c-di-GMP receptors.
  • Here we show that the PelD protein of Pseudomonas aeruginosa is a novel c-di-GMP receptor that mediates c-di-GMP regulation of PEL polysaccharide biosynthesis.
  • Analysis of PelD orthologues identified a number of conserved residues that are required for c-di-GMP binding as well as synthesis of the PEL polysaccharide.
  • Secondary structure similarities of PelD to the inhibitory site of diguanylate cyclase suggest that a common fold can act as a platform to bind c-di-GMP.
  • The combination of a c-di-GMP binding site with a variety of output signalling motifs within one protein domain provides an explanation for the specificity for different cellular responses to this regulatory dinucleotide.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Mol Biol. 2000 Jun 2;299(2):499-520 [10860755.001]
  • [Cites] Curr Opin Microbiol. 2006 Apr;9(2):218-28 [16530465.001]
  • [Cites] Mol Microbiol. 2003 Oct;50(1):15-27 [14507360.001]
  • [Cites] Mol Microbiol. 2004 Feb;51(3):675-90 [14731271.001]
  • [Cites] Curr Opin Microbiol. 2004 Apr;7(2):185-91 [15063857.001]
  • [Cites] Genes Dev. 2004 Mar 15;18(6):715-27 [15075296.001]
  • [Cites] Nucleic Acids Res. 2004 Jul 1;32(Web Server issue):W321-6 [15215403.001]
  • [Cites] J Bacteriol. 2004 Jul;186(14):4449-56 [15231776.001]
  • [Cites] J Bacteriol. 2004 Jul;186(14):4457-65 [15231777.001]
  • [Cites] J Bacteriol. 2004 Jul;186(14):4466-75 [15231778.001]
  • [Cites] Microbiology. 2004 Aug;150(Pt 8):2497-502 [15289546.001]
  • [Cites] Mol Microbiol. 2004 Aug;53(4):1123-34 [15306016.001]
  • [Cites] Mol Microbiol. 2004 Oct;54(1):75-88 [15458406.001]
  • [Cites] Mol Microbiol. 2004 Oct;54(1):264-77 [15458421.001]
  • [Cites] Gene. 1986;48(1):119-31 [3549457.001]
  • [Cites] J Biol Chem. 1990 Nov 5;265(31):18933-43 [2172238.001]
  • [Cites] Mol Microbiol. 2006 May;60(3):602-16 [16629664.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2839-44 [16477007.001]
  • [Cites] Genetics. 2006 Jun;173(2):515-26 [16624907.001]
  • [Cites] J Biol Chem. 2006 Oct 13;281(41):30310-4 [16920715.001]
  • [Cites] J Biol Chem. 2006 Oct 20;281(42):32015-24 [16923812.001]
  • [Cites] Proteins. 2007 Feb 1;66(2):266-71 [17096419.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4112-7 [17360486.001]
  • [Cites] Microbiology. 2007 Apr;153(Pt 4):980-94 [17379708.001]
  • [Cites] J Biol Chem. 2007 Apr 27;282(17):12860-70 [17307739.001]
  • [Cites] Mol Microbiol. 2007 Aug;65(4):876-95 [17645452.001]
  • [Cites] Nature. 1987 Jan 15-21;325(6101):279-81 [18990795.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Apr 15;88(8):3281-5 [1901657.001]
  • [Cites] Science. 1995 Jun 30;268(5219):1899-902 [7604262.001]
  • [Cites] Gene. 1997 Feb 20;186(1):29-35 [9047341.001]
  • [Cites] FEBS Lett. 1997 Oct 20;416(2):207-11 [9369216.001]
  • [Cites] Gene. 1998 May 28;212(1):77-86 [9661666.001]
  • [Cites] Dev Cell. 2004 Nov;7(5):745-54 [15525535.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Dec 7;101(49):17084-9 [15569936.001]
  • [Cites] Genome Res. 2005 Feb;15(2):321-9 [15687295.001]
  • [Cites] Microbiology. 2005 Mar;151(Pt 3):985-97 [15758243.001]
  • [Cites] FEMS Microbiol Lett. 2005 Jun 15;247(2):123-30 [15935569.001]
  • [Cites] Cell Mol Life Sci. 2005 Jun;62(11):1234-46 [15818467.001]
  • [Cites] J Bacteriol. 2005 Jul;187(14):4774-81 [15995192.001]
  • [Cites] Mol Microbiol. 2005 Aug;57(3):629-39 [16045609.001]
  • [Cites] Infect Immun. 2005 Sep;73(9):5873-82 [16113306.001]
  • [Cites] Nature. 2005 Aug 25;436(7054):1171-5 [16121184.001]
  • [Cites] J Bacteriol. 2005 Oct;187(19):6816-23 [16166544.001]
  • [Cites] J Biol Chem. 2005 Sep 30;280(39):33324-30 [16081414.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 4;102(40):14422-7 [16186483.001]
  • [Cites] Bioinformatics. 2006 Jan 1;22(1):3-6 [16249258.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jan 3;103(1):171-6 [16373506.001]
  • [Cites] FEMS Microbiol Lett. 2001 Sep 11;203(1):11-21 [11557134.001]
  • (PMID = 17824927.001).
  • [ISSN] 0950-382X
  • [Journal-full-title] Molecular microbiology
  • [ISO-abbreviation] Mol. Microbiol.
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / R37 AI021451
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / Carrier Proteins; 0 / Escherichia coli Proteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / Polysaccharides, Bacterial; 0 / RetS protein, Pseudomonas aeruginosa; 0 / cyclic GMP-binding protein; 128531-82-8 / exopolysaccharide, Pseudomonas; EC 4.6.- / Phosphorus-Oxygen Lyases; EC 4.6.1.- / diguanylate cyclase
  • [Other-IDs] NLM/ PMC2170427
  •  go-up   go-down


55. Gwin KK, Wallingford KM, Morata TC, Van Campen LE, Dallaire J, Alvarez FJ: Ototoxic occupational exposures for a stock car racing team: II. chemical surveys. J Occup Environ Hyg; 2005 Aug;2(8):406-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The National Institute for Occupational Safety and Health (NIOSH) conducted a series of surveys to evaluate occupational exposure to noise and potentially ototoxic chemical agents among members of a professional stock car racing team.
  • Exposure assessments included site visits to the team's race shop and a worst-case scenario racetrack.
  • Exposures to these chemicals were all below their corresponding Occupational Safety and Health Administration (OSHA) permissible exposure limits (PELs), NIOSH recommended exposure limits (RELs), and American Conference of Governmental Industrial Hygienists (ACGIH) threshold limit values (TLVs).
  • Twenty-five percent of the CO time-weighted average concentrations exceeded the OSHA PEL, NIOSH REL, and ACGIH TLV after being adjusted for a 10-hour workday.
  • Peak CO measurements exceeded the NIOSH recommended ceiling limit of 200 ppm.
  • Based on these data, exposures to potentially ototoxic chemicals are probably not high enough to produce an adverse effect greater than that produced by the high sound pressure levels alone.
  • However, carbon monoxide levels occasionally exceeded all evaluation criteria at the racetrack.
  • [MeSH-major] Air Pollution / analysis. Automobiles. Hearing Disorders / chemically induced. Occupational Exposure / analysis. Vehicle Emissions / analysis. Vehicle Emissions / toxicity
  • [MeSH-minor] Carbon Monoxide / analysis. Environmental Monitoring / methods. Humans. Solvents / analysis. Threshold Limit Values

  • MedlinePlus Health Information. consumer health - Air Pollution.
  • MedlinePlus Health Information. consumer health - Hearing Disorders and Deafness.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • Hazardous Substances Data Bank. Carbon monoxide .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16009649.001).
  • [ISSN] 1545-9624
  • [Journal-full-title] Journal of occupational and environmental hygiene
  • [ISO-abbreviation] J Occup Environ Hyg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Solvents; 0 / Vehicle Emissions; 7U1EE4V452 / Carbon Monoxide
  •  go-up   go-down


56. Ichikawa S, Otawa M, Teishikata Y, Yamada K, Fujimuro M, Yokosawa H, Matsuda A: 9-(2-C-Cyano-2-deoxy-beta-D-arabino-pentofuranosyl)guanine, a potential antitumor agent against B-lymphoma infected with Kaposi's sarcoma-associated herpesvirus. Nucleic Acids Symp Ser (Oxf); 2009;(53):95-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Several 9-(2-C-cyano-2-deoxy-l-beta-D-arabino-pentofuranosyl)purine derivatives were tested against Kaposi's sarcoma-associated herpesvirus (KSHV)-infected primary effusion lymphoma (PEL) cells.
  • Therefore, it was found that compounds 2, 3, 4 and 5 showed selective cytotoxicity against PEL cells infected with KSHV.

  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19749277.001).
  • [ISSN] 1746-8272
  • [Journal-full-title] Nucleic acids symposium series (2004)
  • [ISO-abbreviation] Nucleic Acids Symp Ser (Oxf)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 9-(2-C-cyano-2-deoxy-arabino-pentofuranosyl)guanine; 0 / Antimetabolites, Antineoplastic; 0 / Arabinonucleosides; 12133JR80S / Guanosine
  •  go-up   go-down


57. Bubman D, Guasparri I, Cesarman E: Deregulation of c-Myc in primary effusion lymphoma by Kaposi's sarcoma herpesvirus latency-associated nuclear antigen. Oncogene; 2007 Jul 26;26(34):4979-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary effusion lymphoma (PEL) is a rare subtype of non-Hodgkin's lymphoma, which is associated with infection by Kaposi's sarcoma herpesvirus (KSHV)/human herpesvirus-8.
  • However, no structural abnormalities were found in the c-myc oncogene in PEL.
  • Given that c-Myc is often involved in lymphomagenesis, we hypothesized that it is deregulated in PEL.
  • We report that PEL cells have abnormally stable c-Myc protein.
  • Our data show that the impaired c-Myc degradation in PEL cells is associated with a significant underphosphorylation of c-Myc T58.
  • Conversely, when LANA is eliminated from PEL cells using RNA interference, GSK-3beta-mediated c-Myc T58 phosphorylation is restored.
  • The presence of c-Myc and LANA in GSK-3beta-containing complexes in PEL cells further confirms the significance of these interactions in naturally KSHV-infected cells.
  • [MeSH-minor] B-Lymphocytes / metabolism. B-Lymphocytes / virology. Cell Line. Glycogen Synthase Kinase 3 / metabolism. Humans. RNA Interference. Threonine / metabolism


58. Ruozi B, Riva G, Belletti D, Tosi G, Forni F, Mucci A, Barozzi P, Luppi M, Vandelli MA: Cidofovir-loaded liposomes: an intro-study using BCBL-1 cell line as a model for primary effusion lymphoma. Eur J Pharm Sci; 2010 Oct 9;41(2):254-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cidofovir (HPMPC) was recently reported to exert a valuable antineoplastic activity against primary effusion lymphoma (PEL), a B-cell neoplasm associated with Human Herpesvirus-8 (HHV-8) infection.
  • In this study, we developed and characterized liposomes encapsulating HPMPC to increase drug efficacy reducing the administered dose and the related toxicity, which actually hamper its clinical therapeutic use in patients affected with PEL.
  • Using an in vitro model of PEL (BCBL-1 cell line), the carrier toxicity and the antineoplastic efficacy of liposomes were evaluated by flow cytometry applying apoptosis and cell death analysis.

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. CIDOFOVIR .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20600876.001).
  • [ISSN] 1879-0720
  • [Journal-full-title] European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
  • [ISO-abbreviation] Eur J Pharm Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Liposomes; 0 / Organophosphonates; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down


59. Shim HW, Lee JH, Kim BY, Son YA, Lee CS: Facile preparation of biopatternable surface for selective immobilization from bacteria to mammalian cells. J Nanosci Nanotechnol; 2009 Feb;9(2):1204-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A facile route for cell patterning on functionalized surface with polyelectrolyte (PEL) and polyethylene glycol (PEG) microstructures is presented.
  • Controlled cell adhesion is achieved by a micromolding in capillaries (MIMIC) on PEL coated surface, which produced two orthogonal regions including PEG region as physical and biological barriers to the nonspecific binding of cells and PEL surface for promoting cell adhesion.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19441488.001).
  • [ISSN] 1533-4880
  • [Journal-full-title] Journal of nanoscience and nanotechnology
  • [ISO-abbreviation] J Nanosci Nanotechnol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


60. Xia T, O'Hara A, Araujo I, Barreto J, Carvalho E, Sapucaia JB, Ramos JC, Luz E, Pedroso C, Manrique M, Toomey NL, Brites C, Dittmer DP, Harrington WJ Jr: EBV microRNAs in primary lymphomas and targeting of CXCL-11 by ebv-mir-BHRF1-3. Cancer Res; 2008 Mar 1;68(5):1436-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We analyzed five primary "endemic" pediatric Burkitt's lymphomas (BL), two acquired immunodeficiency syndrome (AIDS)-related type I latency BL lines, a type III latency line, three EBV(+) primary effusion lymphomas (PEL), and three AIDS-related diffuse large B-cell lymphomas (DLBCL) for expression of EBV-encoded miRNAs.
  • A markedly elevated expression of miRNA BHRF1-3 in type III relative to its parental type I BL line was found.
  • Primary unmanipulated type I BLs and EBV(+) PELs expressed high levels of BART2 miRNA, whereas DLBCLs expressed both BART2 and BHRF1-3 species.
  • BHRF1-3 miRNA expression inversely correlated with levels of a putative cellular target, the IFN-inducible T-cell attracting chemokine CXCL-11/I-TAC, and suppression of this factor was reversed by transfection of an antisense oligo to the EBV miRNA BHRF1-3.

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Annu Rev Microbiol. 2000;54:19-48 [11018123.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16164-9 [17911266.001]
  • [Cites] Nat Med. 2002 Oct;8(10):1098-104 [12219084.001]
  • [Cites] J Gen Virol. 2003 Apr;84(Pt 4):949-57 [12655096.001]
  • [Cites] Nucleic Acids Res. 2004;32(4):e43 [14985473.001]
  • [Cites] Science. 2004 Apr 30;304(5671):734-6 [15118162.001]
  • [Cites] Virology. 2004 May 20;323(1):141-52 [15165826.001]
  • [Cites] J Biol Chem. 2004 Jul 16;279(29):30219-27 [15150261.001]
  • [Cites] RNA. 2004 Aug;10(8):1165-73 [15272116.001]
  • [Cites] Methods Mol Biol. 2005;292:449-80 [15507725.001]
  • [Cites] J Virol. 1990 May;64(5):2309-18 [2157887.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Sep 1;89(17):8058-62 [1325642.001]
  • [Cites] J Virol. 1993 Jun;67(6):3182-90 [8388496.001]
  • [Cites] J Virol. 1995 Feb;69(2):1132-41 [7815492.001]
  • [Cites] Blood. 1995 Jul 15;86(2):659-65 [7605996.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1493-501 [7632957.001]
  • [Cites] Blood. 1995 Oct 1;86(7):2708-14 [7670109.001]
  • [Cites] Blood. 1996 Jun 15;87(12):5279-86 [8652843.001]
  • [Cites] Hum Pathol. 1997 Dec;28(12):1408-14 [9416698.001]
  • [Cites] Science. 1998 Apr 10;280(5361):248-53 [9535648.001]
  • [Cites] J Exp Med. 1998 Jun 15;187(12):2009-21 [9625760.001]
  • [Cites] Nucleic Acids Res. 2005;33(4):1290-7 [15741182.001]
  • [Cites] Science. 2005 Apr 22;308(5721):557-60 [15845854.001]
  • [Cites] Nature. 2005 Jun 2;435(7042):682-6 [15931223.001]
  • [Cites] Blood. 2005 Jul 1;106(1):235-40 [15790788.001]
  • [Cites] J Immunother. 2005 Jul-Aug;28(4):343-51 [16000952.001]
  • [Cites] Science. 2005 Sep 2;309(5740):1519-24 [16141061.001]
  • [Cites] Development. 2005 Nov;132(21):4645-52 [16224044.001]
  • [Cites] Nucleic Acids Res. 2005;33(21):e182 [16314296.001]
  • [Cites] Blood. 2006 Jan 1;107(1):13-20 [16099881.001]
  • [Cites] Mamm Genome. 2006 Mar;17(3):189-202 [16518686.001]
  • [Cites] Curr Opin Genet Dev. 2006 Apr;16(2):203-8 [16503132.001]
  • [Cites] Vaccine. 2006 Apr 5;24(15):2966-74 [16503368.001]
  • [Cites] RNA. 2006 May;12(5):733-50 [16540699.001]
  • [Cites] PLoS Pathog. 2006 Mar;2(3):e23 [16557291.001]
  • [Cites] PLoS Pathog. 2007 May 11;3(5):e65 [17500590.001]
  • [Cites] J Virol. 2007 Sep;81(18):9967-75 [17626073.001]
  • [Cites] Int J Cancer. 2002 Jun 10;99(5):635-43 [12115495.001]
  • (PMID = 18316607.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA070058; United States / NCI NIH HHS / CA / R01 CA109232; United States / NIDCR NIH HHS / DE / DE018304; United States / NIDCR NIH HHS / DE / R01 DE018304-02; United States / NCI NIH HHS / CA / CA082274; United States / NIDCR NIH HHS / DE / DE018304-01; United States / NIDCR NIH HHS / DE / R01 DE018304; United States / NIDCR NIH HHS / DE / R01 DE018304-01; United States / NCI NIH HHS / CA / CA70058; United States / NCI NIH HHS / CA / CA109232; United States / NCI NIH HHS / CA / CA121935; United States / NIDCR NIH HHS / DE / R01 DE018304-03; United States / NIDCR NIH HHS / DE / DE018304-02; United States / NCI NIH HHS / CA / R01 CA082274; United States / NCI NIH HHS / CA / R01 CA121935; United States / NIDCR NIH HHS / DE / DE018304-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BHRF1 protein, Human herpesvirus 4; 0 / CXCL11 protein, human; 0 / Chemokine CXCL11; 0 / MicroRNAs; 0 / Oligonucleotides, Antisense; 0 / Viral Proteins; EC 3.1.- / Ribonucleases
  • [Other-IDs] NLM/ NIHMS191351; NLM/ PMC2855641
  •  go-up   go-down


61. Llama-Palacios A, López-Solanilla E, Rodríguez-Palenzuela P: Role of the PhoP-PhoQ system in the virulence of Erwinia chrysanthemi strain 3937: involvement in sensitivity to plant antimicrobial peptides, survival at acid Hh, and regulation of pectolytic enzymes. J Bacteriol; 2005 Mar;187(6):2157-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this work, we have isolated and characterized the phoP and phoQ mutants of E. chrysanthemi strain 3937.
  • (v) in planta Pel activity of both mutant strains was drastically reduced; and (vi) both mutants lagged behind the wild type in their capacity to change the apoplastic pH.

  • Hazardous Substances Data Bank. PECTIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Microbiol. 2001 Mar;39(5):1345-55 [11251849.001]
  • [Cites] FEMS Microbiol Lett. 1997 Feb 15;147(2):173-80 [9119190.001]
  • [Cites] J Bacteriol. 2003 Jul;185(13):3696-702 [12813061.001]
  • [Cites] Mol Microbiol. 2003 Jul;49(2):347-57 [12828634.001]
  • [Cites] Nucleic Acids Res. 1997 Sep 1;25(17):3389-402 [9254694.001]
  • [Cites] J Bacteriol. 1998 May;180(9):2409-17 [9573193.001]
  • [Cites] Mol Microbiol. 1998 Apr;28(2):217-26 [9622348.001]
  • [Cites] Mol Plant Microbe Interact. 2000 Apr;13(4):421-9 [10755305.001]
  • [Cites] Infect Immun. 2000 Jun;68(6):3419-25 [10816493.001]
  • [Cites] Mol Plant Microbe Interact. 2000 Aug;13(8):882-6 [10939260.001]
  • [Cites] Plant Cell. 1998 Jun;10(6):917-24 [9634580.001]
  • [Cites] Biopolymers. 1998;47(6):479-91 [10333739.001]
  • [Cites] J Bacteriol. 1999 Jun;181(11):3525-35 [10348866.001]
  • [Cites] J Lab Clin Med. 1954 Aug;44(2):301-7 [13184240.001]
  • [Cites] J Biol Chem. 1956 Jan;218(1):97-106 [13278318.001]
  • [Cites] Biochim Biophys Acta. 1960 Mar 11;38:460-9 [13838951.001]
  • [Cites] J Bacteriol. 1990 Feb;172(2):771-8 [2404956.001]
  • [Cites] J Bacteriol. 1982 Apr;150(1):122-31 [6277860.001]
  • [Cites] J Mol Biol. 1983 Jun 5;166(4):557-80 [6345791.001]
  • [Cites] J Bacteriol. 1984 Sep;159(3):825-31 [6090392.001]
  • [Cites] J Bacteriol. 1985 Oct;164(1):51-6 [2995324.001]
  • [Cites] Vet Rec. 1988 Oct 15;123(16):416-21 [3201669.001]
  • [Cites] Science. 1989 Feb 24;243(4894 Pt 1):1059-62 [2646710.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Jul;86(13):5054-8 [2544889.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Sep;86(18):7077-81 [2674945.001]
  • [Cites] J Appl Bacteriol. 1991 Feb;70(2):161-5 [1902205.001]
  • [Cites] Mol Microbiol. 1992 Aug;6(16):2363-76 [1406275.001]
  • [Cites] Mol Plant Microbe Interact. 1994 Sep-Oct;7(5):573-81 [7949326.001]
  • [Cites] Res Microbiol. 1994 Jun-Aug;145(5-6):473-80 [7855434.001]
  • [Cites] Annu Rev Microbiol. 1995;49:145-74 [8561457.001]
  • [Cites] Cell. 1996 Jan 12;84(1):165-74 [8548821.001]
  • [Cites] Infect Immun. 1996 Apr;64(4):1085-92 [8606063.001]
  • [Cites] Microbiology. 1996 Nov;142 ( Pt 11):3195-200 [8969516.001]
  • [Cites] Microbes Infect. 2001 Nov-Dec;3(14-15):1327-34 [11755422.001]
  • (PMID = 15743964.001).
  • [ISSN] 0021-9193
  • [Journal-full-title] Journal of bacteriology
  • [ISO-abbreviation] J. Bacteriol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Acids; 0 / Antimicrobial Cationic Peptides; 0 / Bacterial Proteins; 0 / Culture Media; 0 / Fatty Acids, Volatile; 0 / Pectins; 0 / PhoQ protein, Bacteria; 0 / Plant Proteins; 125360-99-8 / PhoP protein, Bacteria; 9000-69-5 / pectin
  • [Other-IDs] NLM/ PMC1064042
  •  go-up   go-down


62. Berakis M: Case study: working safely with beryllium oxide. Occup Health Saf; 2009 May;78(5):34, 36, 38 passim
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At the facility studied, only two air samples out of 110 were above the detection limit, and none was close to the California PEL.
  • Even though we found no beryllium levels close to the PEL, the facility could still easily make a number of changes that would add extra assurance it is not likely to find measurable levels in the future.
  • [MeSH-minor] Humans. Maximum Allowable Concentration. Occupational Exposure

  • Hazardous Substances Data Bank. BERYLLIUM OXIDE .
  • Hazardous Substances Data Bank. BERYLLIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19480368.001).
  • [ISSN] 0362-4064
  • [Journal-full-title] Occupational health & safety (Waco, Tex.)
  • [ISO-abbreviation] Occup Health Saf
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Air Pollutants, Occupational; 2S8NLR37S3 / beryllium oxide; OW5102UV6N / Beryllium
  •  go-up   go-down


63. Ehrlich K, Viirlaid S, Mahlapuu R, Saar K, Kullisaar T, Zilmer M, Langel U, Soomets U: Design, synthesis and properties of novel powerful antioxidants, glutathione analogues. Free Radic Res; 2007 Jul;41(7):779-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we report the design and synthesis of a library of tetrapeptidic GSH analogues called UPF peptides.
  • We also found that UPF peptides do not influence the viability and membrane integrity of K562 human erythroleukemia cells even at 200 microM concentration.
  • The results, together with an earlier finding that UPF1 showed protective effects in global cerebral ischemia model in rats, suggest that UPF peptides might serve both as potent antioxidants as well as leads for design of powerful non-peptidic antioxidants that correct oxidative stress-driven events.

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17577738.001).
  • [ISSN] 1071-5762
  • [Journal-full-title] Free radical research
  • [ISO-abbreviation] Free Radic. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Biphenyl Compounds; 0 / Free Radical Scavengers; 0 / Hydrazines; 0 / Picrates; 1898-66-4 / 2,2-diphenyl-1-picrylhydrazyl; 3352-57-6 / Hydroxyl Radical; GAN16C9B8O / Glutathione
  •  go-up   go-down


64. Al-Dasooqi N, Gibson R, Bowen J, Keefe D: HER2 targeted therapies for cancer and the gastrointestinal tract. Curr Drug Targets; 2009 Jun;10(6):537-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HER2 (v-erb-b2 erythroblastic leukemia viral oncogene) is a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases.
  • Since the discovery of a role for HER2 and other EGF receptors in the development and progression of cancer, they have become targets for a number of targeted anti-cancer drugs.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19519356.001).
  • [ISSN] 1873-5592
  • [Journal-full-title] Current drug targets
  • [ISO-abbreviation] Curr Drug Targets
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / Protein Kinase Inhibitors; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  • [Number-of-references] 65
  •  go-up   go-down


65. Barnache S, Le Scolan E, Kosmider O, Denis N, Moreau-Gachelin F: Phosphatidylinositol 4-phosphatase type II is an erythropoietin-responsive gene. Oncogene; 2006 Mar 2;25(9):1420-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phosphatidylinositol 4-phosphatase type II is an erythropoietin-responsive gene.
  • The erythroleukemia developed by spi-1/PU.1 transgenic mice is a multistep process.
  • At disease onset, preleukemic cells are arrested in differentiation at the proerythroblast stage (HS1 stage) and their survival and growth are under the tight control of erythropoietin (Epo).
  • During disease progression, malignant proerythroblasts characterized by Epo autonomous growth and in vivo tumorigenicity can be isolated (HS2 stage).
  • During analysis of transcriptional profiling representive of discrete stages of leukemic progression, we found that the phosphatidylinositol 4-phosphatase type II gene was turned off in malignant cells.
  • Using malignant cells engineered to stably express PI-4-phosphatase II, we showed that PI-4-phosphatase II reduced Akt activation level.
  • Moreover, stimulation of malignant cells with Epo-induced PI-4-phosphatase II transcription pointing this gene as an Epo-responsive gene.
  • [MeSH-major] Erythropoietin / physiology. Gene Expression Regulation, Neoplastic. Leukemia, Erythroblastic, Acute / genetics. Leukemia, Erythroblastic, Acute / physiopathology. Phosphoric Monoester Hydrolases / biosynthesis. Phosphoric Monoester Hydrolases / genetics
  • [MeSH-minor] Animals. Blotting, Northern. Cell Differentiation. Cell Survival. Cell Transformation, Neoplastic. Erythroblasts. Gene Expression Profiling. Mice. Mice, Transgenic. Oncogene Protein v-akt / physiology. Phosphatidylinositol 3-Kinases / physiology. Reverse Transcriptase Polymerase Chain Reaction. Signal Transduction. Transcription, Genetic. Tumor Cells, Cultured


66. Lo RK, Liu AM, Wise H, Wong YH: Prostacyclin receptor-induced STAT3 phosphorylation in human erythroleukemia cells is mediated via Galpha(s) and Galpha(16) hybrid signaling. Cell Signal; 2008 Nov;20(11):2095-106
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostacyclin receptor-induced STAT3 phosphorylation in human erythroleukemia cells is mediated via Galpha(s) and Galpha(16) hybrid signaling.
  • Human prostacyclin receptor (hIP) stimulates STAT3 via pertussis toxin-insensitive G proteins in human erythroleukemia (HEL) cells.
  • Taken together, our observations illustrate that co-stimulation of G(s) and G(q) can result in the fine-tuning of STAT3 activation status, and this may provide the basis for cell type-specific responses following activation of hIP.
  • [MeSH-major] GTP-Binding Protein alpha Subunits, Gq-G11 / metabolism. GTP-Binding Protein alpha Subunits, Gs / metabolism. Leukemia, Erythroblastic, Acute / metabolism. Leukemia, Erythroblastic, Acute / pathology. Receptors, Epoprostenol / metabolism. STAT3 Transcription Factor / metabolism. Signal Transduction

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18755267.001).
  • [ISSN] 0898-6568
  • [Journal-full-title] Cellular signalling
  • [ISO-abbreviation] Cell. Signal.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Receptors, Epoprostenol; 0 / STAT3 Transcription Factor; 21820-51-9 / Phosphotyrosine; DCR9Z582X0 / Epoprostenol; EC 1.13.12.- / Luciferases; EC 2.7.1.- / MAP2K2 protein, human; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.10.2 / Janus Kinases; EC 2.7.10.2 / src-Family Kinases; EC 2.7.11.11 / Cyclic AMP-Dependent Protein Kinases; EC 2.7.12.2 / MAP Kinase Kinase 1; EC 2.7.12.2 / MAP Kinase Kinase 2; EC 3.6.5.1 / G protein alpha 16; EC 3.6.5.1 / GTP-Binding Protein alpha Subunits, Gq-G11; EC 3.6.5.1 / GTP-Binding Protein alpha Subunits, Gs; EC 4.6.1.1 / Adenylyl Cyclases; NE94J8CAMD / cicaprost
  •  go-up   go-down


67. He N, Pezda AC, Zhou Q: Modulation of a P-TEFb functional equilibrium for the global control of cell growth and differentiation. Mol Cell Biol; 2006 Oct;26(19):7068-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modulation of a P-TEFb functional equilibrium for the global control of cell growth and differentiation.
  • To investigate the physiological significance of this phenomenon, we analyzed the responses of HeLa cells and murine erythroleukemia cells (MELC) to hexamethylene bisacetamide (HMBA), which inhibits growth and induces differentiation of many cell types.
  • For HeLa cells, as HMBA produced only a minor, temporary effect on their growth, the equilibrium gradually returned to its pretreatment level.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jan 6;95(1):162-6 [9419346.001]
  • [Cites] Int J Hematol. 1996 Jan;63(1):1-17 [8713572.001]
  • [Cites] PLoS Biol. 2005 Feb;3(2):e76 [15719065.001]
  • [Cites] J Biol Chem. 2005 Apr 22;280(16):16368-76 [15713661.001]
  • [Cites] J Biol Chem. 2005 Apr 22;280(16):16360-7 [15713662.001]
  • [Cites] J Biol Chem. 2005 Aug 5;280(31):28819-26 [15965233.001]
  • [Cites] Mol Cell. 2005 Aug 19;19(4):523-34 [16109376.001]
  • [Cites] Mol Cell. 2005 Aug 19;19(4):535-45 [16109377.001]
  • [Cites] Cancer Biol Ther. 2005 Mar;4(3):277-81 [15753651.001]
  • [Cites] J Cell Physiol. 2006 Mar;206(3):603-10 [16222702.001]
  • [Cites] J Biol Chem. 2004 Feb 6;279(6):4153-60 [14627702.001]
  • [Cites] Mol Cell Biol. 2000 Apr;20(8):2629-34 [10733565.001]
  • [Cites] J Biol Chem. 2001 Aug 24;276(34):31793-9 [11431468.001]
  • [Cites] Nature. 2001 Nov 15;414(6861):317-22 [11713532.001]
  • [Cites] Nature. 2001 Nov 15;414(6861):322-5 [11713533.001]
  • [Cites] Mol Cell Biol. 2002 Jun;22(11):3794-802 [11997514.001]
  • [Cites] Genes Dev. 2002 Aug 15;16(16):2135-46 [12183367.001]
  • [Cites] Nat Med. 2002 Nov;8(11):1310-7 [12368904.001]
  • [Cites] Cancer Biol Ther. 2002 Jul-Aug;1(4):342-7 [12432243.001]
  • [Cites] Mol Cell Biol. 2003 Jul;23(14):4859-69 [12832472.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):5151-8 [12941847.001]
  • [Cites] Mol Cell. 2003 Oct;12(4):971-82 [14580347.001]
  • [Cites] Mol Cell Biol. 2004 Jun;24(12):5094-105 [15169877.001]
  • [Cites] Mech Dev. 2004 Jun;121(6):559-72 [15172687.001]
  • [Cites] EMBO J. 2004 Jul 7;23(13):2608-19 [15201869.001]
  • [Cites] J Pathol. 2004 Aug;203(4):946-52 [15258998.001]
  • [Cites] Gene. 2004 Aug 4;337:15-23 [15276198.001]
  • [Cites] Genes Dev. 2004 Oct 15;18(20):2437-68 [15489290.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Jan;79(2):471-5 [6952199.001]
  • [Cites] Mol Cell Biol. 1991 Jul;11(7):3432-45 [1646389.001]
  • [Cites] J Gen Virol. 1993 Nov;74 ( Pt 11):2401-8 [8245855.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Oct 25;91(22):10251-4 [7937935.001]
  • [Cites] EMBO J. 1995 Jan 16;14(2):321-8 [7835343.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7208-13 [10377393.001]
  • (PMID = 16980611.001).
  • [ISSN] 0270-7306
  • [Journal-full-title] Molecular and cellular biology
  • [ISO-abbreviation] Mol. Cell. Biol.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / R01 AI041757; United States / NIAID NIH HHS / AI / AI41757
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Acetamides; 0 / Chromatin; 0 / HEXIM1 protein, human; 0 / RNA-Binding Proteins; 0 / Ribonucleoproteins, Small Nuclear; EC 2.7.11.- / Positive Transcriptional Elongation Factor B; LA133J59VU / hexamethylene bisacetamide
  • [Other-IDs] NLM/ PMC1592901
  •  go-up   go-down


68. Reed-Inderbitzin E, Moreno-Miralles I, Vanden-Eynden SK, Xie J, Lutterbach B, Durst-Goodwin KL, Luce KS, Irvin BJ, Cleary ML, Brandt SJ, Hiebert SW: RUNX1 associates with histone deacetylases and SUV39H1 to repress transcription. Oncogene; 2006 Sep 21;25(42):5777-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RUNX1 (AML1) is a gene that is frequently disrupted by chromosomal translocations in acute leukemia.
  • Both Runt and RUNX1 are required for gene silencing during development and a central domain of RUNX1, termed repression domain 2 (RD2), was defined as being required for transcriptional repression and for the silencing of CD4 during T-cell maturation in thymic organ cultures.
  • Therefore, we tested whether RD2 contacts histone-modifying enzymes that may mediate both repression and gene silencing.
  • We found that RD2 contacts SUV39H1, a histone methyltransferase, via two motifs and that endogenous Suv39h1 associates with a Runx1-regulated repression element in murine erythroleukemia cells.
  • The association between RUNX1, histone deacetylases and SUV39H1 provides a molecular mechanism for repression and possibly gene silencing mediated by RUNX1.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16652147.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA68485; United States / PHS HHS / / R01-87549; United States / NCI NIH HHS / CA / R01-CA64140; United States / NCI NIH HHS / CA / R01-CA77274; United States / NHLBI NIH HHS / HL / R01-HL49118
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / RUNX1 protein, human; 0 / Repressor Proteins; EC 2.1.1. / SUV39H1 protein, human; EC 2.1.1.- / Methyltransferases; EC 3.5.1.98 / Histone Deacetylases
  •  go-up   go-down


69. Papapetrou EP, Ziros PG, Micheva ID, Zoumbos NC, Athanassiadou A: Gene transfer into human hematopoietic progenitor cells with an episomal vector carrying an S/MAR element. Gene Ther; 2006 Jan;13(1):40-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene transfer into human hematopoietic progenitor cells with an episomal vector carrying an S/MAR element.
  • Episomally maintained self-replicating systems present attractive alternative vehicles for gene therapy applications.
  • Recent insights into the ability of chromosomal scaffold/matrix attachment regions (S/MARs) to mediate episomal maintenance of genetic elements allowed the development of a small circular episomal vector that functions independently of virally encoded proteins.
  • In this study, we investigated the potential of this vector, pEPI-eGFP, to mediate gene transfer in hematopoietic progenitor cell lines and primary human cells. pEPI-eGFP was episomally maintained and conferred sustained eGFP expression even in nonselective conditions in the human cell line, K562, as well as in primary human fibroblast-like cells.
  • In contrast, in the murine erythroleukemia cell line, MEL, transgene expression was silenced through histone deacetylation, despite the vector's episomal persistence.
  • Hematopoietic semisolid cell colonies derived from transfected human cord blood CD34(+) cells expressed eGFP, albeit at low levels.
  • [MeSH-minor] Animals. Antigens, CD34. Cells, Cultured. Gene Expression. Green Fluorescent Proteins / genetics. Humans. Mice. Plasmids. Time Factors. Transgenes

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16094410.001).
  • [ISSN] 0969-7128
  • [Journal-full-title] Gene therapy
  • [ISO-abbreviation] Gene Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD34; 147336-22-9 / Green Fluorescent Proteins
  •  go-up   go-down


70. Akula SM, Ford PW, Whitman AG, Hamden KE, Bryan BA, Cook PP, McCubrey JA: B-Raf-dependent expression of vascular endothelial growth factor-A in Kaposi sarcoma-associated herpesvirus-infected human B cells. Blood; 2005 Jun 1;105(11):4516-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 (KSHV/HHV-8) is etiologically linked to Kaposi sarcoma (KS), primary effusion lymphoma (PEL), and multicentric Castleman disease.
  • All of the KSHV-infected cell lines (derived from PEL) expressed higher levels of B-Raf and VEGF-A when compared with uninfected cells.
  • Interestingly, we did not observe mutation in the B-Raf gene of the KSHV-infected PEL cell lines.
  • [MeSH-major] B-Lymphocytes / virology. Gene Expression Regulation. Herpesviridae Infections / metabolism. Herpesvirus 8, Human. Proto-Oncogene Proteins B-raf / physiology. Vascular Endothelial Growth Factor A / genetics

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15705790.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases
  •  go-up   go-down


71. Chatterjee T, Panigrahi I, Agrawal N, Naithani R, Mahapatra M, Pati HP, Wadhwa S, Saxena R: Cytochemical, immunophenotypic and ultrastructural characterization of acute leukemias: a prospective study of fifty cases: haematological malignancy. Hematology; 2006 Jun;11(3):147-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytochemical, immunophenotypic and ultrastructural characterization of acute leukemias: a prospective study of fifty cases: haematological malignancy.
  • Cytochemistry and immunophenotyping are established methods in the diagnosis of most leukemias but the role of electron microscopy in diagnosis, apart from understanding the cellular morphology is less studied.
  • We present here 50 cases of acute leukemias that were studied for morphology, conventional cytochemistry, immunophenotyping and transmission electron microscopy (TEM), including ultrastructural cytochemistry using myeloperoxidase (MPO) and platelet peroxidase activity.
  • TEM morphology using ultrastructural cytochemistry helped in definitive typing in one mixed lineage leukemia case, one AML-M5b, one AML-M6b and one microgranular variant of APML.
  • Thus, ultrastructural studies may be useful in accurate diagnosis of biphenotypic leukemia and further classification of acute leukemias.
  • Also, in cases with hypercellular marrow and with associated myelofibrosis, where the marrow aspirate gives low cell count, ultrastructural studies are a valuable aid to arriving at an accurate diagnosis.
  • [MeSH-major] Leukemia / pathology
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Antigens, CD / analysis. Antigens, Neoplasm / analysis. Child. Child, Preschool. Female. Humans. Immunophenotyping. Male. Microscopy, Electron. Middle Aged. Neoplasm Proteins / analysis. Neoplastic Stem Cells / chemistry. Neoplastic Stem Cells / ultrastructure. Peroxidase / analysis. Prospective Studies

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17325954.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Neoplasm; 0 / Neoplasm Proteins; EC 1.11.1.7 / Peroxidase
  •  go-up   go-down


72. Yamaguchi T, Hashiguchi K, Katsuki S, Iwamoto W, Tsuruhara S, Terada S: Activation of the intrinsic and extrinsic pathways in high pressure-induced apoptosis of murine erythroleukemia cells. Cell Mol Biol Lett; 2008;13(1):49-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activation of the intrinsic and extrinsic pathways in high pressure-induced apoptosis of murine erythroleukemia cells.
  • We previously demonstrated that caspase-3, an executioner of apoptosis, is activated in the pressure-induced apoptosis of murine erythroleukemia (MEL) cells (at 100 MPa).
  • [MeSH-major] Apoptosis / physiology. Leukemia, Erythroblastic, Acute / pathology. Signal Transduction / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17952376.001).
  • [ISSN] 1689-1392
  • [Journal-full-title] Cellular & molecular biology letters
  • [ISO-abbreviation] Cell. Mol. Biol. Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Caspase Inhibitors; EC 3.4.22.- / Caspases
  •  go-up   go-down


73. Spadavecchia S, Gonzalez-Lopez O, Carroll KD, Palmeri D, Lukac DM: Convergence of Kaposi's sarcoma-associated herpesvirus reactivation with Epstein-Barr virus latency and cellular growth mediated by the notch signaling pathway in coinfected cells. J Virol; 2010 Oct;84(20):10488-500
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Kaposi's sarcoma-associated herpesvirus (KSHV) is the etiologic agent of primary effusion lymphoma (PEL).
  • All PEL cell lines are infected with KSHV, and 70% are coinfected with Epstein-Barr virus (EBV).
  • EBV transformation of primary B cells requires EBV nuclear antigen 2 (EBNA-2) to interact with RBP-Jk to direct the latent viral and cellular gene expression program.
  • We have found that the EBV latent protein LMP-1 is expressed in less than 5% of KSHV(+)/EBV(+) PEL cells but is induced in an Rta-dependent fashion when KSHV reactivates.
  • Complementation of EBNA-2 deficiency by Rta depends on RBP-Jk and LMP-1, and Rta transactivation is required for optimal growth of KSHV(+)/EBV(+) PEL lines.
  • Our data suggest that Rta can contribute to EBV-driven cellular growth by transactivating RBP-Jk-dependent EBV latency genes.

  • COS Scholar Universe. author profiles.
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] EMBO J. 1997 Nov 3;16(21):6478-85 [9351829.001]
  • [Cites] Blood. 1998 Feb 1;91(3):747-55 [9446632.001]
  • [Cites] Mol Cell Biol. 1998 May;18(5):2835-44 [9566902.001]
  • [Cites] Oncogene. 1998 Apr 2;16(13):1731-42 [9582021.001]
  • [Cites] J Gen Virol. 1998 Jun;79 ( Pt 6):1445-52 [9634087.001]
  • [Cites] Dev Biol. 1999 Sep 1;213(1):33-53 [10452845.001]
  • [Cites] Virology. 1999 Sep 15;262(1):18-30 [10489337.001]
  • [Cites] J Virol. 1999 Nov;73(11):9348-61 [10516043.001]
  • [Cites] Science. 1999 Oct 8;286(5438):300-3 [10514374.001]
  • [Cites] J Virol. 2005 Mar;79(6):3479-87 [15731242.001]
  • [Cites] J Virol. 2005 Nov;79(22):14371-82 [16254371.001]
  • [Cites] Blood. 2006 Jan 1;107(1):277-84 [16150942.001]
  • [Cites] J Virol. 2006 Oct;80(19):9697-709 [16973574.001]
  • [Cites] Physiol Rev. 2007 Jan;87(1):99-163 [17237344.001]
  • [Cites] J Virol. 2007 Jun;81(11):6068-78 [17376914.001]
  • [Cites] J Virol. 2007 Jun;81(11):5788-806 [17392367.001]
  • [Cites] Anal Biochem. 2007 Jul 15;366(2):197-206 [17512890.001]
  • [Cites] J Virol. 2007 Aug;81(16):8451-67 [17537858.001]
  • [Cites] J Virol. 2007 Dec;81(24):13299-314 [17913801.001]
  • [Cites] PLoS One. 2008;3(2):e1569 [18253508.001]
  • [Cites] J Virol. 2008 Nov;82(21):10709-23 [18715905.001]
  • [Cites] J Virol. 2009 May;83(10):5014-27 [19264782.001]
  • [Cites] Dev Cell. 2009 May;16(5):633-47 [19460341.001]
  • [Cites] J Virol. 1999 Dec;73(12):10525-30 [10559372.001]
  • [Cites] Leuk Lymphoma. 2000 Jul;38(3-4):401-9 [10830748.001]
  • [Cites] J Virol. 2000 Nov;74(21):10187-93 [11024147.001]
  • [Cites] J Virol. 2001 Mar;75(5):2033-40 [11160707.001]
  • [Cites] J Biol Chem. 2001 Jan 12;276(2):1195-203 [11031256.001]
  • [Cites] J Virol. 2001 Apr;75(8):3537-46 [11264343.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10866-71 [9724796.001]
  • [Cites] Leukemia. 1998 Oct;12(10):1507-17 [9766492.001]
  • [Cites] Virology. 1998 Dec 20;252(2):304-12 [9878608.001]
  • [Cites] J Virol. 1999 Apr;73(4):2770-80 [10074124.001]
  • [Cites] J Biol Chem. 1999 Jun 4;274(23):16085-96 [10347160.001]
  • [Cites] J Virol. 2001 Jul;75(13):5899-912 [11390591.001]
  • [Cites] Genes Dev. 2002 Aug 1;16(15):1977-89 [12154127.001]
  • [Cites] J Biol Chem. 2003 Feb 7;278(6):3694-704 [12446712.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8490-5 [12832621.001]
  • [Cites] Blood. 2004 Jan 1;103(1):313-6 [12969959.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):141-6 [14691250.001]
  • [Cites] J Virol. 2004 Apr;78(8):3941-52 [15047810.001]
  • [Cites] Oncogene. 2004 Apr 8;23(15):2681-93 [14767477.001]
  • [Cites] J Exp Med. 1984 May 1;159(5):1554-9 [6325575.001]
  • [Cites] J Exp Med. 1990 Jul 1;172(1):61-8 [2162905.001]
  • [Cites] J Virol. 1992 Nov;66(11):6496-501 [1404600.001]
  • [Cites] J Biol Chem. 1992 Dec 5;267(34):24157-60 [1332946.001]
  • [Cites] J Exp Med. 1993 Mar 1;177(3):763-74 [8382256.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] EMBO J. 1995 Jan 3;14(1):88-96 [7828599.001]
  • [Cites] Oncogene. 1995 Feb 2;10(3):549-60 [7845680.001]
  • [Cites] Cell. 1995 Feb 10;80(3):389-99 [7859281.001]
  • [Cites] J Virol. 1995 May;69(5):2968-76 [7707523.001]
  • [Cites] Blood. 1995 Oct 1;86(7):2708-14 [7670109.001]
  • [Cites] Nature. 1995 Sep 28;377(6547):355-8 [7566092.001]
  • [Cites] J Virol. 1996 Jan;70(1):549-58 [8523568.001]
  • [Cites] EMBO J. 1996 Jan 15;15(2):375-82 [8617212.001]
  • [Cites] Nat Med. 1996 Mar;2(3):342-6 [8612236.001]
  • [Cites] Blood. 1996 Jul 15;88(2):645-56 [8695812.001]
  • [Cites] Nat Med. 1996 Aug;2(8):918-24 [8705863.001]
  • [Cites] Nat Med. 1996 Aug;2(8):925-8 [8705864.001]
  • [Cites] Br J Haematol. 1996 Sep;94(3):533-43 [8790156.001]
  • [Cites] Lancet. 1996 Oct 26;348(9035):1133-8 [8888167.001]
  • [Cites] Science. 1996 Dec 6;274(5293):1739-44 [8939871.001]
  • [Cites] Cytometry. 1996 Dec 1;25(4):333-40 [8946140.001]
  • [Cites] Oncogene. 1996 Nov 21;13(10):2243-54 [8950992.001]
  • [Cites] J Virol. 1997 Jan;71(1):314-24 [8985352.001]
  • [Cites] EMBO J. 1996 Dec 16;15(24):7070-8 [9003782.001]
  • [Cites] Blood. 1997 Aug 1;90(3):1186-91 [9242551.001]
  • [Cites] Development. 1997 Oct;124(20):4133-41 [9374409.001]
  • (PMID = 20686042.001).
  • [ISSN] 1098-5514
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / R01 AI078138; United States / NIAID NIH HHS / AI / AI 078138
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Culture Media, Conditioned; 0 / DNA Primers; 0 / EBNA-2 protein, Human herpesvirus 4; 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / Epstein-Barr Virus Nuclear Antigens; 0 / Immediate-Early Proteins; 0 / Immunoglobulin J Recombination Signal Sequence-Binding Protein; 0 / Receptors, Notch; 0 / Rta protein, Human herpesvirus 8; 0 / Trans-Activators; 0 / Viral Matrix Proteins; 0 / Viral Proteins
  • [Other-IDs] NLM/ PMC2950570
  •  go-up   go-down


74. Carbone A, Gloghini A: KSHV/HHV8-associated lymphomas. Br J Haematol; 2008 Jan;140(1):13-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This review looks at the current state of knowledge on primary effusion lymphoma (PEL) and other Kaposi sarcoma herpesvirus (KSHV)/human herpesvirus 8 (HHV8)-associated lymphomas.
  • In 1995, KSHV DNA sequences were identified within a distinct subgroup of acquired immunodeficiency syndrome-related non-Hodgkin lymphomas localized in body cavities and presenting as pleural, peritoneal and pericardial lymphomatous effusions.
  • KSHV/HHV8 infection is also in multicentric Castleman disease-associated plasmablastic lymphoma.

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17991301.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 105
  •  go-up   go-down


75. Kirisits MJ, Prost L, Starkey M, Parsek MR: Characterization of colony morphology variants isolated from Pseudomonas aeruginosa biofilms. Appl Environ Microbiol; 2005 Aug;71(8):4809-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They also exhibit increased hydrophobicity and reduced motility compared to the wild-type parent strain.
  • These variants form biofilms with significant three-dimensional structure and more biomass than the wild-type parent.
  • The variants generally showed increased expression of the psl and pel loci, which have been previously implicated in the adherence of P. aeruginosa to solid surfaces.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 2000 May 19;288(5469):1251-4 [10818002.001]
  • [Cites] Gene. 1998 May 28;212(1):77-86 [9661666.001]
  • [Cites] Nature. 1998 Jul 2;394(6688):69-72 [9665128.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):4028-33 [10097157.001]
  • [Cites] Clin Infect Dis. 1999 Sep;29(3):621-5 [10530458.001]
  • [Cites] Dev Cell. 2004 Nov;7(5):745-54 [15525535.001]
  • [Cites] J Bacteriol. 2004 Dec;186(23):8066-73 [15547279.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Nov 23;101(47):16630-5 [15546998.001]
  • [Cites] Appl Environ Microbiol. 2004 Dec;70(12):7418-25 [15574944.001]
  • [Cites] J Infect Dis. 2001 Feb 1;183(3):444-52 [11133376.001]
  • [Cites] J Bacteriol. 2001 Feb;183(4):1195-204 [11157931.001]
  • [Cites] Environ Microbiol. 2000 Oct;2(5):542-54 [11233162.001]
  • [Cites] Methods Enzymol. 2001;336:41-7 [11398416.001]
  • [Cites] Methods Enzymol. 2001;336:48-59 [11398418.001]
  • [Cites] J Bacteriol. 2001 Sep;183(18):5395-401 [11514525.001]
  • [Cites] Nature. 2001 Oct 25;413(6858):860-4 [11677611.001]
  • [Cites] Nature. 2002 Apr 18;416(6882):740-3 [11961556.001]
  • [Cites] Nature. 2002 May 30;417(6888):552-5 [12037568.001]
  • [Cites] J Bacteriol. 2002 Dec;184(23):6481-9 [12426335.001]
  • [Cites] J Bacteriol. 2003 Apr;185(7):2066-79 [12644476.001]
  • [Cites] J Med Microbiol. 2003 Apr;52(Pt 4):295-301 [12676867.001]
  • [Cites] Science. 2003 May 30;300(5624):1404-9 [12775833.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8484-9 [12815109.001]
  • [Cites] Mol Microbiol. 2003 Oct;50(1):15-27 [14507360.001]
  • [Cites] Mol Microbiol. 2004 Feb;51(3):675-90 [14731271.001]
  • [Cites] Anal Biochem. 2004 Jun 1;329(1):120-30 [15136174.001]
  • [Cites] J Bacteriol. 2004 Jun;186(12):3837-47 [15175297.001]
  • [Cites] Environ Microbiol. 2004 Jul;6(7):726-32 [15186351.001]
  • [Cites] J Bacteriol. 2004 Jul;186(14):4449-56 [15231776.001]
  • [Cites] J Bacteriol. 2004 Jul;186(14):4457-65 [15231777.001]
  • [Cites] J Bacteriol. 2004 Jul;186(14):4466-75 [15231778.001]
  • [Cites] J Bacteriol. 2004 Nov;186(21):7312-26 [15489443.001]
  • [Cites] J Bacteriol. 1980 Nov;144(2):844-7 [6776099.001]
  • [Cites] EMBO J. 1993 Feb;12(2):625-30 [8440252.001]
  • [Cites] Microbiol Rev. 1995 Mar;59(1):143-69 [7535888.001]
  • [Cites] Arch Microbiol. 1995 Sep;164(3):165-72 [7545384.001]
  • [Cites] J Bacteriol. 1998 Feb;180(3):722-31 [9457880.001]
  • [Cites] Science. 1998 Apr 10;280(5361):295-8 [9535661.001]
  • [Cites] Mol Microbiol. 1998 Apr;28(2):249-64 [9622351.001]
  • [Cites] Mol Microbiol. 1998 May;28(3):449-61 [9632250.001]
  • [Cites] Nature. 2000 Oct 12;407(6805):762-4 [11048725.001]
  • (PMID = 16085879.001).
  • [ISSN] 0099-2240
  • [Journal-full-title] Applied and environmental microbiology
  • [ISO-abbreviation] Appl. Environ. Microbiol.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM067248; United States / NIGMS NIH HHS / GM / GM 67248-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / Culture Media
  • [Other-IDs] NLM/ PMC1183349
  •  go-up   go-down


76. Keriel A, Mahuteau-Betzer F, Jacquet C, Plays M, Grierson D, Sitbon M, Tazi J: Protection against retrovirus pathogenesis by SR protein inhibitors. PLoS One; 2009;4(2):e4533
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this model, all newborn mice infected with a fully replicative murine leukemia virus (MLV) develop erythroleukemia within 6 to 8 weeks of age.
  • We show here that two of these IDC, IDC13 and IDC78, selectively altered splicing-dependent production of the retroviral envelope gene, thus inhibiting early viral replication in vivo, sufficiently to protect mice from MLV-induced pathogenesis.
  • [MeSH-major] Indoles / pharmacology. Leukemia Virus, Murine / pathogenicity. Leukemia, Erythroblastic, Acute / prevention & control. Nuclear Proteins / antagonists & inhibitors

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 1986 Jan;57(1):389-93 [3001361.001]
  • [Cites] Virology. 1985 Feb;141(1):110-8 [2983493.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Jul 1;88(13):5932-6 [2062871.001]
  • [Cites] Curr Top Microbiol Immunol. 1996;211:191-9 [8585950.001]
  • [Cites] Genes Dev. 1998 Jan 1;12(1):55-66 [9420331.001]
  • [Cites] J Cell Biol. 1999 Jun 14;145(6):1145-52 [10366588.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jun 14;102(24):8764-9 [15939885.001]
  • [Cites] Trends Biochem Sci. 2005 Aug;30(8):469-78 [16009556.001]
  • [Cites] Curr HIV/AIDS Rep. 2004 Apr;1(1):47-53 [16091223.001]
  • [Cites] Cell. 2005 Aug 12;122(3):365-78 [16096057.001]
  • [Cites] Curr Top Microbiol Immunol. 2006;303:67-95 [16570857.001]
  • [Cites] Prog Mol Subcell Biol. 2006;44:65-87 [17076265.001]
  • [Cites] Mol Cell Biol. 2007 Aug;27(15):5393-402 [17526736.001]
  • [Cites] Retrovirology. 2007;4:46 [17617899.001]
  • [Cites] PLoS Pathog. 2007 Oct 26;3(10):1530-9 [17967062.001]
  • [Cites] Science. 2008 Aug 1;321(5889):686-91 [18669861.001]
  • [Cites] J Virol. 1999 Dec;73(12):10472-9 [10559365.001]
  • [Cites] J Virol. 2000 Apr;74(8):3709-14 [10729146.001]
  • [Cites] RNA. 2000 Sep;6(9):1197-211 [10999598.001]
  • [Cites] Mol Cell. 2001 Apr;7(4):899-905 [11336712.001]
  • [Cites] Genes Dev. 2002 Mar 1;16(5):594-607 [11877379.001]
  • [Cites] Mol Biol Cell. 2002 Jul;13(7):2436-47 [12134081.001]
  • [Cites] Prog Mol Subcell Biol. 2003;31:89-126 [12494764.001]
  • [Cites] Adv Cancer Res. 2003;88:53-99 [12665053.001]
  • [Cites] Mol Cell. 2003 Mar;11(3):837-43 [12667464.001]
  • [Cites] Genes Dev. 2004 Apr 1;18(7):755-68 [15082528.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9666-70 [15210956.001]
  • [Cites] J Biol Chem. 2004 Jul 16;279(29):29963-73 [15123677.001]
  • [Cites] Virology. 1981 Jul 15;112(1):131-44 [6787798.001]
  • [Cites] Virology. 1983 Jul 15;128(1):221-33 [6308893.001]
  • [Cites] J Virol. 1984 Oct;52(1):248-54 [6090701.001]
  • [Cites] Cell. 1986 Dec 26;47(6):851-9 [3465451.001]
  • (PMID = 19225570.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Indoles; 0 / Nuclear Proteins; 0 / RNA-Binding Proteins; 170974-22-8 / Serine-Arginine Splicing Factors
  • [Other-IDs] NLM/ PMC2640060
  •  go-up   go-down


77. McCullumsmith RE, Gupta D, Beneyto M, Kreger E, Haroutunian V, Davis KL, Meador-Woodruff JH: Expression of transcripts for myelination-related genes in the anterior cingulate cortex in schizophrenia. Schizophr Res; 2007 Feb;90(1-3):15-27
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of transcripts for myelination-related genes in the anterior cingulate cortex in schizophrenia.
  • Several recent studies have found changes in the expression of genes functionally related to myelination and oligodendrocyte homeostasis in schizophrenia.
  • In the present study, we examined the expression of myelination-related genes previously implicated in schizophrenia by microarray or QPCR.
  • Using in situ hybridization, we measured transcript expression of 2',3'-cyclic nucleotide 3'-phosphodiesterase (CNP), myelin-associated glycoprotein (MAG), transferrin (TF), quaking (QKI), gelsolin, myelin oligodendrocyte glycoprotein, v-erb-b2 erythroblastic leukemia viral oncogene homolog 3, erbb2 interacting protein, motility-related protein-1, SRY-box containing gene 10, oligodendrocyte transcription factor 2, peripheral myelin protein 22, and claudin-11 in both gray and white matter of the anterior cingulate cortex (ACC) in subjects with schizophrenia (n=41) and a comparison group (n=34).

  • Genetic Alliance. consumer health - Schizophrenia.
  • MedlinePlus Health Information. consumer health - Schizophrenia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Psychiatry. 2003 Sep;8(9):811-20 [12931208.001]
  • [Cites] Brain Res. 1988 Apr 1;467(2):183-91 [2454146.001]
  • [Cites] Lancet. 2003 Sep 6;362(9386):798-805 [13678875.001]
  • [Cites] Am J Psychiatry. 1995 Feb;152(2):197-207 [7840352.001]
  • [Cites] Arch Gen Psychiatry. 1998 Mar;55(3):205-11 [9510214.001]
  • [Cites] Neuroreport. 1998 Feb 16;9(3):425-30 [9512384.001]
  • [Cites] J Neurosci Res. 1998 Feb 15;51(4):417-22 [9514195.001]
  • [Cites] Arch Gen Psychiatry. 1998 Apr;55(4):346-52 [9554430.001]
  • [Cites] Neurochem Res. 1999 Feb;24(2):235-48 [9972870.001]
  • [Cites] Arch Gen Psychiatry. 1999 Apr;56(4):367-74 [10197834.001]
  • [Cites] Psychiatry Res. 1999 Aug 31;91(2):93-100 [10515464.001]
  • [Cites] Psychiatry Res. 2004 Dec 15;132(2):117-30 [15598546.001]
  • [Cites] Neuroreport. 2003 Oct 6;14(14):1833-6 [14534430.001]
  • [Cites] J Neurosci Res. 2003 Nov 15;74(4):479-85 [14598291.001]
  • [Cites] Arch Dermatol Res. 1989;281(5):336-41 [2802664.001]
  • [Cites] J Biol Chem. 1991 Apr 5;266(10):6201-8 [1848850.001]
  • [Cites] J Neurochem. 1991 Jul;57(1):318-22 [1711099.001]
  • [Cites] J Neurosci Res. 1993 Dec 1;36(5):501-7 [7511695.001]
  • [Cites] Am J Psychiatry. 2005 Mar;162(3):602-5 [15741480.001]
  • [Cites] Psychiatry Res. 2005 Feb 28;138(2):99-113 [15766634.001]
  • [Cites] Schizophr Res. 2005 Sep 15;77(2-3):241-52 [15923110.001]
  • [Cites] Schizophr Res. 2005 Nov 15;79(2-3):157-73 [16139990.001]
  • [Cites] Neurobiol Dis. 2006 Mar;21(3):531-40 [16213148.001]
  • [Cites] Mol Neurobiol. 2006 Apr;33(2):155-79 [16603794.001]
  • [Cites] J Neurol Sci. 2006 Aug 15;247(1):11-5 [16626749.001]
  • [Cites] Am J Psychiatry. 2006 Oct;163(10):1834-7 [17012699.001]
  • [Cites] J Microsc. 1982 Oct;128(Pt 1):79-94 [7143439.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2000 Jan;68(1):70-4 [10601405.001]
  • [Cites] J Neurosci Res. 2000 Aug 15;61(4):388-95 [10931525.001]
  • [Cites] Am J Psychiatry. 2001 Feb;158(2):234-43 [11156806.001]
  • [Cites] J Neurochem. 2001 Apr;77(1):165-72 [11279272.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4746-51 [11296301.001]
  • [Cites] Brain. 2001 May;124(Pt 5):882-92 [11335691.001]
  • [Cites] Psychiatry Res. 2001 May 30;106(3):161-70 [11382538.001]
  • [Cites] Nat Rev Neurosci. 2001 Jun;2(6):417-24 [11389475.001]
  • [Cites] Neuroreport. 2001 Jul 20;12(10):2251-4 [11447344.001]
  • [Cites] Brain Res Bull. 2001 Jul 15;55(5):597-610 [11576756.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Feb 19;99(4):1807-12 [11842207.001]
  • [Cites] Neurochem Res. 2002 Oct;27(10):1193-200 [12462417.001]
  • [Cites] Neurochem Res. 2002 Nov;27(11):1459-63 [12512950.001]
  • [Cites] Nat Genet. 2003 Mar;33(3):366-74 [12590258.001]
  • [Cites] Arch Gen Psychiatry. 2003 May;60(5):443-56 [12742865.001]
  • [Cites] J Neurosci Res. 2003 Jun 1;72(5):587-94 [12749023.001]
  • [Cites] Biol Psychiatry. 2003 Jun 15;53(12):1075-85 [12814859.001]
  • [Cites] Arch Gen Psychiatry. 2003 Aug;60(8):779-88 [12912761.001]
  • [Cites] Crit Rev Neurobiol. 1989;4(3):235-301 [2537684.001]
  • [Cites] Curr Opin Neurobiol. 2003 Oct;13(5):545-51 [14630216.001]
  • [Cites] Schizophr Res. 2004 Apr 1;67(2-3):269-75 [14984887.001]
  • [Cites] Am J Psychiatry. 2004 Mar;161(3):573-5 [14992988.001]
  • [Cites] Am J Psychiatry. 2004 Apr;161(4):707-15 [15056518.001]
  • [Cites] Am J Psychiatry. 2004 May;161(5):882-8 [15121654.001]
  • [Cites] Arch Gen Psychiatry. 2004 Jul;61(7):649-57 [15237077.001]
  • [Cites] Arch Gen Psychiatry. 2004 Jul;61(7):658-68 [15237078.001]
  • [Cites] J Neurosci Res. 2004 Sep 15;77(6):858-66 [15334603.001]
  • [Cites] J Neurosci Res. 2004 Sep 1;77(5):681-9 [15352214.001]
  • [Cites] J Biol Chem. 1980 Oct 25;255(20):9523-5 [6776100.001]
  • [Cites] J Microsc. 1984 Oct;136(Pt 1):1-22 [6512851.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Oct;82(19):6706-10 [3901006.001]
  • [Cites] In Vitro Cell Dev Biol. 1987 Mar;23(3):221-6 [3549678.001]
  • [Cites] Brain Res Bull. 1987 Apr;18(4):573-6 [3300864.001]
  • [Cites] Nat Rev Neurosci. 2003 Sep;4(9):703-13 [12951563.001]
  • (PMID = 17223013.001).
  • [ISSN] 0920-9964
  • [Journal-full-title] Schizophrenia research
  • [ISO-abbreviation] Schizophr. Res.
  • [Language] ENG
  • [Grant] United States / NIMH NIH HHS / MH / MH064673; United States / NIMH NIH HHS / MH / MH66392; United States / NIMH NIH HHS / MH / MH45212; United States / NIMH NIH HHS / MH / R01 MH064673; United States / NIMH NIH HHS / MH / P50 MH066392
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Lectins; 0 / MAG protein, human; 0 / Molecular Chaperones; 0 / Myelin Proteins; 0 / Myelin-Associated Glycoprotein; 0 / Neoplasm Proteins; 0 / QKI protein, human; 0 / RNA, Messenger; 0 / RNA-Binding Proteins; 0 / Transcription Factors
  • [Other-IDs] NLM/ NIHMS19729; NLM/ PMC1880890
  •  go-up   go-down


78. Apaydin N, Uz A, Evirgen O, Loukas M, Tubbs RS, Elhan A: The phrenico-esophageal ligament: an anatomical study. Surg Radiol Anat; 2008 Feb;30(1):29-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The phrenico-esophageal ligament (PEL), which is claimed by some to be an important anti-reflux barrier, has been accepted as an important structure by some surgeons dealing with the surgical treatment of hiatal hernias.
  • The aim of this study was to define this anatomic structure and to point out the clinical importance of the PEL.
  • The PEL was observed to be derived from the transversalis and endothoracic fascia attaching the esophagus to the diaphragmatic crura at the region of the esophageal hiatus.
  • The endothoracic fascia turned superiorly at the level of esophageal hiatus and attached on to the esophagus by uniting with the upper leaflet of the transversalis fascia in 11 of the specimens.
  • In three of the specimens, it attached on the esophagus at a higher level than the transversalis fascia.
  • The histologic sections of our study revealed that the PEL is formed by collagen and elastic fibers composed of fibroblasts and blood vessels.
  • Since the PEL is a strong structure that firmly attached to the esophageal wall and surrounded the upper part of the distal esophagus like a skirt, it is reasonable that it may play an important role in the gastroesophageal sphincteric mechanism.
  • Histological evidence for decrease in collagen fibers with age and the loose arrangement of the elastic fibers due to this decrement might decrease the resistance and the elasticity of the PEL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterol Clin North Am. 1990 Sep;19(3):501-16 [2228160.001]
  • [Cites] Am Surg. 1975 Oct;41(10):626-31 [1099953.001]
  • [Cites] Surg Clin North Am. 2000 Feb;80(1):241-60 [10685151.001]
  • [Cites] Am J Surg. 1966 Jan;111(1):70-9 [5901379.001]
  • [Cites] Thorax. 1961 Mar;16:36-41 [13712529.001]
  • [Cites] Thorax. 1961 Mar;16:41-5 [13712530.001]
  • [Cites] Am J Surg. 1965 Nov;110(5):814-7 [5862392.001]
  • [Cites] J Clin Gastroenterol. 1999 Jun;28(4):352-4 [10372935.001]
  • [Cites] J Laryngol Otol. 1953 Mar;67(3):139-52 [13035306.001]
  • [Cites] J Surg Res. 1970 Jul;10(7):327-31 [4910812.001]
  • [Cites] Gastroenterol Clin North Am. 1990 Sep;19(3):745-75 [2228172.001]
  • [Cites] Surg Gynecol Obstet. 1964 Jun;118:1291-4 [14177845.001]
  • [Cites] Anat Clin. 1985;7(4):271-83 [3833289.001]
  • [Cites] Surgery. 1970 May;67(5):735-40 [5438672.001]
  • [Cites] Clin Anat. 1999;12(3):164-70 [10340456.001]
  • [Cites] J Gastroenterol. 2004 Sep;39(9):815-20 [15565398.001]
  • [Cites] Ann Surg. 1966 Oct;164(4):643-54 [5924786.001]
  • [Cites] Clin Anat. 2006 Jan;19(1):25-31 [16287124.001]
  • [Cites] Am J Surg. 1967 Sep;114(3):480-1 [5340069.001]
  • [Cites] Acta Anat (Basel). 1973;86(1):137-50 [4755742.001]
  • (PMID = 18058057.001).
  • [ISSN] 0930-1038
  • [Journal-full-title] Surgical and radiologic anatomy : SRA
  • [ISO-abbreviation] Surg Radiol Anat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


79. Mandal D, Bertolasi V, Aromí G, Ray D: A ketone oximate based cyclic cationic [Ni(II)4] inverse metallacrown from simultaneous chelation and bridging of two ligands. Dalton Trans; 2007 May 28;(20):1989-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Ni(4) inverse metallacrown (NHEt(3)) [Ni(4)(bmo)4(Hael)2(ael)2](ClO(4))3 [(NHEt(3)).1.(ClO(4))3], with the inverse 12-MC-4 motif, has been assembled via simultaneous chelation and bridging of butan-2,3-dionemonoxime (Hbmo) and 2-amino ethanol (Hael).

  • Hazardous Substances Data Bank. 1,2:3,4-DIEPOXYBUTANE .
  • Hazardous Substances Data Bank. NICKEL, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17502931.001).
  • [ISSN] 1477-9226
  • [Journal-full-title] Dalton transactions (Cambridge, England : 2003)
  • [ISO-abbreviation] Dalton Trans
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Amino Alcohols; 0 / Cations, Divalent; 0 / Chelating Agents; 0 / Epoxy Compounds; 0 / Ethers, Cyclic; 0 / Ketones; 0 / Ligands; 0 / Organometallic Compounds; 0 / Oximes; 1464-53-5 / erythritol anhydride; 7OV03QG267 / Nickel
  •  go-up   go-down


80. Strowig T, Chijioke O, Carrega P, Arrey F, Meixlsperger S, Rämer PC, Ferlazzo G, Münz C: Human NK cells of mice with reconstituted human immune system components require preactivation to acquire functional competence. Blood; 2010 Nov 18;116(20):4158-67
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After preactivation, both CD16(+) and CD16(-) NK cells efficiently produce interferon-γ and degranulate in response to stimulation with NK cell-susceptible targets, including K562 erythroleukemia cells.

  • MedlinePlus Health Information. consumer health - Immune System and Disorders.
  • COS Scholar Universe. author profiles.
  • Jackson Laboratory JAX®Mice Database. culture/stock collections - NOD.Cg-Prkdc<scid> Il2rg<tm1Wjl>/SzJ (subscription/membership/fee required).
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 1999 Apr;5(4):405-11 [10202929.001]
  • [Cites] J Exp Med. 2009 Jun 8;206(6):1423-34 [19487422.001]
  • [Cites] Blood. 2004 Dec 15;104(13):3886-93 [15319293.001]
  • [Cites] Blood. 2005 Jan 1;105(1):266-73 [15331446.001]
  • [Cites] J Immunol. 2005 Jan 15;174(2):727-34 [15634892.001]
  • [Cites] Annu Rev Immunol. 2005;23:225-74 [15771571.001]
  • [Cites] Blood. 2005 Jun 1;105(11):4416-23 [15728129.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):709-13 [16079848.001]
  • [Cites] Nature. 2005 Aug 25;436(7054):1186-90 [15995699.001]
  • [Cites] Annu Rev Immunol. 2006;24:287-320 [16551251.001]
  • [Cites] J Exp Med. 2006 Apr 17;203(4):1033-43 [16606675.001]
  • [Cites] Immunity. 2006 Aug;25(2):331-42 [16901727.001]
  • [Cites] J Exp Med. 2000 Mar 6;191(5):771-80 [10704459.001]
  • [Cites] Immunity. 2000 Jul;13(1):143-53 [10933402.001]
  • [Cites] Annu Rev Immunol. 2001;19:197-223 [11244035.001]
  • [Cites] J Immunol Methods. 2001 Jun 1;252(1-2):83-92 [11334968.001]
  • [Cites] Blood. 2001 May 15;97(10):3146-51 [11342442.001]
  • [Cites] Eur J Immunol. 2001 Oct;31(10):3121-7 [11592089.001]
  • [Cites] J Exp Med. 2002 Feb 4;195(3):327-33 [11828007.001]
  • [Cites] J Exp Med. 2002 Feb 4;195(3):335-41 [11828008.001]
  • [Cites] J Exp Med. 2002 Feb 4;195(3):343-51 [11828009.001]
  • [Cites] Blood. 2002 Mar 1;99(5):1723-9 [11861289.001]
  • [Cites] Cancer Res. 2002 Nov 1;62(21):6178-86 [12414645.001]
  • [Cites] Eur J Immunol. 2003 Feb;33(2):306-13 [12548561.001]
  • [Cites] Blood. 2003 Apr 15;101(8):3052-7 [12480696.001]
  • [Cites] J Exp Med. 2003 Apr 21;197(8):977-84 [12695489.001]
  • [Cites] Eur J Haematol. 2003 Jul;71(1):29-38 [12801296.001]
  • [Cites] Nat Rev Immunol. 2003 Oct;3(10):781-90 [14523385.001]
  • [Cites] J Immunol. 2004 Feb 1;172(3):1333-9 [14734707.001]
  • [Cites] J Immunol. 2004 Feb 1;172(3):1455-62 [14734722.001]
  • [Cites] Adv Immunol. 1989;47:187-376 [2683611.001]
  • [Cites] J Exp Med. 1997 Jun 16;185(12):2079-88 [9182679.001]
  • [Cites] J Exp Med. 1998 Jan 5;187(1):117-22 [9419217.001]
  • [Cites] Eur J Immunol. 2006 Sep;36(9):2394-400 [16917961.001]
  • [Cites] Nat Immunol. 2006 Nov;7(11):1217-24 [17013389.001]
  • [Cites] J Immunol. 2007 Apr 15;178(8):4947-55 [17404276.001]
  • [Cites] Blood. 2007 May 1;109(9):3776-85 [17218381.001]
  • [Cites] Immunity. 2007 Apr;26(4):503-17 [17398124.001]
  • [Cites] J Immunol. 2007 Jul 1;179(1):89-94 [17579025.001]
  • [Cites] J Clin Invest. 2007 Nov;117(11):3316-29 [17948125.001]
  • [Cites] Nat Immunol. 2007 Dec;8(12):1313-23 [17982459.001]
  • [Cites] PLoS Pathog. 2008 Feb 8;4(2):e27 [18266470.001]
  • [Cites] J Immunol. 2008 Jun 15;180(12):7785-91 [18523242.001]
  • [Cites] Blood. 2008 Aug 15;112(4):1231-9 [18519810.001]
  • [Cites] Immunol Rev. 2008 Aug;224:70-84 [18759921.001]
  • [Cites] J Immunol. 2008 Nov 1;181(9):6170-7 [18941207.001]
  • [Cites] J Exp Med. 2009 Jan 16;206(1):25-34 [19103877.001]
  • [Cites] J Exp Med. 2009 Feb 16;206(2):287-98 [19171762.001]
  • [Cites] J Clin Immunol. 2009 May;29(3):265-73 [19280325.001]
  • [Cites] Immunity. 2005 Mar;22(3):295-304 [15780987.001]
  • [Cites] J Immunol. 2005 May 15;174(10):6477-89 [15879151.001]
  • [Cites] J Exp Med. 2009 Jul 6;206(7):1495-503 [19528259.001]
  • [Cites] PLoS One. 2009;4(12):e8132 [19997637.001]
  • [Cites] PLoS One. 2009;4(12):e8379 [20027308.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Dec 22;106(51):21783-8 [19966223.001]
  • [Cites] Nat Immunol. 2010 Apr;11(4):321-7 [20190757.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Nov 23;101(47):16606-11 [15536127.001]
  • (PMID = 20671122.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA108609; United States / NCI NIH HHS / CA / CA108609-08; United States / NCI NIH HHS / CA / R01 CA101741; United States / NCI NIH HHS / CA / R01CA101741; United States / NCI NIH HHS / CA / R01CA108609; United States / NCI NIH HHS / CA / R01 CA108609-08
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Antigens, CD56; 0 / Interleukin-15; 0 / Natural Cytotoxicity Triggering Receptor 1; 0 / Receptors, Interleukin-2; 126465-35-8 / Perforin; 24939-03-5 / Poly I-C; 82115-62-6 / Interferon-gamma; EC 3.4.21.- / Granzymes
  • [Other-IDs] NLM/ PMC2993621
  •  go-up   go-down


81. Huang SC, Cho A, Norton S, Liu ES, Park J, Zhou A, Munagala ID, Ou AC, Yang G, Wickrema A, Tang TK, Benz EJ Jr: Coupled transcription-splicing regulation of mutually exclusive splicing events at the 5' exons of protein 4.1R gene. Blood; 2009 Nov 5;114(19):4233-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coupled transcription-splicing regulation of mutually exclusive splicing events at the 5' exons of protein 4.1R gene.
  • We also implicate distinctive regulatory elements that promote the splicing of exon 1A to the distal 3' ss and exon 1B to the proximal 3' ss in murine erythroleukemia cells.
  • Taken together, our results suggest that 4.1R gene expression involves transcriptional regulation coupled with a complex splicing regulatory network.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10752-7 [12960380.001]
  • [Cites] Nat Struct Biol. 2003 Sep;10(9):679-80 [12942140.001]
  • [Cites] J Biol Chem. 2003 Dec 26;278(52):52166-71 [14530256.001]
  • [Cites] J Biol Chem. 2004 Jul 9;279(28):29740-51 [15123727.001]
  • [Cites] Nucleic Acids Res. 2004;32(15):4550-62 [15328367.001]
  • [Cites] Mol Cell Biol. 2004 Oct;24(20):8963-9 [15456870.001]
  • [Cites] Nucleic Acids Res. 1983 Mar 11;11(5):1475-89 [6828386.001]
  • [Cites] J Cell Biol. 1987 Dec;105(6 Pt 2):3105-18 [2961771.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Dec;85(23):9062-5 [3194408.001]
  • [Cites] J Cell Biol. 1990 Mar;110(3):617-24 [2307701.001]
  • [Cites] J Clin Invest. 1993 Jan;91(1):329-38 [8423229.001]
  • [Cites] Blood. 1996 May 1;87(9):3934-41 [8611723.001]
  • [Cites] Science. 1996 Sep 20;273(5282):1706-9 [8781232.001]
  • [Cites] Nature. 1997 May 29;387(6632):523-7 [9168118.001]
  • [Cites] J Biol Chem. 1997 Oct 31;272(44):27493-6 [9346875.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2061-6 [9482838.001]
  • [Cites] Mol Cell. 1998 Apr;1(5):765-71 [9660960.001]
  • [Cites] Curr Opin Cell Biol. 1999 Jun;11(3):347-51 [10395561.001]
  • [Cites] Mol Cell. 1999 Aug;4(2):251-8 [10488340.001]
  • [Cites] J Cell Sci. 2004 Dec 1;117(Pt 25):6197-206 [15564380.001]
  • [Cites] Nat Biotechnol. 2005 Jan;23(1):69-74 [15619619.001]
  • [Cites] Blood. 2005 Mar 1;105(5):2146-53 [15522963.001]
  • [Cites] Curr Opin Cell Biol. 2005 Jun;17(3):262-8 [15901495.001]
  • [Cites] Nat Methods. 2004 Nov;1(2):163-7 [16144086.001]
  • [Cites] Blood. 2006 Mar 15;107(6):2557-61 [16293607.001]
  • [Cites] J Biol Chem. 2006 May 5;281(18):12468-74 [16537540.001]
  • [Cites] Nat Struct Mol Biol. 2006 Sep;13(9):815-22 [16921380.001]
  • [Cites] Genes Dev. 2006 Nov 1;20(21):2922-36 [17079683.001]
  • [Cites] Nat Struct Mol Biol. 2006 Nov;13(11):973-80 [17028590.001]
  • [Cites] Mol Cell. 2007 Jun 22;26(6):867-81 [17588520.001]
  • [Cites] Blood. 2008 Jan 1;111(1):392-401 [17715393.001]
  • [Cites] EMBO J. 2008 Jan 9;27(1):122-31 [18079699.001]
  • [Cites] Nature. 1999 Dec 16;402(6763):832-5 [10617206.001]
  • [Cites] Nature. 1999 Dec 16;402(6763):838-41 [10617208.001]
  • [Cites] Trends Biochem Sci. 2000 Jun;25(6):290-3 [10838569.001]
  • [Cites] Genes Dev. 2000 Jun 15;14(12):1415-29 [10859161.001]
  • [Cites] Exp Hematol. 2000 Oct;28(10):1113-9 [11027829.001]
  • [Cites] J Biol Chem. 2001 Jun 15;276(24):21062-9 [11274164.001]
  • [Cites] Blood. 2001 Dec 15;98(13):3809-16 [11739190.001]
  • [Cites] Oncogene. 2002 Feb 14;21(8):1285-94 [11850848.001]
  • [Cites] Oncogene. 2002 Feb 28;21(10):1556-62 [11896584.001]
  • [Cites] Nature. 2002 Apr 4;416(6880):499-506 [11932736.001]
  • [Cites] Trends Genet. 2002 Apr;18(4):186-93 [11932019.001]
  • [Cites] Oncogene. 2002 Sep 5;21(39):6007-16 [12203113.001]
  • [Cites] Nature. 2002 Sep 26;419(6905):407-11 [12353038.001]
  • [Cites] EMBO J. 2002 Nov 15;21(22):6195-204 [12426391.001]
  • [Cites] Blood. 2003 May 15;101(10):4164-71 [12522012.001]
  • [Cites] IUBMB Life. 2003 Apr-May;55(4-5):235-41 [12880204.001]
  • [Cites] Trends Genet. 2003 Nov;19(11):640-8 [14585616.001]
  • (PMID = 19729518.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL024385; United States / NHLBI NIH HHS / HL / HL24385
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 5' Untranslated Regions; 0 / Blood Proteins; 0 / Cytoskeletal Proteins; 0 / DNA Primers; 0 / Epb4.1 protein, mouse; 0 / Membrane Proteins; 0 / Microfilament Proteins; 0 / Nuclear Proteins; 0 / Protein Isoforms; 0 / RNA-Binding Proteins; 0 / Ribonucleoproteins; 0 / erythrocyte membrane band 4.1 protein; 0 / splicing factor 2 protein, mouse; 0 / splicing factor U2AF; EC 2.7.7.- / DNA Polymerase II
  • [Other-IDs] NLM/ PMC2774555
  •  go-up   go-down


82. Kimchi-Sarfaty C, Vieira WD, Dodds D, Sherman A, Kreitman RJ, Shinar S, Gottesman MM: SV40 Pseudovirion gene delivery of a toxin to treat human adenocarcinomas in mice. Cancer Gene Ther; 2006 Jul;13(7):648-57
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SV40 Pseudovirion gene delivery of a toxin to treat human adenocarcinomas in mice.
  • A truncated Pseudomonas exotoxin gene (PE38) was delivered into various human cells (HeLa, KB-3-1, human lymphoblastoids, and erythroleukemia cells), in vitro using pseudovirions.
  • These results indicate that SV40 in vitro packaging is an effective system for cancer gene delivery using two different routes of injection and in combination with chemotherapy.

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Appl Microbiol Biotechnol. 1999 Oct;52(4):524-33 [10570800.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jul 19;91(15):6889-93 [8041715.001]
  • [Cites] Appl Microbiol Biotechnol. 2000 May;53(5):558-67 [10855716.001]
  • [Cites] N Engl J Med. 2001 Jul 26;345(4):241-7 [11474661.001]
  • [Cites] Expert Opin Biol Ther. 2001 Mar;1(2):291-300 [11727536.001]
  • [Cites] Hum Gene Ther. 2002 Jan 20;13(2):299-310 [11812285.001]
  • [Cites] World J Surg. 2002 Jul;26(7):783-9 [11948367.001]
  • [Cites] Drug Discov Today. 2002 Apr 15;7(8):479-85 [11965397.001]
  • [Cites] Hum Gene Ther. 2003 Jan 20;14(2):167-77 [12614568.001]
  • [Cites] Cancer Immunol Immunother. 2003 May;52(5):338-41 [12700949.001]
  • [Cites] Cancer Gene Ther. 2003 Jul;10(7):501-8 [12833130.001]
  • [Cites] J Neurooncol. 2003 Oct;65(1):15-25 [14649882.001]
  • [Cites] Hum Gene Ther. 2003 Dec 10;14(18):1787-98 [14670129.001]
  • [Cites] Expert Opin Biol Ther. 2004 Apr;4(4):519-30 [15102601.001]
  • [Cites] Int J Med Microbiol. 2004 Apr;293(7-8):577-82 [15149034.001]
  • [Cites] J Immunol. 2004 Jul 1;173(1):61-7 [15210759.001]
  • [Cites] Ann Thorac Surg. 2004 Aug;78(2):436-43; discussion 436-43 [15276492.001]
  • [Cites] Biotechniques. 2004 Aug;37(2):270-5 [15335219.001]
  • [Cites] Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6231-8 [15448012.001]
  • [Cites] J Med Chem. 2004 Nov 4;47(23):5690-9 [15509168.001]
  • [Cites] Somat Cell Mol Genet. 1985 Mar;11(2):117-26 [3856953.001]
  • [Cites] J Biol Chem. 1990 Sep 25;265(27):16306-10 [2118903.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Nov;87(21):8291-5 [2236041.001]
  • [Cites] J Urol. 1993 Jun;149(6):1626-32 [8501821.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Aug 15;90(16):7538-42 [8356052.001]
  • [Cites] Ann N Y Acad Sci. 1993 Jun 23;685:740-5 [8363279.001]
  • [Cites] Blood. 1994 Jan 15;83(2):426-34 [8286741.001]
  • [Cites] Ann N Y Acad Sci. 1994 May 31;716:126-38; discussion 138-43 [7912913.001]
  • [Cites] Hum Gene Ther. 1997 May 1;8(7):843-9 [9143910.001]
  • [Cites] Virology. 1997 Oct 27;237(2):414-21 [9356352.001]
  • [Cites] J Mol Biol. 1998 Aug 21;281(3):475-83 [9698563.001]
  • [Cites] Hum Gene Ther. 1999 Apr 10;10(6):923-34 [10223726.001]
  • [Cites] Immunol Res. 2004;30(3):339-49 [15531774.001]
  • [Cites] Curr Pharm Biotechnol. 2004 Oct;5(5):451-8 [15544493.001]
  • [Cites] Blood. 2005 May 1;105(9):3707-13 [15626735.001]
  • [Cites] Cancer Gene Ther. 2000 Jan;7(1):91-6 [10678361.001]
  • (PMID = 16498428.001).
  • [ISSN] 0929-1903
  • [Journal-full-title] Cancer gene therapy
  • [ISO-abbreviation] Cancer Gene Ther.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / BC / Z01 BC005598-16; United States / Intramural NIH HHS / /
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Bacterial Toxins; 0 / Exotoxins; 0 / Virulence Factors; 80168379AG / Doxorubicin; EC 2.4.2.- / ADP Ribose Transferases; EC 2.4.2.31 / toxA protein, Pseudomonas aeruginosa
  • [Other-IDs] NLM/ NIHMS7889; NLM/ PMC1482740
  •  go-up   go-down


83. Siegler U, Kalberer CP, Nowbakht P, Sendelov S, Meyer-Monard S, Wodnar-Filipowicz A: Activated natural killer cells from patients with acute myeloid leukemia are cytotoxic against autologous leukemic blasts in NOD/SCID mice. Leukemia; 2005 Dec;19(12):2215-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activated natural killer cells from patients with acute myeloid leukemia are cytotoxic against autologous leukemic blasts in NOD/SCID mice.
  • They participate in the immune response against residual acute myeloid leukemia (AML) after hematopoietic stem cell transplantation with partial HLA class I disparity.
  • However, the role of NK cells in autologous leukemia-specific immunity remains poorly understood.
  • We studied the function of NK cells in AML patients at diagnosis.
  • The polyclonal population of activated AML-NK cells expressed normal levels of the activating receptor NKG2D and the major natural cytotoxicity receptor NKp46.
  • AML-NK cells were highly effective with respect to interferon-gamma production, cytotoxicity against HLA class I-deficient K562 erythroleukemia cells in vitro and retardation of tumor growth in vivo in K562-bearing NOD/SCID mice.
  • Importantly, when AML blasts were injected into NOD/SCID mice, a single dose of adoptively transferred autologous AML-NK cells significantly reduced the AML load by 8-77%.
  • Recognition of AML blasts may be related to the observed upregulation of ligands for NKG2D and natural cytotoxicity receptors in vivo.
  • We conclude that AML patient-derived NK cells are fully functional, in support of exploring the benefit of AML immunotherapy with IL-2-stimulated autologous NK cells.
  • [MeSH-major] Blast Crisis / therapy. Cytotoxicity, Immunologic. Killer Cells, Natural / physiology. Leukemia, Myeloid / immunology. Leukemia, Myeloid / pathology
  • [MeSH-minor] Acute Disease. Animals. Humans. Immunotherapy, Adoptive. K562 Cells. Lymphocyte Activation. Mice. Mice, Inbred NOD. Mice, SCID. Transplantation, Heterologous. Tumor Burden. Tumor Cells, Cultured. Up-Regulation

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16224486.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


84. Doctor PB, Bhagia LJ, Derasari AY, Vyas JB, Amin RJ, Ghosh SK: A preliminary study on gram-negative bacteria (GNB) and their endotoxins in a gin house in India. J Occup Environ Hyg; 2006 Dec;3(12):707-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The presence of byssinosis, an occupational disease found among cotton mill workers, has been well documented in different parts of the world.
  • The disease develops due to exposure to environmental cotton dust.
  • Evidence suggests that the causative agent for the disease is gram-negative bacteria (GNB) and their endotoxins present on the cotton fibers.
  • Airborne dust concentrations were very high in the working environment: 2.11 mg/m3 in ginning and 0.95 mg/m3 in the press department (p < 0.05), which was higher than the threshold limit value collected by VE (0.2 mg/m3), and higher than the permissible exposure limit for respirable dust (0.5 mg/m3 for nontextile industries using cotton).
  • The Occupational Safety and Health Administration's cotton dust standard permissible exposure limit for respirable dust is 0.2 mg/m3 in yarn manufacturing, 0.75 mg/m3 in slashing and weaving, and 0.5 mg/m3 in nontextile industries using cotton.
  • Total enumeration of airborne GNB was carried out qualitatively by the petri plate exposure method and quantitatively by an Andersen 6-stage viable sampler and VE.
  • [MeSH-major] Air Pollutants, Occupational / analysis. Endotoxins / analysis. Gram-Negative Bacteria / chemistry. Occupational Exposure. Textile Industry

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17133691.001).
  • [ISSN] 1545-9624
  • [Journal-full-title] Journal of occupational and environmental hygiene
  • [ISO-abbreviation] J Occup Environ Hyg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Air Pollutants, Occupational; 0 / Dust; 0 / Endotoxins
  •  go-up   go-down


85. Piazza R, Ruiz-Fernández AC, Frignani M, Vecchiato M, Bellucci LG, Gambaro A, Pérez-Bernal LH, Páez-Osuna F: Historical PCB fluxes in the Mexico City Metropolitan Zone as evidenced by a sedimentary record from the Espejo de los Lirios lake. Chemosphere; 2009 May;75(9):1252-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Historical PCB fluxes in the Mexico City Metropolitan Zone as evidenced by a sedimentary record from the Espejo de los Lirios lake.
  • The accumulation of PCBs over time was studied in a sediment core collected from Espejo de los Lirios, an ecological reserve located within the heart of Cuatitlan Izcalli, in the Northern part of Mexico City Metropolitan Zone.
  • A phase of decrease, after the ban of the use in open systems, ended in 1989 and in 1995, at the time of sampling, the trend was toward a new increase to the highest levels.
  • Nonetheless, the contamination levels found in the sediments are relatively high, reaching values above the threshold effect level (TEL) guidelines and, in two cases, close to the probable effect level (PEL) which mean that some adverse effects on the fauna may have occurred all over the time interval represented by the core.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19251301.001).
  • [ISSN] 1879-1298
  • [Journal-full-title] Chemosphere
  • [ISO-abbreviation] Chemosphere
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Lead Radioisotopes; 0 / Soil Pollutants; DFC2HB4I0K / Polychlorinated Biphenyls
  •  go-up   go-down


86. Zong JC, Arav-Boger R, Alcendor DJ, Hayward GS: Reflections on the interpretation of heterogeneity and strain differences based on very limited PCR sequence data from Kaposi's sarcoma-associated herpesvirus genomes. J Clin Virol; 2007 Sep;40(1):1-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ever since the original identification of fragments of KSHV DNA in Kaposi's sarcoma (KS) tissue by Chang et al. in 1994, PCR has been used successfully and extensively to detect the virus in clinical samples from the accepted etiological diseases of KS, PEL and MCD.
  • Here, we evaluate the validity and interpretations of previous results in the context of both the observed rates and global patterns of sequence variability within an extended ORF26 locus, as well as from the perspective of the overall levels of KSHV variability found after sampling multiple loci across the complete KSHV genome.
  • In addition, we describe several observations that help to explain likely sources of the often either unexpectedly high or unexpectedly low levels of sporadic variability seen in the PCR DNA sequence data reported in some of those studies.

  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AIDS. 1997 Jul 15;11(9):1119-22 [9233458.001]
  • [Cites] J Infect Dis. 1997 Jul;176(1):94-102 [9207354.001]
  • [Cites] Br J Dermatol. 1997 Aug;137(2):179-84 [9292063.001]
  • [Cites] J Med Virol. 1997 Sep;53(1):81-4 [9298737.001]
  • [Cites] J Virol. 1997 Oct;71(10):8082-3 [9311909.001]
  • [Cites] Arch Dermatol. 1997 Oct;133(10):1247-51 [9382563.001]
  • [Cites] Blood. 1997 Dec 1;90(11):4278-82 [9373238.001]
  • [Cites] Lancet. 1997 Dec 6;350(9092):1655-61 [9400509.001]
  • [Cites] Science. 1997 Dec 12;278(5345):1972; author reply 1972-3 [9417645.001]
  • [Cites] J Infect Dis. 1998 Jan;177(1):213-6 [9419191.001]
  • [Cites] Am J Epidemiol. 1998 Feb 1;147(3):217-21 [9482495.001]
  • [Cites] Lancet. 1998 Feb 28;351(9103):679-80 [9500364.001]
  • [Cites] J Clin Invest. 1998 Apr 1;101(7):1500-8 [9525993.001]
  • [Cites] Blood. 1998 Jun 1;91(11):4393-4 [9596693.001]
  • [Cites] Blood. 1998 Oct 15;92(8):2681-7 [9763550.001]
  • [Cites] Hum Pathol. 1998 Oct;29(10):1091-6 [9781647.001]
  • [Cites] J Infect Dis. 1998 Nov;178(5):1546-7 [9780286.001]
  • [Cites] J Infect Dis. 1998 Dec;178(6):1610-5 [9815212.001]
  • [Cites] Blood. 1999 Feb 1;93(3):1110-1 [10025982.001]
  • [Cites] Blood. 1999 Mar 1;93(5):1482-6 [10029574.001]
  • [Cites] J Virol. 1999 May;73(5):4156-70 [10196312.001]
  • [Cites] Blood. 1999 May 15;93(10):3157-9; discussion 3164-6 [10233867.001]
  • [Cites] Blood. 1999 May 15;93(10):3159-63; discussion 3163-4 [10233868.001]
  • [Cites] Semin Cancer Biol. 1999 Jun;9(3):187-99 [10343070.001]
  • [Cites] J Virol. 1999 Aug;73(8):6646-60 [10400762.001]
  • [Cites] J Leukoc Biol. 1999 Aug;66(2):357-60 [10449181.001]
  • [Cites] J Infect Dis. 1999 Nov;180(5):1466-76 [10515805.001]
  • [Cites] Am J Respir Crit Care Med. 2005 Dec 15;172(12):1581-5 [16192453.001]
  • [Cites] Intervirology. 2006;49(3):133-43 [16428889.001]
  • [Cites] Adv Dent Res. 2006;19(1):91-5 [16672557.001]
  • [Cites] J Clin Microbiol. 2006 Jul;44(7):2409-15 [16825357.001]
  • [Cites] Curr Top Microbiol Immunol. 2007;312:1-42 [17089792.001]
  • [Cites] J Clin Virol. 2007 Sep;40(1):19-25 [17690010.001]
  • [Cites] Rev Med Virol. 2002 Jan-Feb;12(1):47-63 [11787083.001]
  • [Cites] Br J Haematol. 2000 Jan;108(1):197-8 [10712004.001]
  • [Cites] J Infect Dis. 2000 May;181(5):1785-90 [10823785.001]
  • [Cites] Nature. 2000 Sep 14;407(6801):151-2 [11001045.001]
  • [Cites] Clin Cancer Res. 2000 Nov;6(11):4226-33 [11106236.001]
  • [Cites] J Mol Diagn. 2001 Feb;3(1):32-8 [11227070.001]
  • [Cites] Cancer. 2001 Apr 15;91(8):1409-13 [11301386.001]
  • [Cites] J Clin Virol. 2002 Jan;23(3):119-48 [11595592.001]
  • [Cites] J Gen Virol. 2002 Jul;83(Pt 7):1613-9 [12075079.001]
  • [Cites] J Virol. 2003 Jun;77(11):6546-50 [12743312.001]
  • [Cites] J Clin Microbiol. 2003 Jun;41(6):2492-7 [12791871.001]
  • [Cites] J Infect Dis. 2003 Sep 1;188(5):678-89 [12934184.001]
  • [Cites] N Engl J Med. 2003 Sep 18;349(12):1113-22 [13679525.001]
  • [Cites] J Virol. 2004 Apr;78(8):4074-84 [15047824.001]
  • [Cites] Oral Microbiol Immunol. 2004 Jun;19(3):201-4 [15107073.001]
  • [Cites] Biotechniques. 1994 Feb;16(2):242-4, 246 [8179886.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] Lancet. 1995 Mar 25;345(8952):759-61 [7891487.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1181-5 [7700310.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1276-80 [7632932.001]
  • [Cites] Lancet. 1995 Sep 23;346(8978):799-802 [7674745.001]
  • [Cites] N Engl J Med. 1996 May 2;334(18):1168-72 [8602183.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4937-43 [8652805.001]
  • [Cites] J Clin Microbiol. 1996 Oct;34(10):2635-8 [8880542.001]
  • [Cites] J Infect Dis. 1997 Mar;175(3):703-7 [9041349.001]
  • [Cites] Blood. 1997 Mar 1;89(5):1686-9 [9057651.001]
  • [Cites] J Virol. 1997 May;71(5):4138-44 [9094697.001]
  • [Cites] Science. 1997 Jun 20;276(5320):1851-4 [9188529.001]
  • [Cites] J Neurol. 1997 Jul;244(7):450-4 [9266465.001]
  • (PMID = 17698410.001).
  • [ISSN] 1386-6532
  • [Journal-full-title] Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
  • [ISO-abbreviation] J. Clin. Virol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA081400-040001; United States / NCI NIH HHS / CA / R01 CA081422; United States / NIAID NIH HHS / AI / AI24576; United States / NCI NIH HHS / CA / P01 CA113239; United States / NCI NIH HHS / CA / R01 CA081422-05; United States / NCI NIH HHS / CA / CA73585; United States / NCI NIH HHS / CA / R01 CA073585-10; United States / NCI NIH HHS / CA / P01 CA081400; United States / NIAID NIH HHS / AI / R01 AI024576; United States / NCI NIH HHS / CA / CA081422-05; United States / NCI NIH HHS / CA / CA81422; United States / NCI NIH HHS / CA / CA073585-10; United States / NIAID NIH HHS / AI / R01 AI024576-20; United States / NCI NIH HHS / CA / CA081400-049001; United States / NCI NIH HHS / CA / R01 CA073585; United States / NIAID NIH HHS / AI / AI024576-20; United States / NCI NIH HHS / CA / P01 CA081400-040001; United States / NCI NIH HHS / CA / CA81400; United States / NCI NIH HHS / CA / P01 CA081400-049001
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 61
  • [Other-IDs] NLM/ NIHMS30402; NLM/ PMC2084348
  •  go-up   go-down


87. Koma D, Yamanaka H, Moriyoshi K, Ohmoto T, Sakai K: Overexpression and characterization of thermostable serine protease in Escherichia coli encoded by the ORF TTE0824 from Thermoanaerobacter tengcongensis. Extremophiles; 2007 Nov;11(6):769-79
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A novel extracellular serine protease derived from Thermoanaerobacter tengcongensis, designated tengconlysin, was successfully overexpressed in Escherichia coli as a soluble protein by recombination of an N-terminal Pel B leader sequence instead of the original presequence and C-terminal 6x histidine tags.

  • Hazardous Substances Data Bank. SODIUM LAURYL SULFATE .
  • Hazardous Substances Data Bank. UREA .
  • Hazardous Substances Data Bank. 2-MERCAPTOETHANOL .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biochem Mol Biol. 2002 Sep 30;35(5):498-507 [12359093.001]
  • [Cites] FEMS Microbiol Lett. 1994 Jul 1;120(1-2):69-74 [8056296.001]
  • [Cites] Microbiol Mol Biol Rev. 2001 Mar;65(1):1-43 [11238984.001]
  • [Cites] Extremophiles. 2002 Jun;6(3):233-43 [12072959.001]
  • [Cites] J Mol Biol. 2004 Jul 16;340(4):783-95 [15223320.001]
  • [Cites] Mol Microbiol. 1991 Jun;5(6):1507-10 [1686294.001]
  • [Cites] Curr Opin Biotechnol. 2004 Aug;15(4):330-4 [15296930.001]
  • [Cites] Eur J Biochem. 1999 Mar;260(3):752-60 [10103004.001]
  • [Cites] Trends Biotechnol. 1998 Aug;16(8):329-32 [9720321.001]
  • [Cites] Extremophiles. 2003 Oct;7(5):391-9 [12908102.001]
  • [Cites] Genome Res. 2002 May;12(5):689-700 [11997336.001]
  • [Cites] Nucleic Acids Res. 1991 Aug 11;19(15):4300 [1870987.001]
  • [Cites] Protein Sci. 1997 Mar;6(3):501-23 [9070434.001]
  • [Cites] Biosci Biotechnol Biochem. 1995 Aug;59(8):1438-43 [7549094.001]
  • [Cites] J Biol Chem. 1996 Aug 23;271(34):20426-31 [8702780.001]
  • [Cites] Int J Syst Evol Microbiol. 2001 Jul;51(Pt 4):1335-41 [11491330.001]
  • [Cites] J Bacteriol. 1987 Sep;169(9):4379-83 [3040692.001]
  • [Cites] Protein Sci. 1994 Aug;3(8):1329-40 [7987227.001]
  • [Cites] Eur J Biochem. 1992 Aug 1;207(3):1035-44 [1499549.001]
  • [Cites] Trends Biochem Sci. 1998 Oct;23(10):403-5 [9810230.001]
  • [Cites] J Biol Chem. 1990 Apr 25;265(12):6576-81 [2182621.001]
  • [Cites] Biochemistry. 1999 Feb 23;38(8):2570-6 [10029552.001]
  • [Cites] Microbiology. 1995 Jul;141 ( Pt 7):1731-8 [7551039.001]
  • [Cites] J Biol Chem. 1987 Jul 25;262(21):10035-8 [3611052.001]
  • [Cites] Gene. 1998 Mar 16;209(1-2):95-103 [9524234.001]
  • [Cites] Eur J Biochem. 1988 Feb 1;171(3):441-7 [3162211.001]
  • [Cites] J Mol Microbiol Biotechnol. 1999 Aug;1(1):101-5 [10941791.001]
  • [Cites] FEBS Lett. 1997 Oct 6;415(3):329-34 [9357994.001]
  • [Cites] Biochem J. 1987 Oct 1;247(1):121-33 [3120701.001]
  • [Cites] Biotechniques. 1992 Feb;12(2):222-3 [1616713.001]
  • [Cites] Acta Biol Med Ger. 1982;41(1):89-102 [7051706.001]
  • [Cites] Biosci Biotechnol Biochem. 1996 Feb;60(2):271-6 [9063975.001]
  • (PMID = 17657405.001).
  • [ISSN] 1431-0651
  • [Journal-full-title] Extremophiles : life under extreme conditions
  • [ISO-abbreviation] Extremophiles
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / DNA, Bacterial; 0 / Protease Inhibitors; 0 / Recombinant Proteins; 368GB5141J / Sodium Dodecyl Sulfate; 60-24-2 / Mercaptoethanol; 8W8T17847W / Urea; EC 3.4.21.- / Serine Endopeptidases; SY7Q814VUP / Calcium
  •  go-up   go-down


88. Kitagawa J, Hara T, Tsurumi H, Oyama M, Moriwaki H: Pure erythroid leukemia with hemophagocytosis. Intern Med; 2009;48(18):1695-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pure erythroid leukemia with hemophagocytosis.
  • Biochemistry showed increased ferritin levels.
  • Pure erythroid leukemia with hemophagocytic syndrome (HPS) was diagnosed.
  • Complete remission was attained, and HPS also improved.
  • However, leukemia relapsed during chemotherapy and the patient died.
  • This is the first report of pure erythroid leukemia complicated with HPS.
  • [MeSH-major] Leukemia, Erythroblastic, Acute / complications. Lymphohistiocytosis, Hemophagocytic / etiology

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. METHYLPREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19755777.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 04079A1RDZ / Cytarabine; X4W7ZR7023 / Methylprednisolone; ZRP63D75JW / Idarubicin
  •  go-up   go-down


89. Kuramoto T, Yokoe M, Yagasaki K, Kawaguchi T, Kumafuji K, Serikawa T: Genetic analyses of fancy rat-derived mutations. Exp Anim; 2010;59(2):147-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • During inbreeding, we isolated 9 mutations: 5 coat colors, American mink (am), Black eye (Be), grey (g), Pearl (Pel), siamese (sia); 1 coat pattern, head spot (hs); 2 coat textures, Rex (Re), satin (sat); and an ear pinnae malformation, dumbo (dmbo).
  • Candidate gene analysis revealed that a missense mutation in the tyrosinase gene, Ser79Pro, was responsible for sia.

  • National BioResource Project. culture/stock collections - NBRP resources .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20484848.001).
  • [ISSN] 1881-7122
  • [Journal-full-title] Experimental animals
  • [ISO-abbreviation] Exp. Anim.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


90. Lu XG, Zhu L, Wang WQ, Zhang XH, Zhao XY, Xu GB, Xu Z: Morphological study on the megakaryocytes with nuclear extrusion and nucleocytoplasmic separation in four cases. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Dec;13(6):1082-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To investigate the morphological changes of megakaryocytes with nuclear extrusion and nucleocytoplasmic separation, the morphological characteristics of megakaryocytes in peripheral blood films, bone marrow smears, and bone marrow biopsies from 4 newly diagnosed patients with primary myelofibrosis (PMF), myelodysplastic syndrome (MDS), myeloblastic leukemia with maturation (M(2)) and erythroleukemia (M(6)) were studied by using light microscope.

  • MedlinePlus Health Information. consumer health - Blood Disorders.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16403285.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  •  go-up   go-down


91. de Thonel A, Vandekerckhove J, Lanneau D, Selvakumar S, Courtois G, Hazoume A, Brunet M, Maurel S, Hammann A, Ribeil JA, Zermati Y, Gabet AS, Boyes J, Solary E, Hermine O, Garrido C: HSP27 controls GATA-1 protein level during erythroid cell differentiation. Blood; 2010 Jul 8;116(1):85-96
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HSP27 controls GATA-1 protein level during erythroid cell differentiation.
  • In 2 models of erythroid differentiation; that is, in the human erythroleukemia cell line, K562 induced to differentiate into erythroid cells on hemin exposure and CD34(+) human cells ex vivo driven to erythroid differentiation in liquid culture, depletion of HSP27 provokes an accumulation of GATA-1 and impairs terminal maturation.
  • More specifically, we demonstrate that, in the late stages of the erythroid differentiation program, HSP27 is phosphorylated in a p38-dependent manner, enters the nucleus, binds to GATA-1, and induces its ubiquitination and proteasomal degradation, provided that the transcription factor is acetylated.
  • We conclude that HSP27 plays a role in the fine-tuning of terminal erythroid differentiation through regulation of GATA-1 content and activity.
  • [MeSH-major] Cell Differentiation. Erythroid Cells / metabolism. GATA1 Transcription Factor / metabolism. HSP27 Heat-Shock Proteins / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • SciCrunch. OMIM: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20410505.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / GATA1 Transcription Factor; 0 / GATA1 protein, human; 0 / HSP27 Heat-Shock Proteins; 0 / HSPB1 protein, human; 0 / Imidazoles; 0 / Interleukin-6; 0 / Leupeptins; 0 / Proteasome Inhibitors; 0 / Pyridines; 0 / SB 203580; 0 / Transforming Growth Factor beta; 133407-82-6 / benzyloxycarbonylleucyl-leucyl-leucine aldehyde; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases; EC 3.4.25.1 / Proteasome Endopeptidase Complex
  •  go-up   go-down


92. Li YS, Wu P, Zhou XY, Chen JG, Cai L, Wang F, Xu LM, Zhang XL, Chen Y, Liu SJ, Huang YP, Ye DY: Formyl-peptide receptor like 1: a potent mediator of the Ca2+ release-activated Ca2+ current ICRAC. Arch Biochem Biophys; 2008 Oct 1;478(1):110-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The FPRL1 agonists induced Ca(2+) release from the endoplasmic reticulum and subsequently evoked I(CRAC)-like currents displaying fast inactivation in K562 erythroleukemia cells which expresses FPRL1, but had almost no effect in K562 cells treated with FPRL1 RNA-interference and HEK293 cells which showed no FPRL1 expression.
  • [MeSH-major] Calcium / metabolism. Calcium Channels / chemistry. Gene Expression Regulation. Receptors, Formyl Peptide / metabolism. Receptors, Lipoxin / metabolism

  • Hazardous Substances Data Bank. SODIUM .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18652801.001).
  • [ISSN] 1096-0384
  • [Journal-full-title] Archives of biochemistry and biophysics
  • [ISO-abbreviation] Arch. Biochem. Biophys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Annexins; 0 / Calcium Channels; 0 / FPR2 protein, human; 0 / Lipoxins; 0 / Receptors, Formyl Peptide; 0 / Receptors, Lipoxin; 0 / lipoxin A4; 67526-95-8 / Thapsigargin; 9NEZ333N27 / Sodium; SY7Q814VUP / Calcium
  •  go-up   go-down


93. Emery DW, Gavriilidis G, Asano H, Stamatoyannopoulos G: The transcription factor KLF11 can induce gamma-globin gene expression in the setting of in vivo adult erythropoiesis. J Cell Biochem; 2007 Mar 1;100(4):1045-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The transcription factor KLF11 can induce gamma-globin gene expression in the setting of in vivo adult erythropoiesis.
  • Previous studies in a fetal erythroid cell line demonstrated that the transcription factor, Krüppel-like factor 11 (KLF11), could specifically induce transcription from a gamma-globin gene promoter, and that this induction was mediated through a specific canonical CACCC cis-DNA binding motif.
  • We report here that ectopic expression of KLF11 can also induce fetal gamma-globin gene expression in the setting of adult erythropoiesis both in vitro and in vivo.
  • Studies in an adult-stage murine erythroleukemia (MEL) cell line demonstrated that retrovirus vector-mediated transduction of KLF11 could increase both the amount of expression from a basally active, but not from a overtly silenced, recombinant gamma-globin transgene, as well as the frequency of cells expressing this transgene.
  • A similar pattern of gamma-globin gene induction was also observed both in vitro and in vivo following KLF11 transduction of bone marrow from mice containing a basally active gamma-globin transgene.
  • These studies provide the first evidence that ectopic expression of a transcription factor can induce gamma-globin gene expression in vivo during adult erythropoiesis.
  • [MeSH-major] Erythropoiesis / genetics. Gene Expression. Globins / genetics. Kruppel-Like Transcription Factors / physiology
  • [MeSH-minor] Animals. Bone Marrow Transplantation. Cell Line. Erythroid Precursor Cells / cytology. Erythroid Precursor Cells / metabolism. Flow Cytometry. Green Fluorescent Proteins / genetics. Green Fluorescent Proteins / metabolism. Humans. Mice. Mice, Transgenic. NIH 3T3 Cells. Retroviridae / genetics. Time Factors. Transfection

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17131378.001).
  • [ISSN] 0730-2312
  • [Journal-full-title] Journal of cellular biochemistry
  • [ISO-abbreviation] J. Cell. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Kruppel-Like Transcription Factors; 147336-22-9 / Green Fluorescent Proteins; 9004-22-2 / Globins
  •  go-up   go-down


94. Mitsuma A, Asano H, Kinoshita T, Murate T, Saito H, Stamatoyannopoulos G, Naoe T: Transcriptional regulation of FKLF-2 (KLF13) gene in erythroid cells. Biochim Biophys Acta; 2005 Feb 14;1727(2):125-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcriptional regulation of FKLF-2 (KLF13) gene in erythroid cells.
  • FKLF-2 (KLF13) was cloned from fetal globin-expressing tissues and has been shown to be abundantly expressed in erythroid cells.
  • In this study we examined the transcriptional regulation of the KLF13 gene.
  • A 5.5 kb 5' flanking region cloned from mouse erythroleukemia (MEL) cell genomic DNA showed that major cis regulatory activities exist in the 550 bp sequence to the unique transcription start site, and that the promoter is more active in K562 cells than in COS-7 cells.
  • The promoter was trans-activated by co-expressed GATA-1 through the sequence containing two CCAAT motifs, suggesting that GATA-1 is involved in the abundant expression of KLF13 mRNA in the erythroid tissue.
  • Dual action, i.e. activating effect in COS-7 and repressive effect in K562 cell, was observed on its own promoter, suggesting a feedback mechanism for the transcriptional control of the KLF13 gene in the erythroid environment.
  • These findings provide an insight on the mechanism of inducible mRNA expression of the KLF13 gene in erythroid cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2001 Sep 14;276(37):34355-8 [11443140.001]
  • [Cites] Genome Biol. 2003;4(2):206 [12620113.001]
  • [Cites] Mol Cell Biol. 2003 Nov;23(22):8295-305 [14585986.001]
  • [Cites] Genes Dev. 1991 Jun;5(6):919-31 [2044960.001]
  • [Cites] Nature. 1992 Aug 6;358(6386):499-502 [1379347.001]
  • [Cites] Mol Cell Biol. 1993 May;13(5):2776-86 [7682653.001]
  • [Cites] EMBO J. 1993 Dec 15;12(13):4993-5005 [8262042.001]
  • [Cites] J Biol Chem. 1994 Jun 3;269(22):15440-4 [8195185.001]
  • [Cites] J Biol Chem. 1995 Jan 27;270(4):1955-9 [7829533.001]
  • [Cites] Nature. 1995 May 25;375(6529):316-8 [7753194.001]
  • [Cites] Nature. 1995 May 25;375(6529):318-22 [7753195.001]
  • [Cites] Mol Cell Biol. 1995 Nov;15(11):5957-65 [7565748.001]
  • [Cites] Mol Cell Biol. 1998 Jan;18(1):102-9 [9418858.001]
  • [Cites] Immunity. 1999 Jan;10(1):93-103 [10023774.001]
  • [Cites] Mol Cell Biol. 1999 May;19(5):3571-9 [10207080.001]
  • [Cites] J Biol Chem. 1999 Jul 23;274(30):21180-5 [10409672.001]
  • [Cites] Biochem J. 2000 Feb 1;345 Pt 3:529-33 [10642511.001]
  • [Cites] Gene. 1999 Oct 18;239(1):15-27 [10571030.001]
  • [Cites] Nucleic Acids Res. 1999 Aug 1;27(15):2991-3000 [10454592.001]
  • [Cites] Blood. 2000 Jun 1;95(11):3578-84 [10828046.001]
  • [Cites] Mol Cell Biol. 2000 Oct;20(20):7662-72 [11003662.001]
  • [Cites] EMBO J. 2001 Jan 15;20(1-2):157-64 [11226166.001]
  • [Cites] Blood. 2001 Sep 15;98(6):1792-801 [11535513.001]
  • (PMID = 15716005.001).
  • [ISSN] 0006-3002
  • [Journal-full-title] Biochimica et biophysica acta
  • [ISO-abbreviation] Biochim. Biophys. Acta
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / HL020899-23; United States / NHLBI NIH HHS / HL / R01 HL020899; United States / NHLBI NIH HHS / HL / HL20899; United States / NHLBI NIH HHS / HL / R01 HL020899-23
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / KLF13 protein, human; 0 / Kruppel-Like Transcription Factors; 0 / RNA, Messenger; 0 / Repressor Proteins
  • [Other-IDs] NLM/ NIHMS168057; NLM/ PMC2808416
  •  go-up   go-down


95. Fernandes-Whaley M, Mühlberger F, Whaley A, Adam T, Zimmermann R, Rohwer E, Walte A: On-line derivatization for resonance-enhanced multiphoton ionization time-of-flight mass spectrometry: detection of aliphatic aldehydes and amines via reactive coupling of aromatic photo ionization labels. Anal Chem; 2005 Jan 1;77(1):1-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The REMPI-TOFMS detection limits obtained for acetaldehyde; acrolein; crotonal; and methyl-, ethyl-, propyl-, and butylamine using this photo ionization labeling method were in the sub-parts-per-million range and, thus, readily below the permissible exposure limits set by OSHA.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15623272.001).
  • [ISSN] 0003-2700
  • [Journal-full-title] Analytical chemistry
  • [ISO-abbreviation] Anal. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aldehydes; 0 / Amines
  •  go-up   go-down


96. Malinova V, Wandrey C: Loading polyelectrolytes onto porous microspheres: impact of molecular and electrochemical parameters. J Phys Chem B; 2007 Jul 26;111(29):8494-501